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Study of the Immune Correlates of Protection in Rhesus Macaques  
Vaccinated against Simian Immunodeficiency Virus 
After more than thirty years since the Human Immunodeficiency Virus (HIV) was identified, only 
the RV144 phase III vaccine clinical trial provided evidence of protection from virus infection, with 
31.2% of the patients protected at three years since the end of the immunisation phase. 
Statistical analyses support serum IgG antibody recognition of the V2 region of viral gp120 as a 
mechanism of protection from acquisition. One hypothesis is that antibodies to this region might 
block the interaction with the integrin 47, which protrudes from the surface of mucosal CD4+ 
T cells and is thought to capture the virus and facilitate infection. However, that 47 blocking 
might be a protective mechanism of RV144 vaccination has yet to be definitively demonstrated. 
In this thesis, I aimed to describe at the molecular level the immune mechanisms of protection 
in a rhesus macaque (Macaca mulatta) vaccinated in an RV144-like schedule and protected from 
Simian Immunodeficiency Virus (SIV) infection, with a particular focus on the humoral immune 
response of the animal. More specifically, vaccine-induced monoclonal antibodies (mAbs) 
directed against the V2 region of SIV were isolated and characterised. One of them, NCI09, has 
been identified as a potent inhibitor of SIV gp120 interaction with human 47. Notably, NCI09 
antigen recognition is negatively affected by the presence of ITS41, a mAb targeting a distant 
epitope on V2. 
Moreover, to experimentally prove this mechanism I performed the passive immunoprophylaxis 
of rhesus macaques using the anti-V2 mAb ITS09. Unfortunately, this mAb proved ineffective in 
providing protection both alone and in combination. 
Finally, a vaccination protocol based on the immunisation regimen of RV144, but modified to 
elicit stronger immune responses was tested. Surprisingly, the protocol failed to afford 
protection. However, in a parallel group immunised with the standard RV144 regimen, protection 
was observed and correlated with the intensity of the innate immune responses.   
These results provide insights into possible mechanisms of protection of RV144 vaccination 
against HIV. Furthermore, these findings suggest that there may be a degree of structural 
plasticity of the V2 region that may impact its interaction with 47 and evasion mechanisms 
from a potentially protective humoral immune response.
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HIV 
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Initial remarks 
 
My PhD studies were based on a collaboration that I established with Prof. Heeney’s Laboratory 
of Viral Zoonotics at the Department of Veterinary Medicine at the University of Cambridge from 
Dr. Genoveffa Franchini’s Animal Models and Retroviral Vaccines Section at the National 
Institutes of Health in Bethesda, Maryland, where I worked from May 2014 to September 2017. 
This collaboration, which formally started with my PhD program in Michaelmas 2014, aimed to 
define the immune mechanisms of protection in P770, a rhesus macaque (Macaca mulatta) 
which was vaccinated and thereby protected from Simian Immunodeficiency Virus infection, with 
a particular focus on the humoral immune response of the animal. For this purpose, I cloned and 
characterised monoclonal antibodies directed against a region of the virus, namely V2, located 
at the apex of the surface glycoprotein gp120. 
In addition, a vaccination protocol based on that of the human clinical trial was modified to elicit 
stronger immune responses and evaluated on rhesus macaques. 
Finally, I tested the efficacy of an anti-V2 mAb in providing protection from SIV infection to rhesus 
macaques. 
 
In the introduction, I review the key concepts of vaccine-mediated immunity and of the 
development of a protective humoral immune response. I then review how the HIV epidemic 
originated and the current state. Finally, I summarise the results and mechanistic clues obtained 
from RV144, the only phase III clinical trial to ever demonstrate protection from HIV acquisition, 




















“I am not happy that I am sick. I am not happy that I have AIDS. But if that is helping others,  




“I am working with people with AIDS on a daily basis. To hear that there is a possible vaccine 
that could come out in two or three years is no good news for these people. Most of the people 
we’re working with now will be dead by that time” 
Bob Scheckey, HIV-infected patient, April 1984 
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CHAPTER 1: Introduction 
 
An introduction to vaccines 
Vaccines are an important tool in Public Health for the prevention of both bacterial and viral 
infections and are estimated to avert 2 to 3 million deaths every year; furthermore, they have 
the potential of saving additional 1.5 million lives if vaccination programs are improved 
worldwide1. So far, tens of vaccines protecting both against viral and bacterial infections are 
approved for clinical use. In addition, vaccines for the treatment of cancer and autoimmune 
diseases are being developed. However, for the purpose of this thesis, the immunological 
mechanisms of protection against viral infections will be illustrated. 
 
Types of Vaccines 
A key difference that distinguishes types of vaccines is the form in which the antigen is delivered. 
Different forms are combined with different non-antigenic ingredients to guarantee the delivery 
of the safest, most cost-effective preparation that can efficiently activate the immune system 
against and provide protection from a given circulating pathogen. 
 
Preparation of the antigen 
Historically, there have been two main types of vaccines that have been used to prevent 
infectious diseases2. 
(I) Attenuated vaccines induce protection by exposing patients to debilitated forms of 
live virus. These are generally obtained by allowing the virus to undergo several cycles 
of replication in tissues or cell cultures and are now commonly used to prevent 
infection of rubella, mumps, measles or chickenpox. 
(II) Inactivated vaccines are formulated with viruses that are first grown in culture and 
then made unable to replicate through heat or chemical treatment, most commonly 
with formaldehyde3. Although these vaccines are considered safer than their 
attenuated counterparts because of lower likelihood to revert to their normal 
virulence, their activation of the immune system is weaker as it induces a shorter-
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lasting immunological memory, and thus require multiple administrations over time 
to maintain protection. The Salk polio and tri- and tetravalent influenza vaccines are 
examples of inactivated vaccines. 
 
Although attenuation and inactivation are the traditional means my which vaccines are made, 
more recently other methods have been developed to specifically deliver antigens for the 
induction of protection. 
These include subunit, synthetic and nucleic acid vaccines4.  
(III) Subunit vaccines (with the most widely used inducing protection against Hepatitis B) 
are based on the administration of a single protein of the virus, either purified from 
whole pathogens grown in laboratory conditions or synthetically produced starting 
from DNA synthesized for the gene of interest.  
(IV) Synthetic vaccines, that have not been approved for clinical study yet, aim to induce 
an immune response directed exclusively against certain areas of the protein of 
interest.  
(V) Finally, nucleic acid vaccines5 (both DNA- and RNA-based) are currently being 
developed in preclinical and clinical settings. Instead of administering the antigen 
directly, these vaccines aim to deliver nucleic acids that lead to the expression of viral 
antigens in transduced patient cells, thus inducing an immune response. These 
vaccines have the advantage that nucleic acids are not costly to produce, and stable 
to transport. Although viral vector-delivered and synthetic DNA vaccines have been 
evaluated in human clinical trials and been shown to be safe and immunogenic, none 
has yet been licensed for human use. Two main categories of mRNA vaccines are also 
being evaluated: self-amplifying and non-amplifying. However, although very 
promising, mRNA vaccines are still relatively far from being licensed for commercial 
distribution. 
 
In addition to the antigenic component, vaccines contain other ingredients: adjuvants, 
preservatives, stabilisers and residues of manufacture3. Although for the purpose of this thesis 
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Adjuvants have the goal of increasing the intensity and influencing the type of immune response 
against the administered antigen6. These are particularly necessary in cases in which the 
administered antigen does not induce a response strong enough to result in protection7. While 
attenuated vaccines are generally protective without the inclusion of an adjuvant in the 
preparation, administration of only parts of the pathogen generally elicit weaker immune 
responses. For this reason, adjuvants are most commonly included in inactivated and subunit 
vaccines. 
Alum, a formulation of aluminium salts which came into clinical practice in the 1920s, is the 
adjuvant most commonly used and at the moment included in vaccines against Hepatitis A and 
B, plus other bacterial vaccines7. The aluminium salts included in vaccines are aluminium 
hydroxide (AH) or alhydrogel (a chemically crystalline form of aluminium hydroxide), as well as 
aluminium phosphate (AP)8,9.However, the identification of the exact mechanism of efficacy of 
alum in inducing potent immune responses remains elusive10. In vitro and in vivo studies have 
resulted in three main hypotheses: (i) depot formation, (ii) antigen targeting, (iii) induction of 
inflammation.  
TAKE REFERENCES BELOW FROM PMC4406982  
(I) Depot formation. Upon studies on guinea pigs vaccinated against Diphtheria Toxoid, 
Glenny, Buttle and Stevens hypothesised that the slow elimination of alum-
precipitated antigens over a long period of time from a single infection time could 
stimulate both primary and secondary immune responses thus resulting in increased 
antibody titres11. This theory might be justified by the fact that alum is identified as a 
strong antigen binder, thus it is plausible to hypothesise that the slow release of the 
antigen in the administration site could result in enhanced immune responses 10. 
Moreover, upon interaction with aluminium salts, protein antigens are demonstrated 
to switch to a particulate form which, as compared to soluble antigens, better 
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interacts with Antigen Presenting Cells (APCs) resulting in enhanced 
phagocytosis10,12,13 . 
(II) Antigen targeting. The formation of particulates as an enhancer of APC recruitment 
was a “linker theory” that paved the way to develop further antigen-targeting 
hypotheses. A study on rabbits demonstrated the uptake of both antigen and AP by 
macrophages recruited to the injection site at 7 days post-vaccination14. Antigen 
targeting was defined in three phases, with the first one involving the recruitment of 
immune cells at the site of injection, the second the induction and maturation signals 
by APCs, and the third the migration of antigen-loaded APCs to the closest draining 
lymph node. 
(III) Inflammation. It is commonly agreed that some degree of inflammation in the 
injection site is essential in developing an effective immune response15, recognised as 
the “Danger Theory” proposed by Matzinger in 199416. According to the danger 
theory, activation of the immune response is not dependent upon recognition of the 
invading viral or bacterial antigen, but rather on the elicitation of tissue damage. The 
signals released at the site of damage would then result in inflammation and lead to 
an adaptive immune response. This would be in line with the observation that 
administration of alum in vaccines results in the release of danger signals in the site 
of infection. The vaccines containing alum lead to a short-term inflammation in a 
normal environment, and long-term inflammation in a pathological environment at 
the site of injection17,18: indeed, alum induces uric acid or monosodium urate crystal 
as danger signals18, as well as heat shock protein 7019 and DNA20,21. The release of 
these molecules results in the activation of an immune response.  
 
The humoral immune response 
Vaccine-elicited protection is mainly attributed to the induction of antigen-specific antibodies22. 
The mechanisms behind B-cell maturation and the development of antigen-specific B cell 
responses, which are of particular interest in this thesis, will be reviewed more in detail below. 
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An overview of these responses and their role in relation to the T-cell arm of the adaptive immune 
response will be provided in the following paragraphs.  
While antigen-specific antibody titres increase dramatically in the days/weeks following antigen 
encounter (Figure 1.1), more than a peak of antigen-specific antibodies is necessary for 
vaccination-mediated protection: affinity, avidity, neutralisation potential and Fc-mediated 
functions may all in fact play a role in providing protection from viral acquisition. These features 
of antibody responses are dependent on the nature of the antigen and the local immune 
response. Antibody affinity maturation and isotype switching are dependent on the co-
stimulatory responses of T-helper cells, specifically T helper follicular cells. Similarly, Fc receptor 
functions are acquired by post-transcriptional modifications and are often developed in local 
tissues where B cell responses expand. Besides antibody-related features per se, a key function 
of vaccines is to induce long-term protection through the induction of long-lived plasma cells and 
memory B cells. While long-lived plasma cells are responsible for a steady, baseline level of 
antigen-specific antibody titres in plasma after the vaccine antigen is cleared, memory B cells are 
responsible for an antigen-reactive humoral immune response. Long-term protection is thus 
achieved when the steady memory is maintained at levels above protective threshold and 
memory B cells are able to steadily react to further interactions with the antigens and rapidly 
boost the titres of antigen-specific blood antibodies23,24. 
 
Figure 1. 1: Kinetic of primary and secondary antibody response. The primary B cell response (blue curve) leads to 
the generation of antigen-specific IgM- and IgG-secreting cells as well as memory B cells. Upon re-exposure, a 
secondary response (maroon curve) follows after which antigen-specific B cells responses are more rapidly 
generated, higher affinity IgG-secreting plasma cells are produced and higher antigen-specific IgG titres are achieved. 
(From reference 25). 
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If on the one hand, however, plasma cell-secreted antigen-specific antibodies are immediate 
effectors of protection, T cells are essential in the induction of high-affinity antibodies and 
immunological memory24. 
 
The critical interaction between T and B cells 
While antibodies act by opsonising, neutralising and possibly through Fc-mediated functions, T 
cells are also essential in limiting the spread of the infection or by sustaining the production of 
useful antibodies23. 
Cytotoxic CD8+ T lymphocytes are able to limit the spread of infection by identifying and killing 
infected cells or through the secretion of antiviral cytokines. Antigen-specific CD8+ lymphocytes 
have been found to be strongly induced by live, attenuated vaccines or vectored vaccines23. 
On the other hand, CD4+ T helper (Th) cells sustain the continuous production, maturation and 
maintenance of antigen-specific B- and CD8+ T-cells responses26. These cells also contribute to 
macrophage activation23. 
Originally divided in two subsets, namely Th1 and Th2, T helper cells were then discovered to 
include many subsets with different functions and homing features27. Particularly relevant in the 
production of high affinity antibodies are follicular T-helper (Tfh) cells, which are located in the 
lymph node to sustain B-cell activation and differentiation into antibody-secreting cells (ASCs)28. 
Because Tfh cells play a major role in providing “help” to B cells for the development of high-
affinity, antigen-specific antibodies, the main mechanisms and molecular players of this 
interaction will be reviewed more in detail in the subsections below. 
However, T-helper 17 (Th17) cells will first be briefly reviewed because of their importance in the 
early stages of HIV infection. These cells, positive both for CCR5 and CD4, are mostly located in 
the skin and mucosa, where they induce neutrophil recruitment and promote local inflammation 
through the secretion of IL-17 (hence their name)29,30. These cells protect from bacteria that 
colonise the skin and mucosa, and a balance is maintained by the suppression exerted by 
regulatory T cells (Tregs) on Th1731. Soon after infection through the sexual route, HIV undergoes 
local replication at the site of infection, and is then transported by Dendritic Cells (DCs) to the 
lymph node, where it further replicates when exposed to resident CD4+ T cells32. As through most 
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of the infection HIV mostly displays preference for the coreceptor CCR5 rather than CXCR4, the 
intestinal mucosa, where large numbers of CCR5+ CD4+ Th17 cells are present, represents a rich 
substrate where HIV undergoes early rounds of rapid viral replication, resulting in the peak of 
viral load typical of acute HIV infection and depletion of the Th17 mucosal reservoir32–34. 
However, recent findings suggest that the integrin 47 may play a fundamental role in the 
establishment of HIV infection in the gut tissue. The observations leading to this theory are 
reviewed more in detail in the last section of this chapter. 
While antigen-specific serum antibodies are able to opsonise viral pathogens that enter the blood 
stream, their presence in the mucosa is essential to prevent pathogen replication at the first site 
of infection22. Peripheral antibodies have been demonstrated to be fundamental in preventing 
pathogen replication in infected wounds in the case of tetanus, in the throat in the case of 
diphtheria or the mucosal surface in the case of polio35. However, to reduce viral binding or 
adhesion to the tissue in the periphery, very high antibody levels need to be reached in the blood 
stream to allow for antibody exudation in the mucosa. The neutralisation of viruses at the 
mucosal level is thus mainly achieved upon vaccination through the transudation of 
immunoglobulin G (IgG) antibodies rather than immunoglobulin A (IgA)23,35. 
In most of the cases, inactivated vaccines do not induce antibodies responses of sufficiently high 
titres to prevent infection in the mucosal surface. Only after breaching through the mucosal 
tissue will a pathogen encounter serum IgG and be subject to the mechanisms of suppression23. 
If it is therefore to be taken into consideration that the first step towards the establishment of 
sustained HIV infection in humans is local replication that follows breach of the mucosal tissue. 
An effective HIV vaccine will therefore induce serum IgG levels that are high enough to exudate 
through the mucosal tissue and will bind to the virus before a local infection is established. 
 
Mechanisms of the interaction between T and B cells 
Tfh cells do not provide help to B cells through a single process or cellular product. Rather, they 
exert their activity through seven main distinct functions28 as shown in Figure 1.2: proliferation, 
survival, plasma cell differentiations, somatic hypermutation, class-switch recombination, 
adhesion and attraction. 
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Figure 1. 2: T cell help is provided in several, different forms with different consequences. The seven main forms of 
this help are essential for a healthy B cell response. For synthesis, only the main factors involved in T cell help are 
shown, although many more molecules have been demonstrated to be involved in the regulation of these processes. 
Because some molecules display functional redundancies, combinatorial possibilities tightly regulate the help 
processes. BAFF, B cell-activating factor; BCL, B cell lymphoma; BLIMP1, B lymphocyte-induced maturation protein 
1; CD40L, CD40 ligand; CXCL13, CXC-chemokine ligand 13; CXCR5, CXC-chemokine receptor 5; IL, interleukin; MCL1, 
myeloid cell leukaemia 1; SAP, SLAM-associated protein; SLAMF, signalling lymphocytic activation molecule F; TGFβ, 
transforming growth factor-β. From reference28. 
These seven different forms of help all contribute to the interactions between Tfh and B cells, 
with each process consisting of multiple pathways25. 
One of the main effects that Tfh cells have on B cells is the induction of proliferation, of which 
CD40 ligand (CD40L) is the most prominent Tfh cell player: the discovery of the interaction 
between B cell membrane CD40 and Tfh cell membrane CD40L created interest in the help that 
occurs via direct interaction between the two cell types, in addition to the secretion of and 
binding to cytokines36. 
Survival signals from Tfh cells are also crucial, since B cells located in the germinal centre (GC) are 
intrinsically pro-apoptotic37. The secretion of IL-4 by Tfh cells triggers pro-survival signals that 
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result in the transmission of survival signals within the B cells mediated by the IL-4 receptor 
complex38. 
As summarised more in detail in the following section, somatic hypermutation (SHM), an 
essential mechanism responsible for B cell affinity maturation within the GC, is mediated by the 
enzyme Activation-Induced Cytidine Deaminase (AID)39–41. It is however essential that B-cell 
lymphoma 6 protein (BCL-6) is co-expressed with AID by the GC B cell to repress the apoptosis 
programme that would otherwise result in self-destruction of the cell upon DNA damage42. 
Although the signals that induce AID and BCL-6 expression by B cells have not been defined in 
detail, it has been found that CD40L, IL-4 and IL-21 contribute to these mechanisms43. As a matter 
of fact, it seems that different ratios of CD40L engagement together with extracellular IL-4 and 
IL-21 are the primary regulators of cell proliferation, SHM and differentiation28. 
Class Switch Recombination (CSR), which is responsible for the switch from IgM secretion to other 
immunoglobulin subtypes (discussed more in detail below) can also be induced following 
instructions from Tfh cells to B cells: AID is a prime mediator of CSR, but the specific targeting of 
heavy chain constant region depends on additional factors that are selectively activated by 
cytokines which are mostly secreted by CD4+ T cells28. For instance, human IgM to IgG CSR is most 
efficiently induced by IL-21, while IgE recombination is triggered at low levels of IL-21 in presence 
of high levels of IL-444,45. 
Because help received by B cells extensively depends on direct contact with T cells, adhesion 
molecules expressed both by Tfh and B cells are fundamental players of this interaction. For 
instance, SLAM-associated protein (SAP) binds to the intracellular domains of surface receptors 
belonging to the SLAM family, which are involved in cell-to-cell adhesion28. Deletion of the SAP-
encoding gene Sh2d1a results in severely impaired GCs and B cell memory46–49, because unstable 
B cell-T cell adhesion does not allow Tfh cells to provide sufficient help signals to B cells. 
Finally, chemoattraction is a main component of the T cell help to B cells: CXC-chemokine ligand 
13 (CXCL13), the ligand for CXCR5, is constitutively secreted by human GC Tfh cells, which 
probably acts by recruiting B cells thus allowing Tfh-B cell colocalization and GC confinement50,51. 
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T cell help is thus demonstrated to consist in a complex interplay of many factors and processes, 
with many inhibitory and stimulatory signals exchanged between Tfh cells and GC B cells over 
many rounds of B cell division, mutation and selection. Although a sufficient level of 
understanding of each of these processes has been reached, how these interactions are 
integrated to develop an efficient B cell responses is still poorly understood. 
 
In the sections below, I will review the functional mechanisms and GC interactions that lead to 
the development of high-affinity plasma and memory B cell responses. 
 
Development of antigen-specific B cell responses.  
The development of antigen-specific B cell responses is a finely tuned phenomenon that occurs 
in GCs, which are specialised areas within the lymph node where B cells are assisted in developing 
effective antibody responses by T cell help and other stimulatory signals41. In the following 
sections, the molecular mechanisms of antibody diversification, the stages of development of 
mature GCs and the processes behind the selection of high-affinity B cell clones will be 
overviewed. 
 
B Cell Receptor Diversity  
The B cell receptor (BCR) serves as a receptor for antigens and is located on the surface of the B 
cells52. This receptor is made up by two immunoglobulin heavy (IgH) and two immunoglobulin 
light (IgL) chains encoded by the IgH and IgL loci, respectively (Figure 1.3). The IgL loci comprise 
the IgK or IgL loci. The three Ig loci are located on different chromosomes in humans and mice. 
The diversification strategies are largely conserved between the two species. The N-terminal 
ends of the heavy and light chains have a highly variable amino acid sequence, termed Variable 
(V) region, and are responsible for BCR-antigen interaction. On the other hand, the C-terminal 
ends only display a few variations in sequence and are called Constant (C) regions. 
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Figure 1. 3: Germ-line organization of human immunoglobulin (Ig) loci. Functional genes of the human heavy chain, 
κ-light chain, and λ-light chain loci are shown. Exons and introns are not drawn to scale. Each CH gene is shown as a 
single box but is composed of several exons, as illustrated for CH. L, leader (signal sequence); V, variable; D, 
diversity; J, joining; C, constant; enh, enhancer. (From reference 25).  
The generation of a broad population of B cells able to react to an enormous variety of antigens 
is essential to generate a humoral adaptive immune response53. However, IgH and IgL variable 
regions are not present in the germline, but assembled during early B cell development in the 
bone marrow or foetal liver before the cell is exposed to antigen54. The process, named V(D)J 
recombination generates a variable IgH VH(D)JH exon through the different combination of one 
of the numerous IgH variable (VH), diversity (D) and joining (JH) segments located within 1 to 3 
Mb from the 5’ end of the IgH locus. In the IgL locus, where a diversity segment is not present, 
combinations of VL and JL exons are assembled54. 
The V(D)J recombination (Figure 1.4) is initiated by lymphocyte-specific endonucleases RAG1 and 
RAG2 (collectively named “RAG”) which recognise recombination signal sequences (RSS) flanking 
the segments V, D and J55. RAG cleaves between the RSSs of two encoding segments, generating 
two double strand breaks that are then joined by the non-homologous end-joining double strand 
repair pathway55–57. Of note, before the ends are joined, random nucleotides are added de novo 
in the joining segments by the terminal deoxynucleotidyl transferase (Tdt), contributing to 
  
Chapter 1                                                                                                                                           Introduction 
   12 
 
Figure 1. 4: Stages of the V(D)J recombination mechanism of the Ig loci. RAG endonucleases RAG1 and RAG2 mediate 
the formation of a synapsis (a loop-structure) in the unrearranged locus. When the synapsis is formed, RAG mediates 
cleavage between the RSSs of two encoding segments (coloured, numbered cones), thus generating double-strand 
breaks that are then repaired by mediators of the non-homologous end-joining double strand pathways. From 
reference 25 
 
increasing the diversity generated in the process, with the generation of an enormous repertoire 
of primary variable region exons58,59. In the final, recombined primary V region, three 
hypervariability regions, responsible for antigen interaction and thus named complementarity-
determining regions (CDRs), are separated by more conserved framework regions (FWRs). While 
CDR1 and CDR2 both lie within the V segment, CDR3 is made up by part of the V and D and J 
segments, and thus more variable than the others60,61. 
Fully assembled IgH and IgL chain transcripts are synthesised starting from the V segment 
promoter in the V(D)J exon and proceeds through the exons that encode for the C regions, 
located downstream within 200 kb62. The mouse IgH locus contains eight groups of exons, each 
one encoding for different CH regions (also named CH genes) in the following order: 5’ VDJ-C-
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C-C3-C1-C2b-C2a-C-C 3’63.The class of the BCR/antibody molecule will be determined by 
the exons that are expressed linked to the V region. At first, IgH variable region is transcribed 
together with the C exons immediately downstream, or together with C exons as well in some 
cells. Alternative splicing events will determine if the molecule is to be expressed with Cm, Cd 
and as a membrane-bound BCR or secreted antibody64.However, before antigenic stimulation, B 
cell exclusively express membrane-bound µ or ∂ BCR53.  
It is important to point out that during B cell development, V(D)J recombination occurs first at 
the IgH locus in progenitor (pro) B cells54,57: these cells generate first D to JH rearrangements in 
both of the two IgH alleles, and only later they proceed with linking the Vh segment to the 
arranged DJh segments in one allele65. If the resulting VDJ segment is in frame, and productive, 
the Ig µ heavy chain protein generates a signal that prevents V – DJ recombination to occur in 
the second allele and directs the cell towards the precursor (pre) B cell stage. Pre B cells have 
thus a productive V(D)J IgH allele and an intermediate DJ allele53. If the TdT-induced 
diversification is out of frame and the resulting IgH chain non-productive, the cell will proceed 
and recombine the second allele which, if in frame, will push the cell to the pre B cell stage. The 
resulting cells will have a non-productive, out of frame and a productive VDJ allele. Generally, 
circa 65% of the V-DJ rearrangements are non-productive, and some 40% of normal B cells display 
two VDJ rearrangements. This mechanism of “allelic exclusion” has probably been developed to 
allow for mono-specificity of the single cells66. Pre B cells will then proceed and rearrange their 
genes for a productive IgL chain, which will pair with the µ heavy chain to yield a complete BCR 
µ molecule54,57. The resulting naïve B cells will then be able to migrate to the periphery to patrol 
the secondary lymphoid organs (lymph nodes, spleen and Peyer’s patches) in search of their 
cognate antigen53. 
 
Somatic Hypermutation and Class Switch Recombination 
Naïve B Cell activation results in the generation of B cells that secrete their BCR as an antibody. 
In addition, this process results in two somatic processes of genetic rearrangement that enhance 
antibody affinity and change antibody function. The first process, SHM, diversifies the antigen-
binding region of the BCR, while CSR switches the CH exon resulting in a change of the function 
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of the antibody, that is the means by which the antigen is eliminated60,67. While SH occurs in the 
GCs, CSR can occur both inside and outside of the GCs37,68,69. Both SHM and CSR are mediated by 
the enzyme AID70,71, which modifies ssDNA resulting in the deamination of cytidine residues60. 
However, the deamination is not casual and is mostly oriented in the context of preferred 
sequences60 (Figure 1.5) Because the target of AID is ssDNA, transcription of the modified enzyme 
needs to be active. Both SHM and CSR rely on the normal mismatch repair processes of Base 
Excision Repair (BER) and mismatch repair (MMR) to convert AID-induced lesions to mutations 
or double strand breaks (DSB)53. 
 
Figure 1. 5: Mechanisms of AID cytidine deamination in SHM and CSR. The deamination of cytosine residues in IgH 
and IgL V(D)J exons results in the reprocessing of the modified cytosines through cellular repair pathways Base 
Excision Repair (BER) and mismatch repair (MMR), which generally convert AID-induce lesions to point mutations 
or, less likely, to double-strand breaks. From reference 53. 
During SHM, AID mediates the deamination of cytosine residues in IgH and IgL V(D)J exons, and 
the products are processed through cellular repair pathways that mostly result in point mutations 
(with 2/3 of substitutions being transitions) although insertions and deletions might be induced 
too60,72–74. The mutation frequency is approximately one mutation per thousand base pair per 
generation, with the highest concentration of mutations being localised in the CDRs60,75,76. The 
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mechanisms by which cells with mutations that increase affinity for the target antigen are 
selected are discussed more in detail below. 
CSR, on the other hand, is mediated by the AID deamination of cytosine residues in noncoding 
switch (S) regions that are located upstream of each set of CH exons (with the exception for C∂ 
exons) and are from 1 to 10 kb in length67,77. CSR is then finalised by the joining of two S regions 
where AID-initiated DSBs were generated63,77. As a result, a switch occurs in secretion from IgM 
to different IgG classes, when Cµ exons are replaced with one of the sets of CH exons located 
downstream53. The functions of each class of Ig are summarised in Table 1.1 and discussed more 
in detail below. 
In this way, CSR alters the effector functions of an antibody to one that may work best to 
eliminate the given pathogen, while maintaining the same antibody-binding specificity53. 
 
Table 1. 1: Properties of the human immunoglobulin isotypes. While IgG1 and IgG3 display stronger activation of the 
classical pathway of the complement, as well as ability to trigger ADCC and ADCP, IgG2 and IgG4 have weaker Fc-
related functions. IgM displays strong ability to activate the complement through the classical pathway, while IgAs 
can recruit macrophages and phagocytes for ADCP. Finally, IgE mostly mediates reactions to parasites such as 
helminths or allergy reactions through recruitment of mast cells and basophils. From reference 78. 
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Immunoglobulin loci in the rhesus macaque 
The rhesus macaque is a critically important animal model in SIV/HIV research. However, Indian-
origin rhesus macaque Ig loci have been assembled at high-coverage only recently79. The authors 
described sequence diversity in ten Indian-origin rhesus macaques of the genes encoding for the 
heavy chain (IGHV, IGHD, IGHJ, IGHC), the kappa light chain (IGKV, IGKJ, IGKC) and the lambda 
light chain (IGLV, IGLJ, IGLC). Below, I will briefly summarise the main differences and similarities 
between these genes in human and rhesus macaque. The information reported in this section is 
obtained from the work of Ramesh and collaborators79. 
 
Heavy Chain Genes 
Humans typically carry 123-129 total IGVH genes in the IGH locus per haploid genome, of which 
38-46 are functional and classified into seven families80. Overall, macaques have a similar number 
of genes, with the macaque IGHV3 family larger as compared to humans. Interestingly, the ten 
macaques studied by Ramesh and collaborators displayed a degree of allelic diversity comparable 
to that of the whole human IGHV genes in the total IMGT database. Regarding IGHD, humans 
typically have 23 functional genes that belong to seven families, and additional 14 open reading 
frames (ORFs)80. As the authors identified 39 genes with 49 alleles distributed in six families, 
macaques have a substantially expanded IGHD repertoire. Similarly, nine macaques IGHJ genes 
were identified, while only six have been found in human. 
Finally, humans have 57 IGHC alleles representing a total of 12 IGHC genes (of which two IGHA, 
one IGHD, one IGHE, two IGHEP, four IGHG, one IGHGP and IGHM, where “P” indicates 
pseudogenes), while macaques appear to only have eight IGHC genes, lacking IGHGP, one of the 
two IGHEP and one IGHA. However, greater IGHC allele numbers are present in macaque than in 
humans. Notably, macaque and human share 80% IGHC exon pairwise identity. 
 
Kappa Light Chain Genes 
41 functional IGKV genes have been identified in humans, with a total of 67 alleles belonging to 
6 families. These genes are organised in three alternating blocks in the IGKV locus. With the 
exception of the IGKV2 family, humans and macaques were found to have a generally similar 
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number of genes, although macaques display six alternating blocks of IGKV genes. Macaque IGKV 
genes are also more polymorphic than the human IGKV genes and, unlike humans, carry 
functional genes in the IGKV7 family. Similarly to humans, macaques have functional IGKV genes 
both in the forward and reverse orientation. 
As per IGKJ genes, humans have five functional genes, and all of the macaque genes were found 
to have distinct human orthologs. 
Both humans and macaques have only one IGKC gene. However, while five alleles were described 
in humans, the authors found six alleles in ten macaques, indicating that IGKC is highly diverse in 
macaques, in comparison to humans. Notably, the pairwise identity between human and 
macaque IGKC is 91.6%. 
 
Lambda Light Chain Genes 
In humans, 33 functional IGLV genes represented by 71 alleles in 10 families, with additional 
seven ORFs with 11 alleles identified. In macaque, most IGLV families are larger and more diverse 
than in human. As per IGLJ, five functional genes and two non-functional genes have been found 
in humans, while five functional genes have been identified in the macaque. Similarly, humans 
have five functional, two non-functional IGLC genes per haploid locus, with the same organisation 
found in macaques. 
 
In summary, relative to humans several V gene families in all of the three Ig loci were expanded 
in macaques. In addition, macaque Ig V gene diversity was found to be several times higher than 
that in humans. These results are particularly of interest having considered that the diversity of 
only ten macaques examined by the authors was compared with that of the Ig loci of all humans 
studied to date and reported in the ImMunoGeneTics database.  
 
Having summarised the genetic and molecular features of the B cell antibody repertoire, the Fc-
related antibody effector functions will be reviewed below before proceeding to summarise the 
cellular mechanisms driving development of an affinity-matured, class-switched antibody 
response.  
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Antibody Effector Functions 
Antibodies act by a number of mechanisms which engage other arms of the immune system25. 
Besides blocking interactions or functions of molecules through their antigen-binding region 
(described more in detail below in the context of HIV neutralisation), antibodies can activate the 
classical complement pathway (complement-dependent cytotoxicity, CDC) by interacting with 
C1q on the C1 complex when clustered, or coordinate the antibody-mediated and cell-mediated 
immune response through the engagement of Fc receptors (Figure 1.6)81. Which effector 
functions the antibody will initiate depends on its isotype or subclass. 
 
Figure 1. 6: Antiviral properties of non-neutralising antibodies. HIV-specific antibodies act by attracting the innate 
immune cells or complement to eliminate the infected cells through different mechanisms, such as ADCC, ADCP, and 
complement activation. From reference 81. 
Fc Receptor-dependent functions 
Fc receptors (FcRs) are immune regulatory receptors with selective, class-specific antibody 
binding properties: FcγR binds to IgG , FcεRI to IgE, FcαRI to IgA, FcμR to IgM and FcδR to IgD82. 
Three classes of IgG-binding receptors have been identified on leukocytes: CD64 (FcγRI), CD32 
(FcγRIIa, FcγRIIb and FcγRIIc) and CD16 (FcγRIIIa and FcγRIIIb)83. FcγRI is identified as the highest 
affinity receptor, while FcγRII and FcγRIII demonstrate low to intermediate affinity84. The 
expression of FcγRs on any given cell type may change according to location, cytokine milieu and 
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activation state81. The formation of a bridge between an antigen-expressing target cell and an 
FcγR-bearing effector cell aims to result in target cell death either by antibody-dependent cellular 
cytotoxicity (ADCC) or antibody-dependent cellular phagocytosis (ADCP)81: 
i. In the context of ADCC, which is a mechanism quite central in Chapter 3, FcγRs on the 
surface of innate effector cells (NK cells, macrophages, monocytes and eosinophils) bind 
to the Fc region of an IgG pre-bound to a target cell81. Upon binding, a signalling pathway 
is activated which leads to the secretion of lytic enzymes, perforin, granzymes and tumour 
necrosis factor, with the final killing of the target cell85. The level of ADCC effector function 
varies for different IgG subtypes, with higher ADCC effector function being mediated by 
IgG1 and IgG3, and lower by IgG2 and IgG425. In the macaque model, vaccine-induced 
ADCC activity has been found to correlate with infection outcomes86–89. However, no 
study to date has directly demonstrate that ADCC-mediating antibodies are alone 
responsible for preventing HIV/SIV infection, as observed in a study where  animals 
infused with nonfucosylated mAb IgG1 b12, modified to increased NK cell-mediated 
ADCC, were not significantly more protected that those administered with unmodified 
mAb81.  
ii. ADCP is a mechanism by which antibody-opsonised target cells activate the FcγR on the 
surface of macrophages, monocytes and dendritic cells thus inducing phagocytosis85. By 
this mechanisms, the target infected cell is degraded through acidification in the 
phagosome90. Like ADCC-inducing antibodies, it is likely that phagocytosis of HIV immune 
complexes increases the antiviral activity of non-neutralising or neutralising antibodies85. 
Despite the proven inability of non-neutralising, functional antibodies to protect from HIV/SIV 
infection86,91–93, the biologic activity behind the protection mediated by neutralising and non-
neutralising antibodies is likely different: unlike neutralising antibodies, non-neutralising 
antibodies must form avid immune complexes that are capable of recruiting low-affinity 
receptors or complement components necessary for their function83. Since HIV exposes a limited 
amount of Env products on its envelope94, non-neutralising antibodies may only marginally 
impact the virus itself. However, since HIV assembles in lipid rafts95, the higher concentration of 
viral products on the survace of infected cells may result in clustering of non-neutralising 
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antibodies and recruitment of FcRs81. Therefore, polyclonal non-neutralising antibodies 
simultaneously targeting several epitopes on a single envelope may have a better opportunity to 
form large immune complexes than non-neutralising monoclonal preparations81. It is therefore 
possible that cocktails of high-affinity, Fc-enhanced non-neutralising antibodies could 
simultaneously opsonise the surface of HIV envelope and mediate sterilising protection from 
infection81. 
 
Fc Receptor-independent functions  
While ADCC and ADCP are antibody functions that depend on FcR binding, the effector function 
of an antibody can also be carried out independently of FcRs through the activation of the 
complement system96. CDC (Figure 1.7) is a function that, when lacking, can result in severely 
impaired antibody responses both in animals and humans97,98.  
 
Figure 1. 7: The complement system in the antibody response. Antibody responses in animals that lack the factors 
and receptors shown in red are severely impaired, whereas lack of factors in green results in largely normal 
phenotype. The classical pathway is activated upon antibody opsonisation of target cells or organisms, the 
alternative pathway in response to bacterial endotoxin and the lectin pathway in response to pathogens containing 
cell walls rich in mannose. The final result of an effective complement response is target opsonisation and lysis 
through the membrane attack complex (MAC). From reference99. 
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The complement system is a set of over 20 proteins that, when activated, lead to a cascade of 
reactions on the surface of the pathogens that ultimately kill the threat thus eliminating 
infection25. The complement system can be activated independently from the adaptive immune 
response through the alternative pathway, in response to presence of bacterial endotoxin, or the 
lectin pathway, in response to the invasion of pathogens containing mannose-rich cellular walls96. 
However, as more related to the subject discussed in this thesis, only the classical, antibody-
dependent pathway of activation will be discussed in detail.  
Classical complement activation occurs in a specific immune response when IgG or IgM bind to 
antigens located on the surface of a cell, and the Fc recruits the first complement protein, C196. 
A cascade of events follows, with the generation of small proteins and peptides upon proteolysis 
of larger, inactivated complement components96. For instance, complement factor C3 is cleaved 
into C3b and C3a upon activation: while C3b remains bound to the complex on the surface of the 
target, acting as opsonin, the peptide C3a is released and diffuses acting as a chemotactic agent 
to cause inflammation25. A similar mechanism is observed with C5, where C5a is released and 
C5b acts as an opsonin25. 
Ultimately, the complement results in the activation of proteins C6, C7 and C8 which bind to the 
accumulating complement complex on the surface of the target, with the final recruitment of C9 
proteins100. These C9 monomers are of elongated shape and form a structure called membrane 
attack complex (MAC), which takes the shape of a cylinder with a hole in the centre that pierces 
the membrane of the cell101. MAC thus initiates cell lysis or apoptosis102. 
 
Germinal Centres - Overview 
The GCs are structures formed within lymph nodes in response to T-cell dependent antigens103. 
It is within GCs that antigen-specific B cells proliferate and differentiate into antibody-secreting 
cells (ASCs or plasma cells) and memory B cells that are responsible for the humoral immunity 
against invading pathogens. Several different cell types drive the differentiation of B cells from 
the GC reaction. Within the GCs, B cells proliferate at extremely high rates, and the 
immunoglobulin variable region (IgV) genes undergo SHM that results in increased affinity 
towards the target antigen104,105. This process, defined as affinity maturation, results in B cells 
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and plasma cells with potent binding affinities towards a defined antigen. It is through several 
rounds of positive selection and T cell help that the clones with highest affinity are selected out 
of a pool of randomly hypermutated cells. As a results, inferior antibody mutants are negatively 
selected41. 
Antigen-specific memory and plasma cells can be detected at 1 week after encounter with the 
antigen106, and are possible thanks to the creation of specialised microenvironments inside of the 
GCs that have the purpose of confining areas of mutation and areas of selection37. 
 
The GC reaction upon antigen encounter 
The lymph node is rich in follicles mainly comprised of naïve B cells with IgM+IgD+ phenotype, 
surrounded by areas rich in T cells and separated by interfollicular regions. GCs form roughly at 
the centre of these follicles where a network of follicular dendritic cells (FDCs), stromal cells that 
have long dendrites and with the ability to carry intact antigens on their surface, is present. 
When an antigen is presented within the follicle, naïve B cells activate and migrate to the border 
of the T cell zone or to the interfollicular region, where they undergo proliferation and activate 
upon interaction with antigen-specific T cells107–109. It is important to notice that not all of the 
antigen-activated B cells will enter the GC reaction, as some will differentiate into short-lived 
plasma blasts and migrate to the medullary chords, which are specialised areas of the lymph 
node. The function of short-lived plasmablasts, able to secrete low-affinity antibodies, will be 
illustrated below. 
However, of those B cells that have high affinity for the antigen, most differentiate into 
plasmablasts, rather than memory B cells. 
 
One day after invasion by a pathogen or immunisation, antigen-specific B cells and T cells are 
interacting within the interfollicular region of the lymph node110,111. After interaction with 
dendritic cells, the T cells at this stage are already committed to differentiating into Tfh 
cells110,112,113. BCL-6, which is considered a fundamental regulator of the Tfh and GC B cell 
differentiation, is found upregulated in Tfh cells as early as at this stage, while B cells start 
expressing low levels of BCL-6 only at two days after immunisation110,113. Among the other 
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functions, this transcriptional repressor turns off genes that are involved in B cell activation and 
differentiation into memory B cells and plasma cells. At day 2, most of the T cells have acquired 
TFH phenotypes (CXCR5+, PD1+, GL7+) and, at day 3, have migrated into the follicle, while it is 
only at day 4 that B cells migrate there. 
 
GC formation and maturation 
At day 4 early GCs within follicles can be observed. At this stage, B cells differentiate into B cell 
blasts, proliferate very rapidly and monopolise the network of FDCs in the centre of the follicle103. 
Of note, B cell blasts displace IgM+ IgD+ B cells, with the resulting formation of a “mantle zone” 
of naïve B cells around the GC. In the following two days, the GC expands rapidly because of the 
quick proliferation of the B cell blasts until day 7. At this stage, the GC has completely matured, 
and can be seen as divided into two microenvironments, namely the dark and the light zone37,103. 
The dark zone, named after its appearance in tissue samples, consists of densely packed, highly 
proliferating blasts and a network of cells similar in morphology to the FDCs of the light zone. The 
light zone is populated by lower numbers of B cells and is characterised by the concurrent 
presence of TFH cells, FDCs and macrophages37. 
 
Functional aspects of the GC reaction 
SHM is the intracellular molecular mechanism that drives affinity maturation of B cells in the GC. 
When a cell has undergone a round of SHM, it moves to the light zone and, if expressing a high-
affinity BCR, is positively selected. Every high-affinity B cell is the result of several rounds of 
mutation and selection, favoured by the circular transit between the dark and the light zone. In 
the matter of a few days, memory B and plasma cells exit the GC, with every ASC releasing 
thousands of monoclonal antibodies per second specific for the target antigen114. Several 
mechanisms contribute to the selection of high affinity B cells: 
i Cellular migration between GC zones. B cells are able to move rapidly between the 
dark and the light zone as a result of cell-intrinsic molecular programmes41,115,116. It 
seems that the spatial separation between the light and the dark zone is essential for 
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efficient rounds of affinity maturation, and is evolutionarily conserved across 
vertebrates117. 
ii Tfh cells. In the light zone, high-affinity B cells must be selected over low-affinity 
clones before they undergo further rounds of SHM in the dark zone. While it was 
originally believed that the selection of B cells was driven by a direct competition for 
the antigen taken up from FDCs103, it is now hypothesised that competition for T help 
is the key factor determining the selection of high-affinity B cell clones37: it seems in 
truth that the higher affinity a B cell displays for an antigen, the more the antigen is 
internalised upon binding with the BCR and the more is presented on MHC complexes 
to Tfh cells118. It is this direct correlation between BCR affinity and density of peptide-
Major Histocompatibility Complex (MHC) on the cell surface that results in higher T 
cell help and thus a selective advantage of high affinity clone: TFH cells form the 
largest, longest contacts with B cells that present the highest concentration of 
antigen-MHC complexes119. It is fundamental to mention that the BCR in the GC is 
mostly dedicated to the task of antigen capture and internalisation rather than 
intracellular signalling120. The B cells that receive the greatest help are induced to 
divide the greatest number of times when re-entering the dark zone121, and this in 
turn results in higher rates of SHM as this process induces a nucleotide exchange per 
1,000 bases into the IgV genes at every round of division within the GC60. Of the new 
mutants which re-enter the light zone, those with mutations that induce higher 
affinity are again sent back to the dark zone for further proliferation and SHM. As a 
result, just a few days following immunisation, the GC reaction is dominated by the 
population with the highest affinity for the antigen41. 
iii Antigen masking. The role of early-originated low-affinity short-lived plasma cells is to 
provide a further mechanism of selection of high affinity clones: only those B cells 
with BCRs of higher affinity than the antibodies secreted by short-lived plasma cells 
will be able to compete for antigen binding and will thus proliferate and undergo 
SHM122. As antibodies with higher affinities are produced over time, the stringency of 
this selection mechanism increases.  
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Interestingly, antibody secretion as a selection mechanism is also fundamental in inter-GC 
communication122, as antibodies secreted by short-lived plasma cells are able to infiltrate 
neighbouring GCs. However, this is not the only mechanism by which GCs communicate: Tfh 
cells are able to transit to and invade more than one GC and newly activated B cells can 
infiltrate pre-existing GCs123,124. This means that, while GCs have been evolved to separate 
sites of B cell maturation so that a variate immune response is present, not dominated by 
only a few clones and antigens can be targeted from different angles, coordination between 
different GCs is still achieved41. The final goal is that of producing as many antibodies with 
the highest affinity towards the highest number of epitopes of a given antigen. Targeting a 
pathogen from different angles is particularly helpful in the case of invasion from pathogens 
that are capable of rapidly escaping the immune responsible through antigenic variation41.  
 
B cell memory 
The neutralising antibody response has been historically recognised of main importance in 
providing protection to the host from invading pathogens. If the pathogen returns a second time 
after a first infection or vaccination, the humoral response responds with two features, that have 
been described by Kurosaki et al. as “constitutive humoral memory” and “reactive immune 
memory”24. 
The constitutive humoral memory is that provided that pre-existing antibodies that were already 
circulating in the blood stream of the patient, secreted by specialised antibody secreting cells, 
that is long-lived plasma cells. Upon re-infection, these antibodies bind to and neutralise the 
pathogen24. 
However, a reactive immune memory is also activated in the case of re-infection, and results not 
only in an increase of antigen-binding antibodies in the blood stream, but also in the rapid 
development of antibodies with new binding properties. Compared with the primary antibody 
response, the reactive humoral memory response is generally faster, results in greater magnitude 
and in antibodies with greater affinity and switched isotype24,125. 
The greater magnitude of the memory as compared to the primary response is mainly caused by 
the survival of memory B cells generated by the primary immune response. 
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It is worth mentioning that recent studies demonstrated the existence of different subsets of 
memory B cells: (i) germinal centre-independent memory B cells24,126,127 and (ii) unswitched IgM+ 
memory B cells128–130 in addition to (iii) the widely studied germinal centre-dependent switched 
memory B cells. These cell types will be illustrated in the following sections, after the mechanisms 
by which they originate are elucidated. 
 
Generation of T cell-dependent memory B cells 
In T cell-dependent B cell responses (Figure 1.8), antigen-activated B cells proliferate and 
differentiate into any of three cell types: (i) germinal centre-independent memory B cells, (ii) 
germinal centre-dependent memory B cells or (ii) extrafollicular short-lived plasma cells (already 
illustrated above)131. At this stage, isotype switching occurs, while SHM is not yet initiated. 
(i) Germinal centre-independent memory B cells 
While high-affinity cells present more peptide-MHC to cognate Tfh cells at the B cell-T cell border 
in the spleen or lymph node, receive more T cell help and are directed towards the germinal 
centre, those with lower affinity receive less T cell help and are therefore more likely to take a 
germinal centre-independent destiny. Because somatic hypermutation has not yet occurred at 
this stage, germinal centre-independent memory B cells reflect the specificities of the naïve B cell 
pool that initially responded. The maintenance of a low-affinity memory has the goal to enable 
the maintenance of cells with a potentially broad range of antigen specificity, thus providing 
protection to pathogens that bear antigens similar, but not identical, to those previously 
encountered. 
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Figure 1. 8: Generation of T cell-dependent B cell memory. Antigen-activated B and T cells migrate to the borders of 
the B cell follicles and the T cell zones in the secondary lymphoid organs, respectively. This leads to the establishment 
of a stable B-T-cell interaction and enables B cells to receive help signals from CD4+ T cells. Activated B and T cells 
then migrate to the outer follicles, where B cells undergo proliferation (a). Some of the proliferating B cells 
differentiate into short-lived plasma cells (b), and others develop into germinal centre-independent memory B cells 
(c). Alternatively, activated B cells can return to the follicle and undergo rapid proliferation to form the germinal 
centre (d). In the dark zone of the germinal centre, clonal expansion of antigen-specific B cells takes place together 
with BCR diversification through SHM. B cells exiting the cell cycle relocate to the light zone, where they are selected 
on the basis of affinity for the antigen through the interaction with FDCs and Tfh cells that are coated with immune 
complexes. Affinity-matured germinal centre B cells can re-enter the germinal centre cycle or exit the germinal 
centre, either as memory B cells (e) or as long-lived plasma cells (f) that contribute to B cell memory. The strength 
of signals received by a B cell determine its fate: stronger signals (bold arrows) favour plasma cell or germinal centre 
B cell development, while weaker signals (narrow arrows) determine memory B cell differentiation. TCR: T cell 
receptor. (From reference 24). 
(ii) Germinal centre-dependent memory B cells 
The precise mechanisms by which some of the germinal centre B cells are directed towards a 
memory phenotype are still unclear, as not a single master regulator of gene transcription has 
been identified to drive gene expression towards this differentiation. It is thus hypothesised that 
memory B cells differentiate randomly from germinal centre B cells into a memory phenotype.  
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Generation of T cell-independent memory B cells 
While the major, conventional B cell population in humans and mice, B2 cells, which arise from 
bone marrow precursor cells have been known for a long time to generate B cell memory 
responses, it was found that B1 cells are also able to generate memory B cells via immune 
responses independent from T cell help132–134. B1 cells are a self-renewing subset of mature B 
cells that are found in abundance in the pleural and peritoneal cavities. They recognise self-
components, bacterial antigens and are responsible for the production of baseline serum IgMs. 
These cells are also detectable, although at low frequency, in the spleen135. B1 cells seem 
responsible for providing antigen-specific B cell memory with binding features similar to those of 
the naïve cells from which they originated132–136. T-cell independent memory seems to be mostly 
responsible for broad specificity rather than high-affinity responses, and it is yet to be 
determined what selective advantage T cell-independent memory B cells have over naïve B cell 
counterparts, that is if they respond more rapidly and/or more robustly to a returning pathogen, 
as observed in the T cell-dependent B cell memory. 
 
Memory B Cell Diversity 
Several types of memory B cells are produced upon primary contact with an antigen, each one of 
them seen to have different functions137. It has been traditionally believed that there are two 
types of memory B cells, that is IgM+ and IgG+ cells, which are activated and take care of different 
tasks upon antigen reencounter138: 
(i) IgM+ memory B cells 
This hypothesis has been corroborated by recent works129,130 where it was seen that upon antigen 
reencounter IgM+ memory B cells undergo proliferation and re-enter the germinal centre 
reaction.  
(ii) IgG+ memory B cells 
While IgM+ cells are more prone to re-enter the germinal centre reaction, IgG+ memory B cells 
are more likely to differentiate into plasmablasts (PBs). However, it is not excluded that some 
IgM+ clones might differentiate into PBs, or some IgG+ clones re-enter the germinal centre 
reaction. 
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(iii) IgE+ memory B cells 
While IgE-mediated hypersensitivity is a key component of the pathogenesis of allergic 
diseases139, IgE memory B cells have not been detected in vivo in physiological conditions. 
However, it is possible that IgE memory responses of high affinity can be generated through class 
switching of IgG1+ memory B cells which already underwent affinity maturation140. 
This is particularly significant as an apparent lack of IgE+ memory B cells, but the possible 
observation of IgE memory responses requires us to reconsider the concept that memory B cells 
of a subtype are responsible for the memory response of that particular class exclusively24. 
 
Properties of memory B cells 
The main feature of the memory B cell response is its response to secondary antigen encounter 
after extended periods of time from the first response and its rapidity and intensity upon antigen 
re-exposure. These features are what makes vaccines successful. 
Let us look into these features more in details: 
 
(i) Stemness 
Haematopoiesis is a system that relies on the maintenance of a pool of somatic stem cells 
together with more differentiated progenitor cells141. The stem cells are not only responsible for 
the replacement of the progenitor cells as they differentiate, but also for the renewal of the stem 
pool. Some hypothesise24 that a similar mechanism might be used by the humoral memory 
system, which needs to efficiently produce effector cells upon antigen re-encounter but also to 
continue to maintain the memory pool. As it seems that the IgG+ memory B cell pool has a greater 
propensity to differentiate towards plasma cells than IgM+ memory cells, it is possible that while 
the IgG+ memory pool is more progenitor cell-like, with a propensity to differentiate towards an 
effective function, IgM+ clones might be responsible to replenish and maintain the memory pool. 
 
(ii) Longevity 
IgG+ memory B cells can survive independently in the absence of T cells , although it has been 
demonstrated in mice that the maintenance of the IgG+ memory B cell pool requires the 
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presence of FCDs142. In mouse models where the FDC activity had been impaired, the primary 
antibody response was unaffected, while the secondary was dramatically impaired with a 
decreased frequency of memory B cells specific for the antigen of challenge. These results were 
interpreted such that FDCs promote IgG+ memory B cell survival, by functioning as a reservoir for 
complexes of antigen-antibody-complement, although the specific role of antigen persistence in 
the memory responses is debated: if on the one hand the need for BCR signalling in the 
maintenance of IgG1+ memory B cell survival has been shown143, on the other hand genetic 
studies have demonstrated that presence of the antigen was not required to generate IgG+ 
memory B cells, implicating that only the presence of a tonic BCR signal is necessary to maintain 
the IgG+ memory pool144. 
As in terms of the different persistence of IgM+ versus IgG+ memory B cells, a mouse study by 
Pape and collaborators found that IgM+ memory B cells persisted for about 500 days after 
antigen priming, while IgG+ memory B cells declined over this time by many factors130. This could 
be explained as a difference in the self-renewal potential of the two B cell memory subtypes or 
by the existence of different cell survival mechanisms. 
However, in humans it seems that IgG+ memory B cells are more long-lived, and more stable over 
time. A famous example is that of IgG+ memory B cells specific for the 1918 pandemic strain of 
influenza virus that were found circulating in the blood of survivors as many as 90 years after 
primary exposure to the virus145. 
 
(iii) Responsiveness 
In T cell-dependent primary B cell responses, the production of high-affinity class-switched 
antibodies demands for the presence of both Tfh cells and FDCs. It is thus necessary to consider 
both intrinsic and extrinsic B cell mechanisms. 
The goal of vaccination is to induce memory B cells that differentiate very rapidly into 
plasmablasts which produce class-switched antibodies which have the ability to clear the 
infection more quickly than naïve B cells. 
To explain this difference in the speed of response, two models, non-mutually exclusive, have 
been postulated: (i) the BCR-intrinsic model hypothesises that the cytoplasmic domain of 
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membrane IgG1, with highly conserved 28 aa (as opposed to the 3 of IgM), is responsible for this; 
(ii) the BCR-extrinsic model hypothesises that other changes, e.g. alterations in the levels of 
expressed transcription factors can take place during priming and are responsible for this 
difference. Studies of nuclear transfer in mice146 have shown the importance of stimulation 
history (BCR-extrinsic model) for the responsiveness of IgG+ memory B cells, but do not exclude 
a role for the cytoplasmic domain of membrane IgG1, which on the other hand has been shown 
to dramatically enhance survival of B cells at the plasmablast stage147. 
 
(iv) Dependence on other cell types 
On the one hand, virus-specific memory B cells can be activated in the absence of T cells148, while 
on the other T cell help is necessary to reactivate memory B cells that identify monomeric protein 
antigens148,149. This is of particular interest considering that the vaccination approaches 
presented in this thesis include multiple administrations of monomeric Simian Immunodeficiency 
Virus surface protein (SU) gp120 monomeric antigens adjuvanted in alum. There exists evidence 
that in this kind of response, memory T cells in the secondary lymphoid tissue or in the peripheral 
blood help B cell activation112,150–155. These memory Tfh cells, in the spleen or lymph node, are 
found in the T cell zone as well as the B- T- cell border and in the B cell follicles152,155. The 
fundamental role of Tfh memory cells was demonstrated in a study by Ise and collaborators, 
where loss of memory Tfh cells abolished the reactivation of memory B cells and differentiation 
into plasma cells155. These results demonstrate how fundamental is the Tfh memory in inducing 
potent secondary antibody responses. The interaction between Tfh cells and B cells is due to the 
B cells presenting antigen via the MHC class II molecules on memory B cells149,156. Therefore, it 
seems that activation of memory Tfh cells by cognate memory B cells which are located next to 
each other in the secondary lymphoid tissue is a crucial determinant for the rapid activation of 
the humoral memory response. 
FDCs also contribute to the maintenance of the memory B cell and recall response142. It has 
historically been hypothesised that FDCs are capable of retaining antigens for long periods of 
time, although the role of antigen persistence in the memory response is debated, and the exact 
role of FDCs in memory B cell maintenance is unclear24. One possibility is that FDCs absorb 
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immune complexes in non-degrading endosomal compartments, where the antigen is protected 
from degradation, thus retaining its availability for B cells for long periods of time157. It is also 
possible that in a secondary response, FDCs contribute by presenting antigens very quickly, as 
exogenous protein molecules and invading pathogens are transported to FDCs rapidly, and this 
transport is accelerated by their binding to pre-existing antibodies secreted during the primary 
response, and the subsequent complement activation. Because IgG1+ memory B cells are located 
near to the contracted germinal centre, rich in FDCs, memory B cells are likely to capture the 
secondary antigen presented by FDCs very promptly149. 
 
(v) Re-diversification 
So far, we have mostly focused on the properties of IgG+ memory B cells. IgM+ memory B cells, 
on their part, can reinitiate germinal centre reaction upon antigen re-encounter158. These cells 
have increased ability to re-enter the germinal centre reaction where they undergo class 
switching and somatic hypermutation, thus having a role in the generation of higher-affinity IgG1 
antibodies129. To summarise, if on the on hand IgG1+ memory B cells are responsible of rapidly 
re-expanding the plasma cell response with antibody binding features similar to those of the 
primary exposure, IgM+ memory B cells are responsible for re-entry into the germinal centre and 
generation of new clones, with different binding properties to guarantee a multi-layered humoral 
immune response24. 
 
Memory B Cell Exhaustion 
It is worth mentioning that an imbalance of the memory B cell response occurs in the case of 
chronic viral infection, where there is a prolonged, high antigen load. Of this condition, HIV 
infection is a typical example. In chronic HIV infection, memory B cells are found to express 
several inhibitory receptors (e.g. immunoreceptor tyrosine-based inhibitory motif (ITIM)-
containing inhibitory receptor Fc receptor-like protein 4 (FCRL4), to be unable to differentiate 
into antibody-secreting cells, and to have impaired proliferation24,159. It seems then that memory 
B cells in chronic HIV infection are in an exhausted state. 
References taken from Origins of HIV and the AIDS pandemic, Sharp, Hahn 
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HIV Epidemiology 
AIDS was identified as a new disease in 1981, when increasing numbers of homosexual men 
started to display uncommon opportunistic infections and rare malignancies160,161. The cause of 
the disease was later identified as HIV-1, a lentivirus of the family Retroviridae which was found 
to spread mainly by the sexual route, although percutaneous and perinatal routes are also 
possible162–166.  
As of today, HIV has infected more than 70 million people and caused as many as 35 million 
deaths, with the highest impact in developing countries especially in sub-Saharan Africa. Globally, 
36.7 million people were living with HIV at the end of 2016167. If on the one hand ART has greatly 
reduced the toll of AIDS-related deaths, treatment requires administration of one pill a day and 
its access is not universal, especially in some parts of the world. That is why the development of 
an effective HIV vaccine is of importance to contain the increasing number of infections and HIV-
related deaths. 
 
From SIV to HIV 
Since its discovery, the sudden origin of HIV has been object of deep study. In 1986, a similar 
virus, although with antigenic differences, was identified as causative of AIDS in individuals in 
west Africa168. The virus, named HIV-2, was found to be only distantly related to HIV-1, but shared 
more genetic identity to a simian virus that resulted in immunodeficiency in macaques169,170. 
Soon other viruses indicated as SIVs were found in several primates in sub-Saharan Africa, such 
as African green monkeys, sooty mangabeys, mandrills, chimpanzees and others171. A suffix is 
added to SIV to indicate the primate species of origin (e.g. SIVcpz indicates SIV endemic in 
chimpanzee populations).  
Interestingly, these viruses were found to be largely non-pathogenic in the primate species they 
naturally infected. 
It was then identified that very close simian relatives of HIV-1 were found in the chimpanzee, and 
relatives of HIV-2 in the sooty mangabey monkey172,173. These genetic relations were considered 
as first evidence that AIDS resulted from zoonotic transmissions of SIV  from primates to 
humans171. Later studies suggested that AIDS in macaques was as well due to the cross-species 
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transmission of SIVsm (sooty mangabey) from African to Asian macaques. The cross-species 
transmission resulted in the generation of SIVmac, by the inoculation in US research centres of 
various species of macaques with biological samples derived from infected sooty 
mangabeys174,175. The origin of HIV-2 was instead identified as monkey-to-human transmission 
of SIVs from African primates176 and remained regional, while the global human pathogen HIV-1 
was acquired from chimpanzee-to-human transmission. 
So far, SIV infections have only been identified in African monkeys and apes, so it seems likely 
that they originated in Africa only after the split of Asian and African lineage of Old World 
monkeys, estimated to have occurred from 6 to 10 million years ago177. However, it is virtually 
possible that SIVs that infect Asian or New World (Central, South American and Mexican 
Monkeys) monkeys exist but have not been identified so far, so one must be cautious in 
concluding that SIVs are exclusively restricted to African primates171. The fact that the majority 
of monkey and ape species are generally infected by a largely species-specific strain of SIV 
indicates that most transmission occur among members of the same primate species, although 
natural cross-species transmission has been identified. For instance, SIVgor in gorillas seems to 
have originated from the transmission of SIVcpz to its great ape cousin, gorillas, some 100-200 
years ago178. Importantly, HIV-1 has likely originated from SIVcpz171 in chimpanzees. Evidence 
indicates that the subspecies of chimpanzees P. t. troglodytes acquired and evolved a chimeric 
form of two different SIVs from monkeys, presumably by hunting and eating different kinds of 
SIV-infected preys179. 
(refs from Heeney Science) 
Insights into host-to-virus adaptation  
Notably, lentivirus infection in chimpanzees is characterised by lack of CD4+ T cell loss, as well as 
the absence of generalised immune activation, in concert with the preservation of secondary 
lymphoid structure, especially considering MHCII APCs in infected lymph nodes180,181. Also, no 
anergy or marked loss of IL-2-producing CD4+ T cells after infection is detected182,183. These 
observations highlight the importance of maintaining normal levels of APC-CD4+ T cell 
interaction, which are the first symptoms of early immune disruption in AIDS-susceptible 
species181. 
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It is to be mentioned that CD8+ CTLs in chimpanzees are able to bind to highly conserved HIV-1 
Gag epitopes, which overlap with the epitopes that are bound and presented by HLA-B*57 and 
HLA-B*27 alleles in patients which slowly progress or do not progress to AIDS184. Phylogeny 
analysis of MHC class I alleles reveals a decrease of HLA-A, HLA-B and HLA-C lineages in 
chimpanzees as compared to humans. These findings are corroborated by the identification of a 
marked reduction in the MHC class I repertoire, especially in the HLA-B locus, by comparative 
analysis of intron 2 sequences185. These findings imply that chimpanzees might have experienced 
a selective bottleneck, possibly exerted by past lentiviral pandemics comparable to the present 
HIV-1 pandemic in humans179. One could hypothesise that, in the absence of antiretroviral 
therapy and prevention strategies, a positive selection for HLA-B alleles beneficial for long-term 
survival might results in humans186. 
It is however by now established that infected chimpanzees are relatively resistant to AIDS, not 
because they control viral replication187, but because many have the ability to avoid the 
immunopathological events that disrupt lymphoid tissue function in infected humans and Asian 
macaques181,183: while chimpanzee CD4+ T cells are susceptible to SIVcpz or HIV-1 infection and 
cytopathology, unlike humans or macaques, most infected chimpanzees maintain their ability to 
replace and sustain sufficient numbers of CD4+ T cells that preserve immunological integrity180. 
References taken from Origins of HIV and the AIDS pandemic, Sharp, Hahn 
HIV lineages  
It is important to mention that HIV-1 comprises four lineages, named groups, M, N, O and P, each 
one originated from separate zoonotic transmission of SIVcpz from infected chimpanzees to 
humans179. Group M (Main) was the first one to be identified, and is the most widely spread form 
of HIV-1: its infection of millions of people worldwide resulted in the current pandemic and has 
now been found in virtually every country in the World171; group O (Outlier) was identified in 
1990 and it represents less than 1% of global HIV-1 infections, being largely restricted to 
Cameroon, Gabon and neighbouring countries188–191. Group N (Non-M, Non-O), identified by 
Simon and collaborators in 1998, has been documented to have caused only 13 cases in 
Cameroon so far192,193. Finally, Group P, discovered in 2009 by Plantier et al., has so far been 
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described in only two patients, namely a Cameroonian woman living in France and another 
person from Cameroon171,194. 
Because all four HIV-1 groups, as well as SIVgor cluster with SIVcpz from central Pan troglodytes 
troglodytes chimpanzees, this subspecies was identified as the reservoir of human and gorilla 
infections Figure 1.9. The exact means by which SIV was transmitted to humans originating HIV-
1 are still unknown. However, based on the transmission mechanisms of these viruses, it is safe 
to hypothesise that transmission occurred through cutaneous or mucous membrane exposure to 
infected ape biological samples, such as blood or bodily fluids171, most likely in episodes of 
bushmeat hunting195 in the early 20th century (groups M and O) or later (groups N and P)196–198. 
These estimations are made using molecular clock methods: HIV-1 evolves at rates that are 
approximately one million times faster than human DNA199,200 because the reverse transcriptase 
responsible of synthesizing DNA for insertion in the human genome from viral genome RNA 
templates is error prone, and new generations of viruses are produced quickly during 
replication201,202. Phylogenetic and statistical analyses have dated the last ancestor of HIV-1 M to 
1910-1930171,196, with the early diversification of group M occurring most likely in the area around 
Kinshasa, the capital of Congo (then called Leopoldville, capital of former Zaire)171,203. 
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Figure 1. 9: HIV-1 origins and phylogenetic relationships of representative SIVcpz, HIV-1, and SIVgor strains. 
Relationships shown for a region of the viral pol gene. SIVcpz and SIVgor sequences are shown in black and green, 
respectively, while the four groups of HIV-1 (each of which originated from an independent cross-species 
transmission) are shown in different colors. White circles designate two possible alternative branches on which 
transmission occurred from chimpanzee to gorilla. Black circles denote the four branches where cross-species 
transmission to humans has occurred.  Brackets at the right denote SIVcpz from P. t. troglodytes (SIVcpzPtt) and P. 
t. schweinfurthii (SIVcpzPts), respectively. The scale bar represents 0.05 nucleotide substitutions per site (from 
reference 171). 
The M Group: A Global Epidemic 
As HIV-1 M spread, its dissemination was characterised by a number of founder events which led 
to the formation of different lineages (subtypes) that are now disseminated in different 
geographic areas. HIV M is categorised into nine subtypes (A-D, F-H, J, K) as well as more than 
forty circulating recombinant forms (CRFs) which originated by the superinfection of multiple 
subtypes of the same population204.  
Subtypes A and D, although originated in central Africa, are now mostly established in eastern 
Africa, while subtype C predominates in southern Africa and subsequently disseminated in India 
and other Asian countries; subtype B, which accounts for the majority of infections in Europe and 
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Northern and Southern America, seems to have originated from a single African strain that firstly 
spread in Haiti in the 1960s and then to the United States and other western countries 
thereafter205. 
CRF01, which is mostly spread in Thailand where it was identified in the late 1980s while causing 
a local heterosexual epidemic, probably originated from a single recombination event that took 
place in Central Africa. In the same period, the country was facing a subtype B epidemic in 
intravenous drug users204. CRF01 is now the dominant AIDS epidemic in southeast Asia171. 
The world distribution of the HIV M subtypes is reported in Figure 1.10, while the 2017 
prevalence of HIV amongst adults (age 15-49) is reported in Figure 1.11. 
 
 
Figure 1. 10: Global distribution of HIV-1 major subtypes and recombinant forms as published in 2003 by the 
International AIDS Vaccine Initiative206. Notably, Northern America, Europe and Australia record distribution of 
mainly B subtype, while the C and CRF02 subtypes are mainly distributed in the African continent. South-East Asia 
registers a distribution of largely C, B and CRF01 subtypes. 
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Figure 1. 11: Global HIV-1 infection situation and trends: since the beginning of the HIV M epidemic, more than 70 
million people have been infected with HIV and circa 35 million have died because of HIV-related complications. 
Globally, an estimate of 36.9 million people were living with HIV at the end of 2017. An estimated 0.8% of adults 
from age 15 to 49 are living with HIV worldwide. The African region remains the most severely affected, with 4.1% 
of adults (nearly 1 every 25) living with HIV and accounting for nearly two-thirds of the HIV-infected people 
worldwide. From reference207. 
Treatment of HIV infection 
Since the identification of HIV-1 as the cause of AIDS in 1983, significant progress has been made 
in the management of HIV infection. Combination ART was introduced as the standard treatment 
of HIV infection in the mid-1990s, and more than 30 agents have since been approved for the 
treatment of HIV-positive individuals. 
As of today, five main classes of combination ART drugs are approved208 (Table 1.2): One class 
contains drugs that interfere with viral entry into the cell (entry inhibitors) by binding to viral 
envelope proteins thus preventing attachment and entry into target cells; a second class contains 
agents that inhibit viral replication inducing chain termination after being incorporated into 
growing DNA strands (nucleoside reverse transcriptase inhibitors, NRTIs). A third class inhibits 
replication by binding directly to the reverse transcriptase (non-nucleoside reverse transcriptase 
inhibitors, NNRTIs). A fourth class contains agents that inhibit viral DNA integration into the target 
cell genome (integrase strand transfer inhibitors, INSTIs). Finally, the class of protease inhibitors  
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Table 1. 2: Available antiretroviral agents approved for use, reported as generic names/abbreviations (trade names). 
NRTI: nucleoside reverse transcription inhibitor; NNRTI, non-nucleoside reverse transcription inhibitor. From 
reference208. 
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(PIs) contains agents that inhibit the viral protease, leading to the formation of immature viral 
particles.  
Despite the many agents available to target diverse stages of the HIV cycle, current national and 
international guidelines now recommend regimens mostly based on the INSTI drug class in 
combination with reverse transcription inhibitors208,209. Administration of ART in this 
combination successfully and durably suppresses plasma HIV RNA levels, restores immunologic 
functions and reduces HIV-associated morbidity prolonging the duration and quality of survival, 
while also preventing HIV transmission208. However, different types of combinations can be 
recommended in particular cases, with drugs being sometimes combined into one pill210. 
Because of the marked improvements in ART potency, generally tolerable side effect profiles and 
relative simplicity of use211, ART has led to increased survival in people living with HIV212. 
Moreover, results from the HIV Prevention Trials Network (HPTN) 052 study have also clearly 
proven the efficacy of ART for prevention of transmission213, while TEMPRANO and START studies 
have shown that early ART initiation diminishes the risk of AIDS development and death214,215. 
 
Limits of HIV-1 infection treatment and need for vaccine 
While the development of AIDS after HIV infection can be now contained by treatment, ART has 
some limits: 
(i) Not a cure. As compared to when the epidemic was first identified, when HIV-1 
infection came with a death sentence on the patient, ART has greatly improved the 
life expectancy of HIV-infected individuals. Combination treatments can allow the 
infected person to lead a healthy life as long as they are under treatment, with blood 
viral loads suppressed to undetectable levels and CD4 counts maintained to healthy 
levels. However, as soon as the treatment is interrupted, viral load soon is restored to 
high levels thus allowing the patient to transmit the virus again216. 
(ii) Adherence. It is necessary that the patient adheres to the ART regimen. While the 
regimens used to be much more complicated than they are now, it is a great progress 
that nowadays ART treatment requires the patient to only ingest one pill a day. 
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However, this solution is still far from ideal and some groups of patients may find it 
difficult to adhere216. 
(iii) Distribution. Distribution of ART in certain parts of the world is difficult, especially 
when considering that the current regimen requiring the administration of one pill a 
day demands the constant distribution of large quantities of drug, with related 
transportation costs and difficulties to access remote areas. Distribution of ART is  
thus more difficult in developing countries217. 
(iv) Selected group lifespan gap. Some studies have identified a small but persistent gap 
in the lifespan of HIV-positive versus HIV-negative individuals belonging to key 
populations218,219. For instance, NA-ACCORD study data show that 20-year-old HIV-
positive adults in ART in USA or Canada have a life expectancy that approaches that 
of the HIV-negative population, although this benefit is not shared by individuals who 
are not white, have history of drug use, or began ART with low CD4 counts220. 
(v) Ageing. Because HIV-infected patients have an expected life span that is only slightly 
shorter if compared to that of uninfected individuals211, the effects of ageing on HIV-
positive people are now beginning to become evident since the introduction of ART 
in the mid-1990s221,222. Several disorders that typically affect the elderly population 
appear in relatively young HIV-positive individuals who can develop different 
pathologies including neurocognitive disorders, metabolic syndrome, cardiovascular 
diseases, bone abnormalities and non-HIV associated cancers223,224. Most of these 
age-associated diseases are caused, at least in part, by the chronic state of 
inflammation and immune activation that is observed typically in the elderlies225, 
often referred to as “inflammageing”226,227 or, in the case of the final phase of HIV 
infection, “inflammAIDS”224. This relatively new condition is extremely complex, and 
involves organs and systems other than those directly responsible for the state of 
constant immune activation224. Beside the behavioural risk factors, toxicity of anti-
retroviral treatments and the above-mentioned chronic inflammation have been 
identified as important factors promoting the development of such conditions, 
leading to a functional decline and a vulnerability to injuries or pathologies228. 
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In a scenario in which the elaboration of a definitive cure is proving extremely elusive, the 
development of a preventive vaccine to contain the HIV epidemic is of utmost importance. In the 
next chapters, I will summarise the progress made and challenges that persist in the development 
of an effective HIV vaccine. 
 
The HIV Envelope Glycoprotein 
The HIV Envelope glycoprotein (Env) is the single virally-encoded structure that is present on the 
surface of the viral envelope229. Functional Env is present as a non-covalently linked trimer of 
heterodimers, each one composed by the surface (SU) subunit gp120 and the transmembrane 
(TM) subunit gp41 (Figure 1.12)229. 
 
Figure 1. 12: Schematic representation of the HIV-1 Env. A) Representation of the major features of gp120 with the 
exclusion of the V1V2 loop; B) Model of gp120 with the inner domain represented in grey, the outer domain in red 
and the bridging sheet in blue. The CD4 binding site upon receptor engagement is represented in yellow cross-
hatching. The epitope of anti-CD4bs mAb VRC01 is in green. C) Cartoon of the Env trimer with indication of the main 
epitopes recognised by broadly neutralising antibodies. D) Molecular model of the Env trimer with glycans, where 
red represents the surface of gp120, yellow the CD4bs, purple the glycans and the epitope of anti-glycan broadly 
neutralising mAb 2G12 in grey. From reference229. 
The Env gp120 and gp41 subunits: mediators of viral entry 
The Env gp120 subunit is the component that engages receptor and coreceptors and initiates the 
entry process. Gp120 is composed of three domains: the inner and outer domains and the 
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bridging sheet (Figure 1.12B)230. Gp120 first establishes contact with the receptor CD4 and, 
subsequently, with either one of the coreceptors CCD5 or CXCR4229. However, optional 
engagement of integrin 47 through the V1V2 domain prior to receptor binding has also been 
described231 (discussed more in detail in the last section of this chapter). 
The CD4 binding site (CD4bs) on gp120 is accessible to CD4, but undergoes continuous 
conformational changes to escape the immune response of the host232. Upon CD4 engagement, 
gp120 is stabilised in a conformation that triggers structural rearrangements which ultimately 
reveal the coreceptor binding site (CRbs)229. 
Following coreceptor engagement by gp120, further conformational rearrangement within Env 
triggers gp41 activation leading to its refolding. It is currently accepted that gp41 penetrates the 
target cell membrane through the formation of a coiled-coil structure that brings the viral and 
cellular membranes into close proximity, leading to their fusion and finally entry of the viral core 
into the cell233,234. 
 
Env-specific antibodies as mediators of viral neutralisation 
Antibody-mediated viral neutralisation is a mechanism by which antibodies binding to a virus 
prevent it from establishing or carrying on infection by interfering with the biological function of 
the target antigen235. Because HIV Env products are the effectors of the processes of entry and 
fusion, neutralising antibodies targeting HIV elicit their effect by hindering the processes of target 
cell recognition and binding (in case of gp120-specific antibodies), or by hindering the fusion 
process (in case of gp41-specific antibodies)236. 
Neutralising antibodies are considered important for optimal protection against HIV since they 
are generally associated with protection against most viral infections237–239, and because they 
provide protection against AIDS virus infection in nonhuman primates240–242. However, the 
development of effectively neutralising antibody responses against HIV through vaccination is 
hindered by viral escape mechanisms from the humoral immune response that are described 
more in detail in the section below. 
Broadly neutralising antibodies (bnAbs) can be detected in approximately 25% of patients with 
untreated HIV infection243, as an immune response to continuous viral replication, with the 
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generation of high numbers of viral variants and exposure to continuously mutating antigens244. 
However, although these bnAbs exert some pressure as they develop, the viral burden is 
generally not reduced, with no significant improvement on the health of the patient and no 
delayed progression to AIDS245. 
 
Continuous research on neutralising antibody responses has led to the identification of multiple 
areas on HIV Env that can be targeted by bnAbs (summarised in Figure 1.13). However, four main 
areas are to date generally considered to be the main targets of broadly neutralising humoral 
responses229: (i) the CD4 binding site, (ii) quaternary epitopes, (iii) the glycan-coated V1V2 and 
V3 viral loops and (iv) the membrane-proximal external region (MPER). bnAbs targeting these 
areas reduce SIV replication in nonhuman primates246 and HIV-1 in humans247, and can prevent 
SHIV infection in nonhuman primates242,248. However, the infection is never cleared through bnAb 
treatment and bnAb monotherapy always results in viral rebound from outgrowth of low-
frequency resistant viral variants242,247 .  
 
Mechanisms of HIV Evasion from the Humoral Immune Response 
The defence mechanisms employed by HIV-1/SIV to escape the humoral immune response of 
the host have been widely studied. A number of structural features have been evolved by the 
virus to reduce antibody recognition of functional, conserved regions on gp120250. 
 
Integration 
Like all retroviruses, HIV/SIV replication goes through a proviral DNA intermediate which is 
integrated into the genome of the host251. Although the conversion of the viral single-stranded 
RNA into linear double stranded DNA may help stabilise the viral genome252, the integration of 
the viral DNA into the host genome permits HIV/SIV to persist for many years also in absence of 
viral replication and shielded from the cellular and humoral immune response253. In addition, 
integration into long-lived cells and the maintenance of a quiescent state allows viral persistence 
in spite of effective ART254. 
 
Chapter 1                                                                                                                                           Introduction 
   46 
 
 
Figure 1. 13: Advances in the identification of bnAb epitopes on HIV Env over time. Each panel depicts a key advance 
in the discovery or refinement of neutralising epitopes. This Env figure was adapted from the BG505 SOSIP.664 
trimer (PDB: 5cez), with gp120 coloured in light grey, and gp41 in dark grey. Epitope locations are indicated by red 
arrows, line and circles and are color-coded for each year as shown in each panel heading. Epitopes are highlighted 
only once in each protomer. A) By 2009, the knowledge on neutralising epitopes on Env was gained mainly by studies 
on bnAbs b12, 2G21, 2F5 and 4E10. B) By 2010, the trimer apex had been described following identification of bnAbs 
PG9 and PG16 in 2009, and the importance of the angle of approach to the CD4bs was highlighted by the discovery 
of VRC01 in 2010. C) The glycan patch epitope was then identified as a site of vulnerability by isolation of bnAbs 
PGT121 and PGT128 in 2011. D) From 2014, the discovery of PGT151, 35O22 and 8ANC195 revealed a neutralising 
area spanning the interface between gp120 and gp41. E) In 2016, bnAbs VRC34 and ACS202 were found to bind the 
gp41 fusion peptide. F) In 2018, bnAbs binding the highly glycosylated “silent” face of gp120 were described to target 
the CD4bs via novel contacts with the gp120 inner domain. From reference249. 
 
Amino Acid Sequence Variability 
The continuous remodelling of the gp120 and gp41 structure and function is necessary to escape 
the neutralising antibodies that are developed by the host. To do this, HIV-1/SIV carries an error-
prone reverse transcriptase which results in the insertion of mutations at every round of viral 
replication, which will in turn lead to sequence or structural modification of epitopes recognised 
by neutralising antibodies250.  
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Variable Regions  
Variable Regions on gp120 may have roles in engaging receptor or co-receptor, as well as 
providing means of escape from the humoral immune response.  
On the one hand, V3 is necessary for virus infectivity through co-receptor engagement, and 
deletion of this region completely abrogates viral replication255. This region is also able to escape 
the humoral immune response through the induction of high variability in its amino acid 
sequence, which is however restricted to about 20% of the positions. Notably, the length of the 
V3 loop is poorly variable, generally constant at around 34-35 amino acids256–262. 
In contrast, V2 is not essential for virus infectivity255, but its deletion results in loss of viral fitness, 
possibly because it participates in shielding the gp120 from antibodies targeting neutralising 
epitopes outside of V2 located in the V3 loop or the CD4 binding site263–266. 
REFERENCES BELOW FROM PANTOPHLET 2006 
 
Glycan Shields  
HIV/SIV can also use glycans to occlude epitopes on gp120, as about 50% of the molecule is 
shielded by carbohydrates that make the protein surface inaccessible to antibodies. This glycan 
shield has been dubbed “the gp120 silent face”267. Notably, the repositioning of glycans may 
affect local protein folding and indirectly affect binding of neutralising antibodies to distant 
epitopes; similarly, the repositioning of glycans may compensate for structural changes in the 




A viral escape mechanism by which non-protective antibodies would negatively affect the binding 
of antibodies to protective epitopes was initially proposed by Dulbecco et al. in 1956 on studies 
on western equine encephalitis virus and poliomyelitis virus268. This mechanism, named antibody 
interference, has since been investigated for SARS Coronavirus, Influenza Viruses and Hepatitis C 
Virus269–272. In the studies on these viruses, antibody interference has been hypothesised to be 
exerted by two possible molecular mechanisms: (i) steric hindrance, i.e. the physical covering of 
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the protective epitope by the Fc or Fab regions of the interfering antibody not directly interacting 
with the protective epitope or (ii) conformational changes, i.e. the induction of alterations in the 
three dimensional structure of the antigen that are propagated to a distant epitope that can thus 
not be recognized by protective antibodies. While the existence of antibody interference in the 
HIV-1 or SIV model has been proposed upon in vitro studies involving anti-HIV fusion glycoprotein 
gp41 mAbs273, to our knowledge the findings reported in this thesis are the first that identify this 
mechanism on viral envelope gp120. 
 
HIV vaccine clinical trials to date 
HIV presents an extreme ability to evade the host immunity, so much that the plausibility of 
developing an HIV vaccine has been questioned repeatedly since the start of the pandemic. 
Increasing evidence suggests that the early stages of transmission are those that are potentially 
vulnerable to a vaccine-primed immune response274. While animal and human studies have 
shown that envelope-specific antibodies correlate with reduced infection risk, cytotoxic T-
lymphocytes (CTLs) also have an important role in controlling viral load levels during natural 
infection, and therefore priming these responses with a vaccine could be useful275,276. It is 
hypothesised that an effective HIV vaccine will need to stimulate both B- and T-cell protective 
responses276. Although much progress is yet to be made to finally obtain an effective HIV vaccine, 
lessons can be learned from the partial or null protection observed in the large scale clinical trials 
performed so far. In the next sections, I will summarise the three vaccine concepts that have 
been tested for efficacy in humans: a gp120 Env protein to elicit cross-binding antibodies, an 
adenovirus vector eliciting CTLs, and a combined canarypox vector and gp120 protein eliciting 
both cellular and humoral immune responses. For the purpose of this thesis, particular attention 
will be dedicated to the latter. 
 
VAX003/VAX004 
The first phase III efficacy trials, of which the results were published in 2005 and 2006, tested the 
efficacy of bivalent gp120 protein in preventing HIV infection in men who have sex with men 
(MSM)277 and injection drug users (IDUs)278, respectively. No vaccine efficacy was recorded in 
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vaccinated as compared to placebo groups, although HIV incidence was lower in those individuals 
who developed stronger antibody responses276,279. Following analyses were unable to 
demonstrate that broadly neutralising antibodies, presumed a requirement for preventing 
infection in NHP, were elicited240,242,248,280,281.  
STEP Study 
The interest for the development of CTL-inducing vaccines was due to the fact that these 
responses have the potential to reduce viral load or delay disease progression. DNA plasmid and 
viral vectors have generally been observed as able to elicit T-cell responses276. An adenovirus 
type 5 vaccine (Ad5) inducing strong CTL responses (MrkAd5 by Merck) was studied in phase 2b 
to detect for vaccine efficacy in preventing infection. Merck and the HIV Vaccine Trials Network 
(HVTN) directed studies in North and South America and in South Africa282,283. However, these 
studies were stopped early in late 2007 when they were found to meet futility thresholds. Later, 
an increment in virus incidence was found in recipients who were uncircumcised and had prior 
immunity to the vector276,282. Although the study was unable to reduce acquisition or post-
infection viral loads, a sieve analysis on biological samples obtained from the study found that 
viruses infecting vaccine recipients were more likely to be antigenically different from the Env 
epitopes encoded by the vaccine284. This result suggests that T cell immunity plays a bottleneck 
on certain virus strains, allowing only for those antigenically distant from the immunisation 
strains to infect the patient. These data were the first evidence to suggest that a T cell vaccine is 
capable of exerting immune pressure on HIV276. 
 
HVTN 505 
In 2009, the clinical trial HVTN 505 started to test a vaccine regimen developed by the Vaccine 
Research Center (VRC) and the National Institutes of Allergy and Infectious Diseases (NIAID), 
which consisted of a DNA prime encoding for clade B gag, pol, nef and multiclade env genes 
followed by administration of recombinant Ad5 boost with gag, pol and env inserts of sequence 
matching those of the DNA prime285. It is to be noted that the VRC Ad5 vector was different from 
that employed in the Step study. However, lessons from the Step study were learned and 
uncircumcised individuals or patients with pre-existing anti-Ad5 neutralising antibodies were 
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excluded. HVTN 505 was opened to evaluate the VRC regimen in men and transgender women 
who have sex with men285, with a total of 2,504 participants. In 2013, HVTN 505 was discontinued 
because interim analyses indicated that the regimen was not efficacious276. 
 
RV144  
RV144 is the only phase III HIV vaccine clinical trial where some degree of protection from 
infection was ever demonstrated286. The study started in 2003, took place in Thailand and 
enrolled a total of 16,402 individuals, divided in a vaccine-receiving and a placebo group. The 
study was possible thanks to a large collaboration, being conducted by the Thai Ministry of Public 
Health, sponsored by the US Army Surgeon General, and managed by the US Military HIV 
Research Program (MHRP) together with Thai scientists, supported by the Thai and US 
governments, private companies and non-profit organisations. The immunisation approach used 
in this trial was designed to elicit immune responses against clades B and E, which circulate in 
Thailand. RV144 was designed to assess the ability of the vaccine to prevent HIV infection, as well 
as to reduce the level of viral RNA in the blood of infected vaccinees286,287. 
 
The effort of setting up RV144 in Thailand 
Thailand is among the first developing countries that was able to reduce the rates of HIV infection 
thanks to the intervention of the government, which focussed its efforts on promoting national 
and international collaborative research to develop and evaluate novel HIV/AIDS vaccines287. 
Despite this, AIDS is still a major cause of death in the 63 million people country, with more than 
one in 100 adults in the country infected by HIV288. After the first case of AIDS was detected in 
the country in 1984289, the virus spread rapidly especially amongst MSM, sex workers, IDUs and 
tourists, until its containment became a national priority in 1991287. However, as nowadays more 
than a half of new cases are transmitted between spouses, a vaccine should be designed to target 
both high- and low-risk groups. RV144 was the first trial designed to vaccinate a cross-section of 
risk groups in the country287. Volunteers were recruited from the provinces of Chon Buri and 
Rayong in the south-eastern region of Thailand. Both provinces were chosen for their high HIV 
incidence, good infrastructures and other favourable characteristics287,290. The statistical 
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assumption of the study required it to be performed on 16,000 subjects. Of the 16,402 finally 
enrolled, 61% were males and 39% were females, all between 18 and 30 years of age and 
randomised according to their sex, age and behavioural risks286. With 7 subjects excluded 
because of positivity to HIV on the day of the first vaccination, the remaining group was split in 
8197 vaccinated and 8198 placebo in a double-blind manner; the vaccines were administered 
through many health centres and facilities. 12,542 volunteers completed all the visits with 
negativity to HIV during the vaccination period286. 
 
HIV Clades in Thailand 
The vaccine regimen of RV144 was developed to match the clades circulating in Thailand, two of 
which are more present in the region: B and recombinant E/A strains. As previously mentioned, 
Clade B is predominant in Europe and America, although the increasing globalisation has caused 
a surge in non-B African and Asian variants287. In Thailand, historically, the epidemic initially was 
mostly caused by subtype B in IDUs291,292. A second epidemic of sexually-transmitted HIV 
followed, with the recombinant form CRF01-AE eventually becoming the dominant subtype (90% 
of the circulating HIV strains in this country belong to this subtype)287. 
 
Vaccination regimen 
The goal of the vaccine tested in RV144 was to induce HIV-specific CTL responses as well as cross-
binding, possibly neutralising antibodies to clades B and A/E. Two different immunogens were 
chosen to be used in combination, ALVAC-HIV and AIDSVAX B/E, to be used as prime and boost, 
respectively. 
(i) ALVAC-HIV 
ALVAC-HIV (virus recombinant Canarypox vCP1521) is a viral vectored vaccine able to elicit T-cell 
immunity287,293. ALVAC-HIV, used for priming, was developed by Virogenetics Corporation (NY, 
USA) and manufactured by Sanofi Pasteur. The Canarypox virus is an agent of disease in birds, 
demonstrated to be host-range restricted and safe because shown to effectively infect human 
cells but not to productively yield new generations of virus294–297. However, despite its abortive 
infection in mammalian cells, ALVAC can express and present foreign proteins298 that are 
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processed by MHC-I and MHC-II thus stimulating both cytotoxic (CD8) and helper (CD4) T cell 
responses299,300. As opposed to other poxvirus-based vectors such as modified vaccinia Ankara 
(MVA) virus and New York Vaccinia (NYVAC) vaccines, canarypox is not affected by pre-existing, 
vaccinia virus-specific immunity301,302 that was elicited by vaccination against smallpox in 
individuals born before 1977287. 
ALVAC-HIV used in RV144 was engineered to induce the expression, in transfected cells, of HIV-
1 Gag and Protease from the first HIV isolated, LAI (IIIB/BRU)162 and HIV-1 gp120 protein from 
clade E. Only subtype B gag was included in the immunogen because the gag gene is fairly 
conserved amongst HIV subtypes as compared to env303. The env gene, on the other hand, carried 
the same sequence of that identified in 92Th023, a recombinant form of clades A and E. In the 
ALVAC vCP1521 construct, gp120 protein from clade E gp120 was linked to the transmembrane 
(TM) portion of the gp41 from LAI (subtype B): gp120 TM. This region was added to anchor the 
gp120 to the cell surface. ALVAC-induced co-expression of Gag, Env and protease results in the 
formation of virus-like particles that are released from the cell membrane304. The vector was 
propagated in chicken embryo fibroblasts and administered at a dose of 1 million 50% tissue 
culture infectious dose (TCID50). The preparation was then lyophilised and reconstituted with 
sterile 0.4% NaCl. 
(ii) AIDSVAX B/E 
AIDSVAX B/E was used as a booster in RV144, and consisted of the recombinant envelope 
glycoprotein gp120-subunit vaccine. This vaccine was developed by Genentech and 
manufactured by VaxGene. The preparation contains a mixture of purified recombinant proteins 
expressed in Chinese Hamster Ovary (CHO) cells, that is the HIV-1 MN gp120 (subtype B) and the 
HIV-1 A244 gp120 (subtype E). AIDSVAX B/E was tested alone in a phase III clinical trial in 1998-
1999, but was demonstrated unable to prevent HIV-1 infection278,287. 
 
RV144 study design 
A total of six immunisations in the course of 6 months were scheduled (Figure 1.14): of which 
four with greater than 1 million TCID50 ALVAC-HIV in 1 ml intramuscularly in the left deltoid at 
weeks 0 (baseline), 4, 12 and 24 and two immunisations with 600 µg (50:50 of each antigen) in 1 
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ml AIDSVAX B/E in the right deltoid at weeks 12 and 24, at the same time of the final two ALVAC-
HIV administrations. In the placebo group, participants received ALVAC Placebo, a mixture of 
virus stabilisers and freEze-drying medium by Sanofi Pasteur and AIDSVAX Placebo, consisting of 
600 µg of alum adjuvant by VaxGen Inc. at the same time with the same route. All the volunteers 
were called for follow-up visits every six months for 3.5 years, with counselling for HIV prevention 
provided at each visit. 
  
Figure 1. 14: Immunisation regimen of the RV144 study, treated group. Patients underwent four administration of 
the viral vector ALVAC encoding for HIV-1 Gag and Protease from the first HIV isolated, LAI (IIIB/BRU)162 and HIV-1 
gp120 protein from clade E at week 0 (baseline), 4, 12 and 24. In the last two administrations also AIDSVAX was 
included, containing 600 µg each of two Env antigens from subtype B and subtype E isolates. ALVAC: ALVAC-HIV; 
AIDSVAX: AIDSVAX B/E; wk: weeks (Adapted from reference305). 
RV144 Protection Results 
Of the 16,402 subjects enrolled, 56 out of 8200 vaccinated and 76 of 8202 placebo were found 
positive for HIV RNA in blood286 which resulted in a small, but significant 31.2 vaccine efficacy (p 
= 0.04) with a 95% confidence interval286 (Figure 1.15). However, a more incisive difference of 
50-60% efficacy was identified between the groups at one year after immunisation, which 
suggested that the vaccine elicited protection which decreased over time. 
Notably, there was no effect on virus level or CD4+ T cell counts in the patients that were 
vaccinated and acquired the virus, which came as a surprise as viral control had been observed 
in rhesus macaques vaccinated and infected with SIV306,307. 
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Figure 1. 15: Kaplan-Meier cumulative rates of infection in RV144. Data reported are of the modified intention-to-
treat analysis. In this group, involving 16,395 subjects (excluding 7 subjects who were found to testing positive to 
HIV infection at baseline), the vaccine efficacy was 31.2% with a confidence interval of 95%, P=0.04). From reference 
286. 
Correlates of Protection  
RV144 effectively elicited binding antibodies against HIV-1 Env immunogens and p24 Gag, CD4+ 
proliferative responses (63%) as well as CD8+ T cell responses (24%), neutralising antibodies 
against subtype B and CRF01_AE viruses (96% and 71%, respectively) and antibody-dependent 
cell-mediated cytotoxicity308. 
The definition of the correlates of protection was limited by the limited sample availability, with 
those at peak immunogenicity, two weeks after the end of the vaccination process, being of 
course the most sought after. The analysis of 41 HIV-infected, vaccinated cases and 205 
uninfected, vaccinated controls to identify correlates of protection identified two immune 
responses: (i) serum IgA binding to 14 HIV-1 envelopes negatively correlated with protection; (ii) 
IgG binding to a gp70 V1V2 Case A (subtype B) scaffold positively correlated with protection309,310. 
Of note, IgA levels were not found to enhance infection, but rather to undo the positive effects 
of vaccination. On the other hand, IgG avidity, antibody-dependent cellular cytotoxicity (ADCC), 
neutralising antibodies (nAbs) and cytotoxic responses were not found to correlate with the rate 
of HIV-1 infection. In the setting of low anti-Env IgA, increased correlation with protection was 
also observed for ADCC and nAbs311,312. 
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V1V2 gp70, a subtype B V1V2 region attached to the murine leukaemia virus gp70 protein310, was 
chosen as a reagent to be tested because preliminary data of serum antibody binding to linear 
overlapping peptides encompassing the whole sequence of HIV-1 Env demonstrated binding to 
the V2 region308. In addition, in the 47 integrin binding site data showing that mAbs 
recognising conformational epitopes within V2 would block RV144 sera binding to gp120313. 
In addition, viruses isolated from HIV-1 positive individuals in vaccine and placebo groups were 
analysed to define if an association could be found between particular viral types and the receipt 
of vaccine (sieve analysis)279,284,314–316: viral strains that matched the vaccine sequence, which 
contained a lysine at position 169 (K169) within V2 were found to be blocked by vaccination, as 
viruses mismatched with position 181. These findings strengthened the hypothesis that 
antibodies directed to V2 correlate with protection from viral infection. In addition, the mAbs 
CH58 and CH59 cloned from vaccine recipients were found to bind within V2, in a region that 
partially overlaps the binding site of bnAbs CH01 and PG9, although these two mAbs were only 
weak virus neutralisers; both mAbs CH58 and CH59 were found to bind to position 169, and, 
although non-neutralisers, were found to mediate ADCC308. 
[ 
The interplay between V2 and 47: an underlying mechanism of protection? 
As previous studies have demonstrated that the C-terminal region of the V2 domain of gp120 
interacts with the integrin 47231,317,318, in this section I will summarise the role of this integrin 
in HIV infection. In addition, structure and function of 47 and the V1V2 domain on gp120 will 
be reviewed. Finally, I will summarise the current knowledge on the interactions between 47 
and the HIV/SIV Env. 
FROM ARTHOS REVIEW 
The gut tropism of HIV 
A significant feature of acute HIV infection is substantial viral replication in the gut-associated 
lymphoid tissue (GALT), with high-level depletion of gut CD4+ T cells319. This gut-directed tropism 
of HIV is accepted to play a fundamental role in the late development of immune deficiency. In 
addition, rapid CD4+ T cell loss is accompanied by significant damage to the structural integrity 
of the gut, which has been identified as a cause of chronic systemic immune activation320,321. 
Chapter 1                                                                                                                                           Introduction 
   56 
While ART significantly extends the life of individuals infected with HIV, treatment does not fully 
reverse the early damage to the structural integrity of the gut, nor does it allow full 
replenishment of the CD4+ T cell reservoir in GALT322. However, in addition to replicating in GALT, 
HIV also replicates in the peripheral lymph nodes, the spleen and other tissues and organs323. 
 
47 and immune cell gut tropism 
Immune cells migrate to and from the GALT through the regulation of receptors that control cell 
trafficking. 47, a prime mediator of gut homing, is comprised of a 180-kDa  chain (4) and a 
130-kDa  chain (7). 47 is expressed on the cell surface of subsets of B cells, CD4+ and CD8+ 
T cells, NK cells and macrophages. While both 4 and 7 can pair with other integrin chains, 47 
is central in promoting lymphocyte trafficking to the GALT through the interaction with mucosal 
addressin cell adhesion molecule (MAdCAM). This molecule is expressed on the surface of high 
endothelial venules of gut inductive sites, as well as in the gut lamina propria. In addition, 47 
is also found on the surface of FDCs in mesenteric lymph nodes324. However, because most of the 
naïve and a subset of memory CD4+ T cells express 47 while circulating in the peripheral 
lymphoid tissue, it is the tissue-specific expression of MAdCAM in the gut that defines 47 as a 
gut homing receptor323. 
Upon ligation, 47 delivers intracellular signals that results in the extravasation of the cell 
through the venules and into the gut tissue323,325. 
  
Chapter 1                                                                                                                                           Introduction 
   57 
47 and viral gut tropism 
A growing number of viruses have been shown to directly interact with integrins, including foot-
and-mouth disease virus, Kaposi’s sarcoma-associated herpesvirus, herpes simplex virus-2, 
adenovirus, human papillomarivur-16, reovirus, and others326. Certain rotaviruses as well as HIV 
and SIV engage 47231,327–329. For HIV and SIV, this interaction is mediated by gp120323. The 
identification of an interaction between HIV and 47 provided new insights into the gut-tropic 
nature of HIV and SIV231. However, this integrin is not fundamental for entry into target cells and 
its exact role in HIV pathogenesis remains to be fully elucidated323. 
HIV gp120 is covered by a variable number of N-linked glycosylation sites, which are found to be 
lower in number in viruses isolated in the first months after infection265. It seems, thus, that in 
the early stages of infection selection is exerted against heavily glycosylated quasispecies323. In 
addition, glycan removal enhances binding of gp120 to 47, allowing for the hypothesis that 
47high memory CD4+ T cells are early targets of infection in the immediate period following 
mucosal transmission330. Studies in the macaque model have shown that 47high memory CD4+ 
T cells are quickly depleted upon mucosal transmission of the virus323. Amongst the cells bearing 
this phenotype, Th-17 cells have been implicated as early targets of infection323. Notably, Sivro 
et al. reported that 47high memory CD4+ T cells are preferentially depleted in the first two 
weeks following infection in HIV-infected women331. In addition, both in human and in the 
macaque model 47high memory CD4+ T cells in blood and in the cervical tissues is associated 
with increased susceptibility to acquisition332,333. It seems therefore 47 plays a central role in 
the early stages of infection. 
 
Anti-47 mAbs in HIV/SIV treatment and prevention 
The first observation that demonstrated that anti-47 mAb treatment could result in controlled 
viral infection were provided by Ansari et al., when macaques treated with anti-47 mAb 3 days 
prior and 3 weeks following intravenous SIVmac239 infection exhibited delayed peak SIV RNA 
and lower plasma SIV RNA level in the chronic phase as compared to untreated control 
macaques334. In addition, the authors found that treatment reduced the amount of virus in the 
GALT and preservation of peripheral CD4+ CCR5+ T cells. Notably, while control animals developed 
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AIDS 60-80 weeks after infection, in treated animals symptom onset occurred 5 years after 
infection323. Finally, CD4+ T cells in colorectal biopsies recovered to almost pre-infection levels at 
more than 60 months post infection after an initial loss during the acute phase of infection335. 
Therefore, treatment with anti-47 mAb resulted in durable effects that were able to limit 
damage to gut tissues and preserve CD4+ T cells for an extended period of time. In addition, the 
authors concluded that early virus replication in GALT and consequent inflammation and damage 
of gut tissue plays a role in the course of the disease throughout the years following infection.  
 
47high memory CD4+ T cells co-express multiple HIV susceptibility markers, with CCR5 
expression being directly correlated with the levels of 47 on these cells336. These features, 
which make of these cells favourable targets of infection, suggest that sexually transmitted 
HIV/SIV may infect 47high memory CD4+ T cells in the rectal mucosa, and that these infected 
cells proceed to migrate to the GALT323. Alternatively, it is possible that after a local bout of 
replication in the rectal mucosa, the virus envelope incorporates cell 47 during budding, and 
virus-associated 47 mediates virus adhesion to ligand MAdCAM on high endothelial venules. 
To determine if interfering with 47-mediated infection spread would reduce the efficiency of 
mucosal transmission of SIV, Byrareddy et al. tested the effect of an anti-47 mAb in preventing 
intravaginal SIVmac251 infection in macaques327. Briefly, animals were pre-treated with anti-
47 mAb at 50 mg/kg or control IgG mAb, then challenged weekly until 10 out of 12 control 
animals were determined to be infected. After six challenges, 10/12 controls resulted infected, 
while 6/12 treated macaques remained uninfected (Figure 1.16). While the specific mechanisms 
underlying protection are to be elucidated, anti-47 mAb treatment did not alter the number 
of CD4+ T cells in the vaginal compartment, although it did mask >99% of 47 in the 
compartment. 
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Figure 1. 16: Kaplan-Meier curves of infection in groups (n=12) of macaques treated with vedolizumab (blue line) or 
with a polyclonal rhesus macaque IgG preparation (red line, negative control). The treated group revealed delayed 
acquisition after SIVmac251 challenge as compared to the control group. From reference327. 
The authors proposed three mechanisms which might have contributed to reduced infection in 
the treated group. Anti-47 mAb might have interfered with (i) infected T cell trafficking by 
blocking of 47 binding to MadCAM, (ii) SIV Env interactions with 47 and/or (iii) 47-
mediated signalling on CD4+ T cells, by MAdCAM or V2. 47 signalling through V2 or MAdCAM 
binding is in fact responsible for LFA-1 activation, an integrin which plays a central role in the 
establishment of virological synapses231. 
It is however not understood if 47+ cells contribute to the establishment of long-term viral 
reservoirs, and if treatment with 47 antagonists can play a role in reducing the size or 
durability of those reservoirs323. 
 
Anti-47 mAb has also been tested as an adjunctive therapy to ART. Current ART is highly 
effective in allowing viremia control for an extended period of time, but since the viral reservoir 
persists during ART, the vast majority of HIV-infected individuals remain on therapy indefinitely 
to prevent blood viral load rebound. In addition, ART does not fully resolve the state of chronic 
immune activation which is associated with HIV infection. Given the previously discussed capacity 
of anti-47 treatment to control viremia in SIV-infected macaques in the absence of ART327,334, 
the anti-47 mAb was used as an adjunctive therapy to ART. Fifteen rhesus macaques  were 
placed on ART at 5 weeks post SIVmac239 infection337. Four weeks later, eight animals underwent 
the first out of eight anti-47 mAb infusions, while seven control animals received irrelevant 
IgG. After nine weeks, ART was terminated.  
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The seven animals that received ART and control IgG showed significant plasma viral rebound, 
while all of the eight ART- and anti-47 mAb- treated animals controlled plasma viremia to low 
or undetectable levels. This control persisted for more than three years, with intermittent blips 
of viremia in some of the animals, while blood CD4+ T cell counts were restored to near pre-
infection levels, with a significant recovery of gut CD4+ T cells. 
PET/CT image analyses determined that the addition of anti-47 mAb reduced the number of 
infected cells in gut tissue as compared to ART alone during the dual therapy period335. However, 
because ART alone is already able to suppress plasma viremia, the mechanisms by which anti-
47 mAb reduced the number of gut infected cells beyond the levels achieved by ART is still 
unclear. Notably, upon interruption of ART and anti-47 mAb the reduction of infected cells in 
the gut persisted. In addition, an increase in NKp44+ cells was observed335,337,338. In terms of 
adaptive immune response, no significant difference of CD8+ T cell activity was found in the two 
groups, and none of the animals generated neutralising antibodies. Finally, all eight of the anti-
47 mAb-treated animals developed measurable anti-V2 antibody responses, while only 3/7 
controls developed antibodies with similar specificity. These antibodies were found to block 
SIVgp120 binding to 47323. 
Despite this wealth of results, defining a clear picture of the mechanisms ultimately responsible 
of control in ART-, anti-47-treated macaques remains a challenging task. 
 
47 as a ligand of gp120 
Arthos, collaborators and others have demonstrated that both HIV and SIV recombinant 
envelope proteins are able to engage the gut homing receptor integrin 47231,317,318,339, 
suggesting that there could be a causal link between the gut-tropic characteristic of HIV/SIV 
infection and the physical interaction between SU and the integrin. However, the specific role of 
this interaction in HIV/SIV entry is not completely understood. It is established that 47 is not 
an entry receptor, as it is not required for cell infection340,341. Possibly, 47 functions as an 
attachment factor342, that is as a lightning rod that, protruding from the cell surface three times 
in length of CD4, takes viral particles closer to cell surface to initiate receptor and coreceptor 
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engagement. It has been reported that gp120 binding to 47 also transduces signals to CD4+ T 
cells that might favour infection in vivo231,340. 
47 is present on the cell surface of naïve as well as memory CD4+ T cells343 and, as mentioned 
above, it is a heterodimer built up by an 4 and a 7 chain344,345. Notably, 47 is structurally 
dynamic and can adopt as many as three conformation states, controlled intracellularly, of which 
two are extended and able to mediate adhesion of the lymphocytes346,347. Besides MadCAM, 
47 is able to bind to VCAM, which is also present in the vascular endothelium348. 
 
V2 structure in the interaction with 47 
A number of studies have demonstrated that the C-terminal region of V2/gp120 interacts with 
47231,317,318. Arthos and collaborators demonstrated that site-directed mutagenesis of HIV 
gp120 in the tripeptide motif L179D180V/I181  (DLV in SIV) plays a fundamental role in the 
interaction231. Notably, the motif is similar to binding epitopes in MAdCAM (LTD), VCAM (IDS) 
and the fragment IIICS of fibronectin (LDV). The common feature of each motif is a core Asp 
flanked by an aliphatic residue. Of note, in each of the natural ligands the Asp coordinates with 
a Mg++ ion that is located in the metal ion-dependent adhesion site (MIDAS) of 7. The presence 
of an Mg++ ion is required for ligand binding346,349. Cardozo and collaborators identified amino 
acids QRV (170-172) in the V1V2 domain to also influence the V2-47 interaction, thus proving 
that the binding site in V2 is not limited to the LDV/I tripeptide exclusively318. Notably, the two 
regions of V2 are flanked by N-linked glycosylation sites (PNGs), and removal of the glycans 
through enzymatic digestion can increase binding of recombinant gp120 to 47350, possibly 
allowing better access of the integrin to the integrin-binding site, or by driving the conformation 
of V2 into a more accessible structure.  
Because the conformation of the V2 domain is structurally dynamic, this portion was deleted 
from the recombinant proteins used to generate the initial high-resolution structures of gp120 
cocrysallised with mAb230,267. Both protein scaffolds and linear peptides were used to determine 
the conformation of V2, and showed that the domain was prone to adopt a -strand 
conformation in the former, and an -helix conformation in the latter setting. 
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-strand Evidence 
Cryo-election microscopy and X-ray diffraction analyses indicate that the V2 domains at the apex 
of the trimeric envelope spike appear in a -strand, in the context of a -barrel, in accordance 
with the structures derived from monomeric gp120 subunits and scaffolded constructs in 
complex with conformation-dependent mAbs351–357. The first V2 structure obtained presented 
V1V2 on a scaffold named 1FD6 in complex with PG9, a broadly neutralising, glycan-dependent 
mAb355 (Figure 1.17). It is in this setting that V2 first appeared in the context of a Greek key motif, 
also comprising the V1 loop. It became clear that, structurally, V1 and V2 were both building up 
a region termed the V1V2 domain. Another study where the 1FD6-V1V2 domain in complex with 
mAb 830A provided more detail and revealed V2 in a similar beta barrel conformation354. 
However, high-resolution crystal structures allocate the LDV/I tripeptide in a buried region that 
would seem inaccessible to the integrin355, and it would be reasonable to conclude that the 
context in which 47 and V2 are engaged must involve a rearrangement of the structures, with 
an alternative presentation of V2. 
 
Figure 1. 17: Overall structure of the 1FD6-scaffolded V1V2 domain of HIV-1 gp120 in complex with mAb PG9. V1V2 
from the CAP45 strain of HIV-1 is shown in magenta ribbons, in complex with the Fab of the antibody PG9, with the 
heavy and light chains shown as yellow and blue ribbons, respectively, with CDRs in different shades. Although the 
rest of HIV-gp120 has been replaced by the 1FD6 scaffold (white ribbons), the positions of V1V2, PG9 and the scaffold 
are consistent with the proposal that the viral spike is positioned towards the top of the page. The disordered region 
in the V2 loop is represented by a dashed line. From reference355. 
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-helix evidence 
When a linear V2 peptide is left unconstrained from a scaffold or protein context, it is capable of 
adopting -helical and coiled structures358. This was observed with two mAbs isolated from a 
patient enrolled in RV144 that remained uninfected. The two mAbs, namely CH58 and CH59, 
were analysed in complex with a linear V2 peptide derived from the gp120 of HIV isolate 
92TH023359. Notably, the two mAbs displayed only weakly neutralising properties and were 
found to recognise a helix (CH58) and coiled (CH59) structure359 (Figure 1.18). Notably, the CH 
mAbs recognise epitopes that are overlapping and that include the region of V2 spanning from 
aa168-181, which also contains residues K169 and I181 that sieve analyses identified as sites of 
vaccine-elicited immune pressure in RV144316. 
 
Figure 1. 18: Vaccine-elicited mAbs CH58 and CH59 recognise alternative conformations of V2 peptide. Left: Ribbon 
representation of the CH58 Fab in complex with a V2 peptide. The sequence of the A244 peptide is shown, with 
modelled residues in green. Orange: HC; blue: LC. Right: structure of CH59 in complex with peptide, as depicted on 
the left. Tan: HC; light blue: LC. From reference359. 
More V2-specific mAbs with a preference for helical structures in V2 have been identified: 
Lertjuthaporn and collaborators recently described Mk16C2, a mAb that was obtained from an 
immunised rabbit (Figure 1.19)360. The mAb binds the same structure as CH58, but from a 
different angle. It is important to note that helix-preferring mAbs are not only elicited by 
vaccination, but can also be induced by infection. It is the case of CAP228-16H, which was derived 
from an infected subject and which was found to recognise a V2 helix structure very similar to 
CH58361. 
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Figure 1. 19: Crystal structure of rabbit mAb Mk16C2 in complex with a V2 peptide. Only the Fv region are shown. 
Cyan: HC; green: LC; magenta: peptide. From reference360. 
To summarise, mAbs reacting to the region of V2 spanning from amino acids 153 to 194 have 
been described to recognise two types of epitopes: mAbs like PG9 and 830A recognise a 
constrained (sheet), and those like CH58 recognise an unconstrained (helical or coiled) structure. 
 
In this thesis, I investigate the immunological mechanisms that mediate protection from SIV 
infection in rhesus macaques. 
 
In Chapter 2, I address the hypothesis that anti-V2 antibodies might exert a protective mechanism 
by reducing viral uptake mediated by binding of gp120 to integrin 47. More specifically, I 
characterised a set of mAbs that I isolated from a rhesus macaque vaccinated in an RV144-like 
fashion and which resulted in protection from repeated low-dose intrarectal SIVmac251 
challenge. The biologic activity of these mAbs was then investigated for binding, neutralisation 
properties and ability to block 47-to-V2 interaction. These studies were informative in the 
definition of the humoral responses to SIV vaccination and also the study of viral features. 
 
In Chapter 3, I carried out on rhesus macaques a vaccination approach aimed at increasing the 
efficacy of RV144 by changing the viral vector used in the prime-boost vaccine protocol. The 
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outcome of this study provided further insights into the nature of the immune response needed 
to achieve protection from a primate lentivirus.  
 
Finally, in Chapter 4 an anti-V2 mAb was tested for its ability to provide protection in passive 
immunisation settings on a group of rhesus macaques then challenged intrarectally with 
SIVmac251. The results allow for a few considerations to be made on the desirable immune 
responses that are to be elicited by a protective vaccine. 
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CHAPTER 2: Isolation and characterisation of monoclonal antibodies  
targeting the V2 region of gp120 from vaccinated macaques  
protected against SIVmac251 acquisition 
 
Introduction 
The RV144 Thai trial was the only HIV-1 vaccine trial to ever demonstrate protection, although 
limited to 31.2%, from viral acquisition in a cohort of 16,402 individuals 286. In the enrolled 
vaccinees, antibody levels targeting the V2 region of the viral surface glycoprotein gp120 
correlated with decreased risk of HIV-1 infection309. Similar findings were reported in rhesus 
macaques (Macaca mulatta), where an RV144-modeled vaccination schedule provided 40% 
protection from SIVmac251 in a group of 27 animals as compared to historical and concurrent 
controls. In line with the results of RV144, mucosal IgG responses targeting the V2 region of 
gp120 were associated with delayed viral acquisition362.  
Here we investigate the hypothesis that the molecular mechanism behind this correlation is that 
anti-V2 antibodies may inhibit the binding of this region to the integrin 47 which, protruding 
for as many as 22 nm out of the cell surface, may capture and lead free viral particles closer to 
the cell membrane thus enhancing their likelihood of engaging receptor CD4 and coreceptors 
CCR5/CXCR4363. 
The structure of V2 has proven elusive to characterise: in complex with the poorly neutralising 
monoclonal antibodies (mAb) CH58 and CH59, derived from RV144 vaccinees, V2 peptides 
acquired helical conformations 359. In contrast, the crystal structure of a V2 scaffold in complex 
with the mAb PG9 revealed that V2 and V1 form a four-stranded Greek key motif -sheet domain 
(V1V2 domain)355.  
The putative site of interaction between 47 and gp120 was identified as the LDI/V motif in HIV 
(DLV in SIVmac251, hereon referred as “tripeptide”), located in the V2 loop connecting the C and 
D  strands of the V1V2 domain 231. However, it is not clear if the tripeptide, necessary for the 
engagement of 47, interacts directly with the integrin or is necessary to maintain the 
conformation of the V1V2 domain with points of interaction with 47 located elsewhere in the 
domain. The notion that V1V2 conformation is necessary for 47 engagement is supported by 
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the observation that mutations in a region (defined by the authors as “cryptic determinant”) 
located distant from the tripeptide can disrupt binding to 47 318.  
Here, I isolated a set of weakly neutralising anti-V2 mAbs from an RV144-like vaccinated rhesus 
macaque which resisted multiple rounds of intrarectal SIVmac251 challenge. I then determined 
binding activity of the mAbs and their ability to inhibit binding of SIV gp120 to human 47 was 
evaluated. Our findings provided insights into the humoral response to SIV immunisation in 
rhesus macaques as well as on the structural plasticity of V2. 
 
Materials and Methods 
 
1J08 V1V2 scaffolds 
The protein scaffold 1J08, was previously demonstrated to present the SIV Env V1V2 domain in 
the conformation naturally found on the native V1V2 protomer basing on stable expression, clash 
score and solvent accessibility, was used to identify V1V2-specific B cell clones and produced as 
described in 364. The expression vector pVRC8400 encoding the C-terminal His-tagged, avitagged 
1J08-scaffolded SIVmac251-M766r or SIVsmE543 V1V2 sequences (GenScript) was used to 
transfect 293Freestyle (293F) cells with 293fectin transfection reagent (Life Technologies) 
following the company’s instructions. 6 days post-transfection, cell culture supernatants were 
harvested and filtered through 0.22 µm filter and supplemented with protease inhibitor tablets 
(Roche). The constructs were passed through a NiSepharose excel affinity media (GE Healthcare) 
and further purified with size exclusion chromatography (SEC) on a HiLoad 16/600 200 pg 
Superdex column (GE Healthcare). 
 
Rhesus macaque P770 
P770 is a colony-bred rhesus macaque obtained from Covance Research Products (Alice, TX) 
previously included in an RV144-like vaccination study (Figure 2.1)362. Briefly, P770 was 
immunised at weeks 0, 4, 12 and 24 with intramuscular inoculations of 108 plaque-forming units 
(PFU) of ALVAC (vCP2432) expressing SIV genes gag-pro and gp120TM (Sanofi Pasteur).  
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Figure 2. 1 A) Immunisation and virus challenge schedule of macaque P770. P770 underwent an RV144-like 
vaccination regimen (blue box) based on the administration of two ALVAC-SIV primes and two ALVAC-SIV + 
monomeric gp120 boosts followed by RLD intrarectal SIVmac251 challenge [3]. Four months after the last viral 
exposure, P770 was enrolled in a second round of immunization consisting of 9 monthly ALVAC-SIV + monomeric 
gp120 boosts (hereon referred as hyperboost phase, green box). 38 weeks later (approximately 9 months) the animal 
underwent a second round of RLD SIVmac251 intrarectal challenges and resulted uninfected. Red Arrow: time at 
which frozen B cells were used for antibody cloning, 2 weeks after the 7th hyperboost. B) Anti-SIVmac251 gp120 
serum antibody titres of P770 and four other animals P888, P651, P878 and R251 remained high throughout the 
immunisation, challenge phases. Solid arrows: immunisation; dashed arrows: viral challenge; grey arrows: 
immunisation prime; Grey boxes: challenge and immunisation phases, as indicated by the arrows. 
The sequence of the SIV genes was that of M766r, a mucosally transmitted founder variant of 
SIVmac251. At weeks 12 and 24, the animal was administered in the thigh opposite to that of 
vector immunisation a protein boost of 200 µg each of monomeric SIVmac251-M766 gp120-gD 
and SIVsmE660 gp120-gD CG7V both formulated in alum. At week 28, four weeks after the final 
immunisation, the animal underwent a challenge phase of 10 low-dose intrarectal 120 TCID50 
SIVmac251 administrations, and remained uninfected. 
At week 53, P770 underwent a second round of 9 immunisations (referred in the text as 
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week 131, the animal was challenged as in week 28, with 10 repeated administration of 
intrarectal 120 TCID50 SIVmac251 administrations, and again remained uninfected. Measurable 
anti-gp120 serum antibody titres were then detected for more than a year after the second 
challenge round. 
Monoclonal antibodies 
Single antigen-specific B cells were isolated with the assistance of Richard Nguyen, Vaccine 
Research Center, NIH, Bethesda, Maryland, USA. The rest of the protocol was carried out by the 
author with the kind assistance and supervision of Dr. Rosemarie Mason, ImmunoTechnology 
Section, Vaccine Research Center, NIH, Bethesda, Maryland, USA. 
The mAbs ITS01, ITS12.01 (hereafter referred to as “ITS12”), ITS09.01 (“ITS09”), ITS03 and ITS41, 
isolated from an SIVsmE660-infected rhesus macaque, were kindly provided by Dr. Mario 
Roederer (ImmunoTechnology Section, Vaccine Research Center, NIAID, NIH) 364; ITS01 
recognises an epitope located in the CD4bs of SIV gp120 and was used as negative control in 
ELISA binding experiments of mAbs to V2; ITS12 and ITS41 bind epitopes located within the V2 
loop. The mAbs NCI05 and NCI09 were isolated from the hyperimmunised, protected rhesus 
macaque P770 following the methods described364. Briefly, frozen P770 PBMCs from week 85 
(two weeks after the 7th hyperimmunisation) were thawed and stained to allow the phenotypic 
identification of CD20+, CD3-, CD4-, CD8-, CD14-, IgG+, IgM- memory B cells. After staining, the 
cells were washed twice with PBS and resuspended in 200 µl of PBS containing 1J08 SIVmac251-
M766 V1V2 conjugated to APC and 1J08 SIVsmE543 V1V2 conjugated to PE and incubated in the 
dark for 15 minutes at room temperature. The cells were then washed in PBS, analysed and 
sorted with a modified 3-laser FACSAria cell sorter using the FACSDiva software (BD Biosciences). 
Antigen (V2)-specific B cells positive for binding to SIVsmE543/V1V2 only or SIVsmE543 and 
SIVmac251/V1V2 (Figure 2.2B) were singularly sorted into well of 96-well plates containing lysis 
solution. Flow cytometric data was analysed with FlowJo 9.7.5. 
Total RNA was reverse transcribed in each well, and rhesus immunoglobulin H, Lκ and Lλ chains 
variable domain genes amplified by nested PCR. Positive amplification products as analysed on 
2% agarose gel (Embi-Tec) were sequenced, and those that were identified as carrying Igγ and 
IgLκ or IgLλ sequences were re-amplified with sequence-specific primers carrying unique 
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restriction sites using the first-round nested PCR products as template. Resulting PCR products 
were run on a 1% agarose gel, purified with QIAGEN Gel Extraction Kit (QIAGEN) and eluted with 
25µl of nuclease-free water (Quality Biological). Purified PCR products were then digested and 
ligated into rhesus Igγ, IgLκ and IgLλ expression vectors designed by Dr. Saunders and kindly 
provided by Dr. Mascola (VRC, NIAID) containing a multiple cloning site upstream of the rhesus 
Igγ, Igκ or Igλ constant regions. Full-length IgG were expressed by co-transfecting 293F cells with 
equal amounts of paired heavy and light chain plasmids then purified using Protein A Sepharose 
beads (GE Healthcare) according to the manufacturer’s instructions. 
Figure 2. 2: Phenotypic characterisation of memory B cells and localisation of isolated NCI mAbs in antigen-binding 
dot-plot. A) Plots represent the gating strategy, where gating is identified by purple shapes and parent-to-daughter 
populations flow from left to right. B) Binding of the probes 1J08 V1V2 SIVmac251 (Y axis) and SIVsmE543 (X axis) in 
P770 and one naïve control, one SIVmac251-infected control. The gating strategy for cell sorting is indicated by the 
purple shape. The sorted events from which the NCI mAbs were cloned are represented in coloured dots. 
ELISA peptide mapping of NCI mAbs  
ELISA peptide mapping of NCI mAbs was carried out by Irene Kalisz, Advanced Bioscience 
Laboratories, Frederick, Maryland, USA. 
Binding of SIV-specific mAbs to overlapping peptides encompassing the V1V2 region of 
SIVmac251 gp120 was measured by enzyme-linked immunosorbent assay (ELISA). Plates were 
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˚C, then blocked with 200 µl of PBS Superblock (Thermo Fisher Scientific) for 1 hour at room 
temperature. After blocking, 100 µl were added to emptied wells, each one containing 10 µg/ml 
of Ig in ELISA sample diluent (Avioq), and incubated for 1 hour at 37˚C. 
After washing, 100 µl of goat anti-human IgG conjugated to HRP (KPL) diluted 1:120,000 in sample 
diluent (Avioq) was added to all wells and incubated for 1 hour at 37 ˚C. After washing, 100 µl of 
K-Blue Aqueous substrate (Neogen) was added to all wells and incubated for 30 minutes at room 
temperature. The reaction was stopped by adding 100 µl of 2N H2SO4 to all wells, and binding 
intensity measured at 450 nm.  
NCI09 Fab expression, crystallisation and refinement 
NCI09 Fab expression, crystallisation and refinement was carried out by Jason Gorman, Structural 
Biology Section, Vaccine Research Center, NIH, Bethesda, Maryland, USA. 
The variable region of the NCI09 heavy chain was synthesized and cloned into a pVRC8400 vector 
containing an HRV3C cleavage site in the hinge region as previously described 355. Heavy and light 
chain plasmids were co-expressed in 1 litre of Expi293F cells. IgG was purified from the 
supernatant through binding to a protein A Plus Agarose (Pierce) column and eluting with IgG 
Binding Buffer (Thermo Fisher). Antibodies were buffer-exchanged to PBS and then 10 mg of IgG 
was cleaved with HRV3C protease. The digested IgG was then passed over a 2 ml protein A Plus 
column to remove the Fc fragment. The Fab was further purified over a Superdex 200 gel filtration 
column in buffer containing 5 mM HEPES 7.5, 50 mM NaCl, and 0.02% NaN3.  
To form NCI09-V2 peptide complexes, 5 mg of purified fab at a concentration of 2 mg/ml was 
incubated at room temperature for 30 minutes with a five-fold molar excess of SIV V2 peptide, 
synthesized by GenScript, and the complex was then concentrated down to 10 mg/ml using 
10,000 MWCO Ultra centrifugal filter units (EMD Millipore). Antibody-peptide complexes were 
then screened against 576 crystallization conditions using a Mosquito crystallization robot mixing 
0.1 µl of protein complex with 0.1 µl of the crystallization screening reservoir. Larger crystals 
were then grown by the vapor diffusion method in a sitting drop at 20ºC by mixing 1 µl of protein 
complex with 1 µl of reservoir solution (22% (w/v) PEG 4000, 0.1 M Na Acetate pH 4.6). Crystals 
were flash frozen in liquid nitrogen supplemented with 20% ethylene glycol as a cryoprotectant. 
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Data were collected at 1.00Å using the SER-CAT beamline ID-22 of the Advanced Photon Source, 
Argonne National Laboratory. 
Diffraction data were processed with HKL2000 (HKL Research). A molecular replacement solution 
was obtained with Phenix 365 contained one Fab molecule per asymmetric unit in space group 
P212121. Model building was carried out using COOT software 366. The Ramachandran plot 
determined by Molprobity 367 shows 98.2% of all residues in favoured regions and 100% of all 
residues in allowed regions for the complex structure. 
Binding and competition assays 
cV2 binding assays were initially carried out by Kristina Peachman, Antigens and Immunology 
Section, U.S. Military HIV Research Program, Silver Spring, Maryland, USA, and then replicated by 
the author. 
Binding of SIV-specific mAbs to viral proteins or synthetic peptides was measured by ELISA. Plates 
were coated overnight at 4˚C with 50µl, 100 ng/well of antigen in PBS, then blocked with 
300µl/well of 1% PBS-BSA for 1 hour at 37°C. When cyclic V2 (cV2), a circularised peptide carrying 
the amino acid sequence of viral V2 was tested, plates were coated at 4˚C overnight with 200 
ng/well of streptavidin (Sigma-Aldrich) in bicarbonate buffer, pH 9.6, then incubated with 
biotinylated cV2 peptide (produced by JPT Peptide Technologies and kindly provided by Dr. Rao, 
Military HIV Research Program) for 1 h at 37°C and blocked with 0.5% milk in 1× PBS, 0.1% Tween 
20, pH 7.4 overnight at 4°C. 
Coated, blocked plates were incubated with 40µl/well of serial dilutions of mAbs in 1% PBS-BSA 
for 1 hour at 37˚C. 40µl/well of a polyclonal preparation of Horseradish peroxidase (HRP)-
conjugated goat anti-monkey IgG antibody (Abcam) was then incubated for 1 hour at 37°C. Plates 
were washed between each step with 0.05% Tween 20 in PBS. Plates were developed using either 
3,3 ́,5,5 ́- tetramethylbenzidine (TMB) (Thermo Scientific) and read at 450 nm. When testing 
binding to linear peptides, cyclic V2 or 1J08 V1V2 scaffolds, a ratio of the molecular weights of 
these constructs to the native glycoprotein monomer was calculated in order to obtain coating 
with the same approximate number of epitopes/well. 
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When testing for glycan dependency of antibody binding, SIVmac251/gp120 was deglycosylated 
with PNGase F (New England BioLabs) according to the manufacturer’s indications and coated at 
100 ng/well. 
Competition assays of anti-V2 mAbs were performed by ELISA as described in 364 and 269. Briefly, 
plates were coated with 100 ng/well of purified proteins SIVmac251-M766 gp120 (Advanced 
BioScience Laboratories, Inc.) or SIVsmE660.CR54 gp140 (kindly provided by Dr. Roederer, 
VRC)364 and blocked with 1% PBS/BSA. Serial dilutions of unbiotinylated competitor mAb in 1% 
PBS-BSA were then added to the wells for 15 minutes prior to addition of biotinylated probe 
mAbs at a concentration to yield ~50% saturating OD450. After incubation with streptavidin-HRP 
(KPL) for 1 hr at 37°C, signal was developed through incubation with 3,3’,5,5’ 
tetramethylbenzidine (TMB) substrate (Thermo Fisher Scientific) and Optical density (OD) read 
at 450 nm. Two negative (1%PBS/BSA or serial dilutions of anti-CD4bs ITS01) and one positive 
(serial dilutions of unbiotinylated probe mAb) control of competition were included in each assay.  
Percent inhibition was calculated as a subtraction of the signal obtained at the highest 
concentration of competitor antibody subtracted to the background BSA control, divided by said 
background control and multiplied by 100. 
 
Viral Neutralisation Assays 
Viral neutralisation assays were carried out in collaboration with Rosemarie Mason, Vaccine 
Research Center, National Institutes of Health, Bethesda, MD, USA. 
Viral neutralisation assays were performed by the HIV-pseudotype assay, in which SIV 
pseudoviruses were produced as previously described368. Briefly, a luciferase reporter plasmid 
containing essential HIV genes was used in combination with a plasmid encoding for SIV gp160 
to yield pseudoviruses exposing SIV Env on their surface. Plasmids encoding SIV gp160, clones 
SIVsmE660.CP3C, SIVsmE660.CR54, SIVmac251.H9 and SIVmac251.30 were kindly provided by 
David Montefiori. Single-round infection of TZM-bl was detected quantitatively in relative light 
units (RLU). Virus neutralisation was measured as the 50% inhibitory concentration of mAb 
necessary to cause a 50% reduction in RLU as compared to virus control wells after subtraction 
of background RLU.  
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47 adhesion to SIVmac251-M766 gp120 
47 adhesion assays were carried out by Matthew Liu, Laboratory of Immunoregulation, 
National Institute of Allergy and Infectious Disease, NIH, Bethesda, Maryland, USA. 
The binding intensity of SIVmac251-M766 gp120 to 47 expressed by the cell line RPMI8866 (a 
human B lymphoma cell line that constitutively expresses 47, purchased from Sigma-Aldrich) 
in presence or absence of mAbs was assessed following the methods described by Lertjuthaporn 
and collaborators360. Briefly, cell line RPMI8866 was cultured in media containing 1µM of Retinoic 
Acid (RA) for at least 7 days before start of the adhesion assay, to increase adhesion to V2 
peptides. Triplicate wells of 96-well flat-bottom plates (Greiner Bio-One) were coated overnight 
at 4˚C with 100 µl of 0.5-2.0 µg of deglycosylated SIV gp120 diluted in 50 mM bicarbonate buffer, 
pH 9.6. The solution from the plates was discarded and then blocked with buffer (25 mM Tris, 2.7 
mM potassium Chloride, 150 mM sodium chloride, 0.5% BSA, 4 mM manganese chloride, pH 7.2) 
for 1 hour at 37˚C. Plates were then washed manually 4 times with blocking buffer, and RPMI8866 
cells were pre-incubated in a volume of 50 µl/well for 40 min at 37˚C with sample buffer while 
using anti-4 mAb 2B4 or anti-47 inhibitor ELN3 as positive controls of inhibition 327,369. If 
competition experiments were being carried out, competitor antibody was added to the well at 
the indicated concentration and incubated for 30 minutes at 37˚C before this stage. Plates were 
then incubated with 50 µl/well of 2x105 RPMI8866 cells at 37˚C (5% CO2) for 1 hour, washed with 
PBS 5 times. Finally, 100 µl of RPMI-1640 containing 1% FBS, 1% pen/strep/glutamine, 25 mM 
HEPES with 10 µl/well of AlamarBlue® dye. Fluoresence (excitation 560 nm, emission 590 nm) 
was detected immediately after dye addition and measured for 8 hours. 
 
Surface plasmon resonance 
Surface plasmon resonance assays were carried out by Donald Van Ryk, Laboratory of 
Immunoregulation, National Institute of Allergy and Infectious Disease, NIH, Bethesda, Maryland, 
USA.  
These experiments were performed using a Biacore 3000 (GE Life Sciences) using CM4 or CM5 
sensor chips as in reference360. Data were analysed using BIAevaluation 4.1 software (GE Life 
Sciences). The chip surface was activated by injection of 35 µl of 0.05 M N-hydroxysuccinimide 
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and 0.2 M N-ethyl-N(dimethylaminopropyl)carbodiimide mixed 1:1 at 5 ≤l/min. NeutrAvidin, 
SIVmac251-M766 gp120 or SIVsmE660.CR54 were immobilised at concentrations of 5 µg/ml in 
10mM NaOAc, PpH4.5 to approximately 750 resonance units (RU). Unreacted sites on each 
surface were then blocked with 35 µl of 1M Tris-HCl (pH 8.0). Biotinylated cV2 (1µg/ml in 20 mM 
Tris-HCl, pH 8.0) was bound to NeutrAvidin to a density of approximately 250-300 RU. One 
surface was kept activated and blocked without ligand to act as a negative control surface for 
non-specific binding of soluble ligands. Any binding detected was then subtracted from the 
remaining surfaces. Running buffer was HBS (pH 7.4), 0.01 mM CaCl2, either 1mM MgCl2 or 
MnCl2, 0.005% Tween-20, 0.05% soluble carboxymethyl-dextran. Binding experiments were then 
performed at a flow rate of 25 µl/min at 25˚C. After a two-minute injection, the surface was 
washed for an additional 2 minutes in running buffer to observe dissociation of the bound ligand 
from the surface. The surfaces were restored with multiple injections of 4.5 MgCl2 at a flow rate 
of 100 µl/min. Inhibition of anti-V2 loop antibodies by linear V2-loop peptides was carried out by 
pre-incubating the mAbs with the peptides in running buffer for 2 hours at room temperature 
prior to passing them over the prepared surfaces as described above. Competition experiments 
were carried out by pre-incubating tested mAbs with overlapping SIVmac239 15-mers. 
Scientist Contribution 
Giacomo Gorini Production of 1J08 probes, isolation of NCI mAbs from memory B cell sorting to 
purification, ELISA binding and competition assays (including cV2), neutralisation assays, 
design of ITS41-NCI09 competition on 47 adhesion assay, data analysis, graph 
editing; first proposed that antibody interference could be a mechanism deployed by 
SIV to evade the humoral immune response of the host. 
Irene Kalisz NCI mAbs ELISA peptide mapping. 
Jason Gorman NCI09 Fab expression, crystallisation and refinement. 
Kristina Peachman cV2 binding assays. 
Rosemarie Mason Neutralisation assays. 
Matthew Liu 47 adhesion assays. 
Donald Van Ryk Surface plasmon resonance assays. 
Richar Nguyen  Memory B cell sorting. 
Table 2. 1 List of collaborators and relative contribution to the experiments reported in this chapter. 
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Results 
 
Isolation of anti-V2 mAbs 
A total of 289 memory B cells were identified and sorted using a rhesus memory B cell staining 
panel. Cells were isolated when resulting positive for binding to the APC-conjugated 1J08 
SIVmac251-M766 V1V2 and PE-conjugated 1J08 SIVsmE543 V1V2 or the SIVsmE543 probe alone 
(Figure 2.2B). This number corresponded to the 0.78% of the memory, and the 0.13% of the total 
B cells in the PBMC sample tested. Nested PCR-amplification of heavy and light V(D)J genes 
resulted in the amplification of 72 matched pairs, of which 40 were cloned and expressed. Of the 
expressed clones, two mAbs, namely NCI05 and NCI09 displayed strong antigen recognition in 
ELISA assays against SIVmac251 and/or SIVsmE543 cV2 and were further tested against whole 
antigens, with the results summarised in Table 2.2 and reported in detail in Figure 2.3. In 
addition, two expressed mAbs, namely NCI04 and NCI06, were found to be V1-specific as 
identified in ELISA assays on a linear SIVmac251 V1 peptide. 
 
Table 2. 2: Summary of ELISA binding profiles of anti-V2 (NCI05, NCI09) and anti-V1 (NCI04, NCI06) mAbs. Cloned 
NCI mAbs were tested against a set of viral antigens with detailed results are reported in Figure 2.3. Binding intensity 
to each antigen as in the legend. 
NCI05 NCI09 NCI04 NCI06 ITS09 ITS12 ITS41
SIVsmE543	cV2 ++ ++ - - ND ND ND
SIVmac251	cV2 ~ ++ - - ND ND ND
SIVsmE543	1J08	V1V2	 ++ ++ - ++ ND ND ND
SIVmac251	1J08	V1V2	 ++ ++ ++ ++ ND ND ND
SIVmac239	1J08	V1V2	 ++ ++ + ++ ND ND ND
SIVmac251	V2	peptide - ++ - - ND ND ND
SIVmac251	V1	peptide - - ~ ++ ND ND ND
Peptide/Epitope TGLKRDKTKEYNETWYSTD KFTMTGLKRDKTKEY PLCITMRCNKSETDRWGLTK RCNKSETDRWGLTK TGLKRDKKKEY ETWYSADLVCE EQEQMISCKFNMTGL
SIVmac251	M766	gp120 ++ ++ ++ ++ ++ - ++




NCI05 NCI09 NCI04 NCI06 - OD450	<	0.5
SIVsmE660.CP3C	(Tier	1) 4.449 >50* >50* >50* 1	-	9.99	µg/ml
SIVsmE660.CR54	(Tier	2) >50* >50* >50* >50* 0.01	-	0.099	µg/ml
SIVmac251.H9	(Tier	1) >50 0.412 >50 0.024 0.1	-	0.99	µg/ml
SIVmac251.30	(Tier	2) >50* >50* >50* >50* >50*		=	curve	plateaued	below	50%
NCI05 NCI09 NCI04 NCI06 ITS09 ITS12 ITS41
SIVsmE543	cV2 ++ ++ - - ND ND ND
SIVmac251	cV2 ~ ++ - - ND ND ND
SIVsmE543	1J08	V1V2	 ++ ++ - ++ ND ND ND
SIVmac251	1J08	V1V2	 ++ ++ ++ ++ ND ND ND
SIVmac239	1J08	V1V2	 ++ ++ + ++ ND ND ND
SIVmac251	V2	peptide - ++ - - ND ND ND
SIVmac251	V1	peptide - - ~ ++ ND ND ND
Peptide/Epitope TGLKRDKTKEYNETWYSTD KFTMTGLKRDKTKEY PLCITMRCNKSETDRWGLTK RCNKSETDRW LTK TGLK DKKKEY ETWYSADLVCE EQEQMISCKFNMTGL
SIVmac251	M766	gp120 ++ ++ ++ ++ ++ - ++




NCI05 NCI09 NCI04 NCI06 - OD450	<	0.5
SIVsmE660.CP3C	(Tier	1) 4.449 >50* >50* >50* 1	-	9.99	µg/ml
SIVsmE660.CR54	(Tier	2) >50* >50* >50* >50* 0.01	-	0.099	µg/ml
SIVmac251.H9	(Tier	1) >50 0.412 >50 0.024 0.1	-	0.99	µg/ml
SIVmac251.30	(Tier	2) >50* >50* >50* >50* >50*		=	curve	plateaued	below	50%
Chapter 2                                                                          Isolation and characterisation of monoclonal antibodies 
   77 
 
Figure 2. 3: ELISA binding data of NCI mAbs to V1 or V2 antigens. Replicate plates were coated with the antigens 
reported in the title of each individual graph. Blocked plates were incubated with serial dilution of test mAbs. After 
incubation with secondary goat anti-monkey*HRP antibody, plates were developed with TMB substrate and 
absorbance data were acquired at 450 nm. 
 
Figure 2. 4: Two-dimensional diagram of the SIVmac251 M766 V1V2 domain with the binding site of the V2-specific 
mAbs NCI05 and NCI09 and V1-specific mAbs NCI04 and NCI06. Binding sites of ITS mAb tested in this thesis and 
kindly provided by Dr. Roederer are shown in light grey and described more in detail in reference364. Pink arrows 
represent the location of the putative four beta strands (A-D) building up the Greek key motif previously described 
in the region355. Residues located in the V1 and V2 loops are represented in black and red, respectively. In all the 
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ELISA Epitope definition and Neutralisation Assays 
To locate the epitope recognised by these antibodies, the NCI mAbs were tested in ELISA against 
a panel of overlapping 20-mer peptides encompassing the V1, V2 regions of SIVmac251 gp120 
consensus sequence. Notably, all of the isolated NCI mAbs were able to bind linear peptide and 
have their epitope located within V1/V2 with the only exception of NCI05 (Figure 2.5). However, 
none of these mAbs demonstrated strong neutralisation potency against a panel of SIV 
pseudoparticles (Figure 2.6 and Table 2.3). 
 
Figure 2. 5: Peptide mapping of NCI mAbs. ELISA binding of A) anti-V1 mAbs NCI04 and NCI06 to overlapping 20-mer 
peptides encompassing the N-terminal region of SIVmac251 gp120 V1 consensus sequence and of B) anti-V2 mAbs 
NCI05 and NCI09 to overlapping 20-mer peptides encompassing the V2 region of SIVmac251 gp120 consensus 
sequence. Binding is found greatest for NCI09 in the region covered by peptides 26 and 27, while no binding was 
detected for NCI05. C) Sequence of the overlapping 20-mer linear SIVmac251 gp120 peptides encompassing the N-
terminal V1 region. Peptides bound with greatest intensity by NCI04 and NCI06 are represented in bold and 
underlined, respectively. D) Sequence of the overlapping 20-mer linear SIVmac251 gp120 peptides encompassing 
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Figure 2. 6: Neutralisation graphs of NCI mAb against a panel of pseudoparticles exposing tier 1 or tier 2 SIV env. 
Single-round infection of TZM-bl cell line was detected quantitatively in RLU, and percent neutralisation extrapolated 
as signal reduction in comparison to antibody-free control wells. 
 
Table 2. 3: Neutralisation potency (IC50) of NCI mAbs. Cloned V1- or V2- specific mAbs were tested for neutralisation 
against tier 1 and tier 2 SIVmac251 and SIVsmE660 pseudoviruses. Reported IC50 values were measured as the 
concentration of mAb necessary to cause a 50% reduction in RLU as compared to antibody-free control wells after 
subtraction of background RLU. >50: no neutralisation.  
Moreover, NCI05 was found to exhibit conformation-, glycan- dependent binding properties 
against SIVmac251 gp120 (Figure 2.7). More in detail, deglycosylation by PNGase treatment of 
SIVmac251 gp120 was found to completely deplete binding of NCI05 to the antigen (Figure 2.7A). 
While we initially inferred that NCI05 binds to a glycan epitope, this conclusion was proved wrong 
in tests against SIVsmE543 cV2 (Figure 2.7B), where the mAb was found in fact to strongly bind 
to the deglycosylated cV2 of this viral strain. We therefore concluded that NCI05 recognises a 
conformational epitope that is represented in the native conformation in cV2 from SIVsmE543 
but not from SIVmac251, where glycosylations are also necessary to switch the NCI05 epitope to 
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Figure 2. 7: ELISA binding profile of NCI05 to A) native, denatured and deglycosylated SIVmac251-M766 gp120 and 
B) linear and cyclic SIVmac V2 peptides. Blocked plates were incubated with serial dilution of test mAbs. After 
incubation with secondary goat anti-monkey*HRP antibody, plates were developed with TMB substrate and 
absorbance data were acquired at 450 nm. 
Antigen Binding Affinity and Peptide Competition 
Association/Dissociation constants (KA/KD, respectively) of NCI05 and NCI09 whole mAbs, as well 
as ITS41 Fab were calculated by surface plasmon resonance against SIVmac251 gp120, 
SIVsmE660 gp140 and SIVmac251 cV2 (Figure 2.8 and Table 2.4). The results revealed that, while 
the two mAbs and the Fab have comparable KA against SIVmac251 gp120, neither ITS41 nor 
NCI09 were found to bind to SIVsmE660 gp140. This finding was unexpected for NCI09, which we 
identified as a strong binder of SIVsmE660 gp140 by ELISA. It is however possible that antigen 
binding to chip surface resulted in masking or alteration of the epitope bound by this mAb. In 
addition, these results also revealed that NCI05 is actually able to bind to SIVmac251 cV2, but the 
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Figure 2. 8: Sensorgram of increasing concentrations of NCI mAbs or ITS41 Fab passed over surface-immobilised SIV 
antigens. NCI05 (top row), NCI09 (middle row) or ITS41 Fab (bottom row) were passed over SIVsmE660 gp140 
antigen (left column), SIVmac251 gp120 (middle column) or SIVmac251 cV2 (right column) for 120 seconds, followed 
by a 120-second washout/dissociation phase. Mass of bound antibody or Fab expressed as response units (RU). 
Concentration of mAb or Fab tested is shown on the right of each row. 
 
Table 2. 4: Table reporting the KA (1/M) and KD (M) values of ITS41 Fab, NCI05 mAb and NCI09 mAb. Values were 
calculated by surface plasmon resonance against a panel of three SIV SU antigen as in Figure 2.8. 
 
However, these findings allowed for further characterisation of the epitope recognised by the 
anti-V2 NCI mAbs, and we were able to locate the epitope bound by NCI05 through competition 
surface plasmon resonance against immobilised SIVmac251-M766 cV2 (Figure 2.9). The same 
test was carried out for NCI09 (Figure 2.10). Before being exposed to the immobilised antigen, 
aliquots of anti-V2 NCI mAbs were incubated with 15-mer overlapping peptides encompassing 
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KA KD KA KD KA KD
SIVmac251-M766	gp120 3.90E+04 2.57E-05 1.78E+08 5.60E-09 8.19E+09 1.22E-10
SIVsmE660.CR54	gp140 N/A N/A 9.60E+10 1.04E-11 N/A N/A
SIVmac251-M766	cV2 1.06E+08 9.46E-09 5.12E+06 1.97E-07 9.13E+11 1.10E-12
ITS41 NCI09NCI05
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overlapping peptides on NCI09, and were able to locate the region bound by NCI05 as overlapping 
that of NCI09. 
 
 
Figure 2. 9: Peptide mapping of mAb NCI05. A) Percentage of binding of mAb NCI05 to a cyclic V2 peptide derived 
from SIVmac251 M766 (grey column) in presence of competitor overlapping 15 a.a. linear peptides (p41-p48, black 
columns) derived from SIVmac239 gp120 and encompassing the V2 region. Inhibition is greatest with p45, with 
partial inhibition mediated by p44. B) Overlapping 15 a.a. linear SIVmac239 gp120 peptides encompassing the V2 
region. Bold: peptides that induce the greatest inhibition of NCI05 binding to SIVmac251 cV2. C) Protein sequence 
alignment of SIVmac251.6 and SIVmac239 V1V2 domain. Stars indicate mutations between the two strains that are 
located within the putative binding site of NCI05 (underlined). 
 
Figure 2. 10: Peptide mapping of mAb NCI09. A) Percentage of binding of mAb NCI09 to a cyclic V2 peptide derived 
from SIVmac251 M766 (grey column) in presence of competitor overlapping 15 a.a. linear peptides (p41-p48, black 
columns) derived from SIVmac239 gp120 and encompassing the V2 region. Inhibition is greatest with p43 and p44. 
B) Overlapping 15 a.a. linear SIVmac239 gp120 peptides encompassing the V2 region. Bold: peptides that induce the 
greatest inhibition of NCI09 binding to SIVmac251 cV2. C) Protein sequence alignment of SIVmac251.6 and 
SIVmac239 V1V2 domain. Star indicates the mutation between the two strains that is located within the putative 
binding site of NCI05 (underlined).  
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Crystal structure of NCI mAbs in complex with V2 constructs 
To characterise more in detail the epitope targeted by NCI09 and NCI05, crystal structures of the 
Fabs in complex with peptide and scaffolded antigen, respectively, were produced. However, 
only NCI09 yielded crystals that could produce data of analysis-standard quality. A peptide of 
sequence N-KFTMTGLKRDKTKEYN-C did not display an organized secondary structure when in 
complex with NCI09 (Figure 2.11). In this peptide, the four N-terminal residues were not ordered 
in the structure. Almost all of the interactions were found to be limited to the HC, with a clear 
electrostatic interaction between the base of the CDRH3 and the peptide amino acids Arginine 
(R9) and Glutamic Acid (E14), as well as main hydrogen bond interactions with a Cysteine located 
in the CDHR3. Notably, we observed a glycosylation site on the CDRL1 of which the first glycan 
residues were visible. 
 
Figure 2. 11: Overall structure of NCI09 in complex with a SIVmac251 linear peptide. The peptide sequence 
(KFTMTGLKRDKTKEYN) is that of consensus SIVmac251, in complex wit Fab of antibody NCI09. The N-terminal 4 
residues were not ordered in the structure. The NCI09 heavy and light chains are displayed as yellow and blue 
ribbons, respectively. The SIVmac251 peptide is displayed in purple. 
ELISA competition assays between pairs of anti-V2 mAbs 
Competition of binding experiments were carried out between pairs of anti-V2 mAbs to roughly 
inter-localise the position of the NCI and ITS epitopes in V2 (summarised in Table 2.5). 
Surprisingly, we found that competition assays were poorly informative as the inhibition of 
binding against other mAbs was unidirectional most of the time, that is most of the antibodies 








Figure 8: Overall structure of NCI09 in complex with a SIVmac251 linear peptide. The pe tide sequence (KFTMTGLKRDKTKEYN) is that of consensus SIVmac251, in complex wit Fab of antibody
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Table 2. 5: A) Matrix recapitulating the pattern of competition between of pairs of anti-V2 mAbs. Red boxes 
represent inhibition >50%, green boxes inhibition <50%, and stars asymmetric inhibition. Percentages of inhibition 
are shown in B) with colour codes as in A). Barred cells represent competition between same mAb tested both as 
competitor and probe in the same replicate. These combinations were included as positive control, always yielded 
>50% inhibition and were excluded from this table as irrelevant in the study of the structural dynamics of 
competition between closely- and far-located epitopes. Percent inhibition was calculated as a subtraction of the 
signal obtained at the highest concentration of competitor antibody subtracted to the background BSA control, 
divided by said background control and multiplied by 100. NA: Not Available. Because ITS41 and ITS12 are weak 
binders of SIVsmE660.CR54 gp140 and SIVmac251-M766 gp120, competition between these two mAbs could not be 
tested. Antigens tested for each antibody pair are reported in Table 2.5; graphs with the results of competition, 
including those of barred cells, are reported in Figure 2.13; Association/dissociation constants of mAbs ITS41, NCI05 
and NCI09 against a panel of SIV SU antigens are reported in Table 2.3. 
 
symmetric competition that is used to inter-locate overlapping antibody epitopes could not be  
observed, not even between antibodies NCI05 and NCI09, suggesting that these mAbs hit the 
same region from different angles. However, amongst the pairs of mAbs tested, we found two 
that gave particularly interesting results: ITS41, targeting the N-terminal region of V2, would 
disrupt binding of NCI05 and NCI09 without, however, being negatively affected by their pre-
binding to the antigen (Figure 2.12). We hypothesise that, when pre-bound to the antigen, ITS41 
induces conformational changes within V2 that inhibit binding of NCI09 and NCI05 to the antigen. 
However, these mAbs do not lead to a disruption of the V2 three-dimensional structure that can 
inhibit binding of ITS41. These observations point towards immunoglobulin-induced 
conformational change as a mechanism by which antibodies binding outside of the tripeptide are 
able to inhibit binding between V2 and 47. The antigens tested for each pair of mAbs and 
relative binding curves are reported in Table 2.7 and Figure 2.13, respectively. 
A B
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Figure 2. 12: Competition experiments between pairs of anti-V2 mAbs. Each NCI mAb has been tested both as 
competitor and as probe against ITS41. While ITS41 was able to prevent the binding of both NCI05 and NCI09 when 
pre-bound to SIVmac251-M766 gp120, the NCI mAbs were unable to affect the binding activity of ITS41. Test curves 
are represented in red. Negative control curves are represented in black, with ITS01 being a non-relevant anti-CD4 
mAb. Positive control curves are in grey.  
 
Table 2. 6: Matrix reporting the antigens tested for each mAb pair. Because ITS41 and ITS12 are weak binders of 
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Figure 2. 13: (continues on next page): Graphs of binding competition between mAbs. In each experiment, BSA 1% 
or serial dilution of anti-CD4 bs ITS01 mAb were used as negative controls of competition (black), while 
unbiotinylated probe mAb was used as positive control of competition (red). Replicate plates were coated with the 
antigens reported in Table 2.6. Blocked plates were incubated with serial dilution of unbiotinylated competitor mAb 
at 37˚C for 10 minutes, then fixed concentration of biotinylated probe mAb were added to each well and incubated 
at 37˚C for 45 minutes. After incubation with streptavidin-HRP, plates were developed with TMB substrate and probe 
mAb binding data acquired at 450 nm. Comp: unbiotinylated competitor mAb; probe: biotinylated probe mAb, 
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14 April 2017SIVsmE660.CR54 gp140
Figure 2.13 (continued from previous page): Graphs of binding competition between mAbs. In each experiment, 
BSA 1% or serial dilution of anti-CD4 bs ITS01 mAb were used as negative controls of competition (black), while 
unbiotinylated probe mAb was used as positive control of competition (red). Replicate plates were coated with 
the antigens reported in Table 2.6. Blocked plates were incubated with serial dilution of unbiotinylated 
competitor mAb at 37˚C for 10 minutes, then fixed concentration of biotinylated probe mAb were added to each 
well and incubated at 37˚C for 45 minutes. After incubation with streptavidin-HRP, plates were developed with 
TMB substrate and probe mAb binding data acquired at 450 nm. Comp: unbiotinylated competitor mAb; probe: 
biotinylated probe mAb, detected with HRP-conjugated Streptavidin. 
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mAb-mediated Inhibition of SIVgp120 binding to 47 
The biologic mechanism by which anti-V2 antibodies elicited by vaccination might protect from 
HIV/SIV acquisition has not yet been explained at the molecular level.  
The two V2-specific mAbs NCI05 and NCI09 were tested for their ability to disrupt binding of 
deglycosylated SIVmac251 gp120 to human 47 exposed on the surface of the human B cell line 
RPMI8866360. Interestingly, NCI09 was repeatedly found to exhibit the most potent blocking 
features of a panel of rhesus anti-V2 mAbs (Figure 2.14), while NCI05 was unable to prevent 
binding between the integrin and the deglycosylated viral antigen (data not shown). However, 
because NCI05 displays glycan-dependent features against SIVmac251 gp120 (Figure 2.7), 
absence of inhibition of binding to 47 is likely due to lack of antibody binding to gp120.  
 
Figure 2. 14: Comparison of the inhibition of binding of SIVmac251-M766 gp120 to human 47 mediated by a panel 
of mAbs. Each mAb was tested at a concentration of 5 µg/ml. VRC01 or polyclonal IgG from naïve macaques (mac. 
IgG) were used as negative controls. Adapted from reference360.  
We then proceeded to test if the interference that we detected in ELISA binding assay 
experiments would show repercussion on the inhibition of 47 binding to V2 mediated by anti-
V2 mAbs. Specifically, we tested if the binding activity of NCI09 would be negatively affected by 
having SIVmac251 gp120 pre-bound by ITS41 (Figure 2.15). However, because ITS41 itself is able 
to mediate binding inhibition to a maximum of 74% at 1.25 µg/ml (Figure 2.15A), we used a 
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(Figure 2.15B). Interestingly, we found that high concentrations of competitor ITS41 pre-bound 
to SIVmac251 gp120 were indeed able to lower the effect of inhibition of binding to 47 
mediated by NCI09, with the potency of the NCI09-mediated inhibition restored as ITS41 was 
progressively diluted (Figure 2.15C).  
 
Figure 2. 15: NCI09-mediated inhibition of binding of 47 to deglycosylated SIVmac251 gp120 preincubated with 
serial dilutions of competitor ITS41. A) Titration of the ITS41-mediated inhibition of gp120 binding to 47 at the 
concentrations tested in the competition experiment with NCI09. B) Binding to human 47 of native SIVmac251 
M766 gp120 and of deglycosylated SIVmac251 M766 gp120 alone, in presence of inhibitory molecule ELN3 at 2.5 
µg/ml or NCI09 at 1.25 µg/ml. NCI09-mediated 81% inhibitory activity is calculated as a ratio of percent binding of 
native gp120 to 47 / percent binding of deglycosylated gp120 to 47 in presence of NCI09. C) NCI09 inhibition 
experiment in presence of pre-bound ITS41. When ITS41 is pre-bound to gp120 at high concentrations (left end of 
the graph) before 81% inhibitory concentration of NCI09 is added (1.25 µg/ml), only the inhibition mediated by ITS41 
is detected (53% at 5 µg/ml of competitor). As the concentration of competitor is serially diluted, the inhibitory 
activity of NCI09 at 1.25 µg/ml is recovered 
Discussion 
In this study, we isolated and characterized anti-V1V2 mAbs obtained from P770, a vaccinated 
rhesus macaque protected from SIVmac251 infection. Two mAbs, both weak SIV neutralisers, 
displayed unique characteristics: (i) NCI05 showed previously undescribed strain-specific 
conformation-, glycan-dependent epitope specificity; (ii) NCI09, targeting a linear epitope 
encompassing the B and C strand of the V1V2 motif, was found to be the most potent inhibitor 
of human 47 binding to SIVmac251 gp120 as compared to an array of anti-V2 mAbs isolated 
from vaccinated, protected and vaccinated, infected animals. Interestingly, the region targeted 
by NCI09 is located distantly from DLV, the tripeptide considered as the putative binding site to 
integrin 47, thus leading to the conclusion that this mAb, when bound to V1V2, disrupts the 
conformation of the domain compromising the binding site of 47 to the viral envelope. 
To better define the effect of NCI09 binding to the conformation of V1V2, we produced the 
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neither as an -helix nor as a -sheet, but rather locked into a loop conformation when bound 
by NCI09. Given that CH58 and CH59 both locked V2 peptides in an alpha-helical conformation 
were only weak inhibitors of V2 binding to 47339, I postulated that a potent antibody inhibitor 
of 47 binding to V2 would need to maintain limited or extensive regions of the V1V2 devoid of 
organized secondary structure. 
The concept that antibody binding to V2 may disrupt the conformation of the domain thus 
preventing the engagement of ligands directed to distant binding sites was corroborated by my 
findings on competition analyses with pairs of mAbs. I observed that mAbs to V2 were able to 
asymmetrically compete with the binding of antibodies directed against distant epitopes within 
the domain. The lack of a clear pattern of asymmetric inhibition between these mAbs implies 
that the conformational changes induced by antibody binding are more dependent on the 
properties of the antibody binding to the antigen, rather than the area of V2 targeted.  
However, our results showed that both NCI05 and NCI09, cloned from a protected animal with 
the latter being a potent inhibitor of 47 binding to V2, were unable to bind to V2 pre-bound 
by mAbs ITS41 isolated from an infected animal. In line with this finding, the potent inhibition of 
binding between 47 and V2 mediated by NCI09 was negatively affected by the presence of 
ITS41 pre-bound to the antigen. I therefore suggest that the elicitation of ITS41-like antibodies is 
to be avoided with vaccination, as these might reduce the beneficial effect of antibodies that 
inhibit binding of 47 to gp120 and thus decrease vaccine efficacy.  
A viral escape mechanism by which antibodies would negatively affect the binding of antibodies 
to protective epitopes by binding to distant regions was initially proposed by Dulbecco et al. in 
1956 on studies on Western Equine Encephalitis virus and poliomyelitis virus 268. This mechanism, 
namely antibody interference, has since been investigated for SARS Coronavirus, Influenza 
Viruses and Hepatitis C Virus 269–272. Antibody interference has been hypothesized to be exerted 
by two possible molecular mechanisms: (i) steric hindrance, i.e. the physical covering of the 
protective epitope by the Fc or Fab regions of the interfering antibody not directly interacting 
with the antigen or (ii) conformational changes, i.e. the induction of alterations in the three-
dimensional structure of the antigen that are propagated to a distant epitope that can thus not 
be recognized by protective antibodies. While the existence of antibody interference in the HIV-
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1 or SIV model has been proposed upon in vitro studies involving anti-HIV fusion glycoprotein 
gp41 mAbs 273, to our knowledge our findings are the first that identify this mechanism on viral 
envelope gp120.  
To conclude, while the elicitation of anti-V2 antibodies with potent inhibition of 47 binding is 
a desired goal of HIV/SIV vaccination, the structural plasticity of the V1V2 domain might act as a 
double-edge sword: antibodies targeting regions outside of the putative binding site of 47 may 
still disrupt V2-mediated virus binding to the human integrin through the induction of 
conformational changes. However, interfering, non-protective antibodies may also prevent 
protective antibodies from blocking the engagement of 47. 
In summary, these findings may inform structural antigen design for a greater efficacy vaccine 
against HIV/SIV infection. 
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CHAPTER 3: ALVAC- but not NYVAC-based vaccination  
decreases the risk of SIVmac251 acquisition in macaques 
 
Introduction 
In addition to vaccine-induced antibody-mediated protection from infection, extensive data 
support the importance of cell-mediated immune responses in virus clearance or containment 
once infection has occurred370–372. This is in contrast with the results of RV144, where antibodies 
targeting the viral envelope glycoprotein gp120 have been the only immune correlate of risk of 
HIV acquisition373. However, in RV144 the recombinant canarypox ALVAC-HIV vCP1521 
immunogen was administered in combination with the AIDSVAX B/E formulation, which consists 
in a combination of two monomeric HIV-1 gp120s from Clade B and AE formulated in alum. This 
composite regimen elicited both antibody- and cellular-mediated immune responses286,374–376.  
The attenuated ALVAC vector was derived by repeated passage of a canarypox virus in chicken 
embryo fibroblasts. This vector has demonstrated a high level of safety and tolerability in phase 
I clinical trials in infants 377,378 and in adults 379. While ALVAC was included in RV144 to elicit 
cellular-mediated immune responses, only 19.7% of the volunteers enrolled demonstrated CD8+ 
CTL responses as measured by IFN-γ ELISpot,  a result that is consistent with the lack of control 
of viral replication in vaccinees that became infected286,380. Notably, most vaccinees developed 
Env-specific CD4+ responses 286,380.  
However, higher T-cell responses were detected in other studies where another poxviral vector, 
NYVAC, was tested381. NYVAC is a highly immunogenic, human-adapted poxviral vector that has 
been safely attenuated through the deletion of 18 genes encoding for viral proteins that affect 
both the virus host range and virulence. This vector has been tested in phase I/IIa clinical studies 
without demonstrating serious adverse events381. A summary of the features of these two 
poxviral vectors can be found in Table 3.1. 
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Table 3. 1: Summary of the taxonomic classification and features of poxviral vectors ALVAC and NYVAC, reviewed in 
detail in reference382. 
Both the poxviral vectors ALVAC and NYVAC have been extensively studied in preclinical settings 
on rhesus macaques. In this animal model, the efficacy of vaccine candidates is traditionally 
evaluated on the basis of two parameters: the delay of virus acquisition and the control of viral 
replication. For brevity, the results of studies of ALVAC or NYVAC immunisation of rhesus 
macaques against HIV, SIV or chimeric Simian-Human Immunodeficiency Virus (SHIV) are 
summarised in Table 3.2. 
Here, we tested the hypothesis that more potent NYVAC-induced responses would improve the 
efficacy of an RV144 schedule. We tested in parallel the efficacy of recombinant NYVAC-SIV and 
recombinant ALVAC-SIV boosted with the native SIVmac251 gp120 formulated in alum in two 
groups of adult female rhesus macaques of Chinese origins. Following immunisation, the 
vaccinated and control animals were challenged weekly intravaginally with up to 12 repeated low 
doses of SIVmac251 to model the natural heterosexual exposure of females to HIV. 
Although the NYVAC-SIV regimen displayed faster anti-Env antibody kinetics and higher anti-Env 
T cell responses as compared to the ALVAC-SIV immunisation, contrary to our hypothesis this 
regimen failed to demonstrate any degree of protection. In contrast, ALVAC-SIV immunisation 
protected with an estimated vaccine efficacy of 50% at each challenge. However, neither regimen 
demonstrated long-term control of viral replication.  
Notably, while we failed to observe correlation between anti-V2 antibody responses and delayed 
viral acquisition, we found that higher levels of 47+ plasmablasts associated with delayed SIV 
acquisition in the ALVAC-SIV group. Similarly, we found that total and classical monocyte lineages 
positively correlated with protection only in the ALVAC-SIV group, while strong nonclassical 




Origin Canarypox virus plaque-purified clone Copenhagen vaccine strain plaque-cloned  isolate
Attenuation 
method
200 passages in chick embryo fibroblasts Deletion of 18 Open Reading Frames implicated 
in pathogenicity and virulence
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of these plasmablast, myeloid responses that correlated with delayed or increased SIV acquisition 
could be associated with vaccine-induced responses. 
Prime Boost Challenge Outcome Ref. 




HIV-1/gp120 High-dose SHIV 
No protection 
Control of CD4 T cell loss 
306 
ALVAC-SIVgpe SIV/gp120 High-dose SIVmac251 
No protection 
Transient control CD4 cells loss 
306 
ALVAC-SIVgpe  RLD mac251 







High-dose SIVmac251 No protection 
384 






RLD IR SIVmac251 44% efficacy each challenge 362 
NYVAC-HIV-2  IV HIV-2 Protection 385 
NYVAC-HIV-2 HIV-2 boost IV HIV-2 Improved protection 386,387 
NYVAC-SIVgpe IL-2 IL-12 IV, IR SIVmac251 
One third of animals protected 6 





 IR SIVmac251 
Protection 
Lower viremia levels correlate 
with anti-Gag specific responses 
389,390 
Table 3. 2: Summary of preclinical studies evaluating poxviral vector-based vaccination regimens in rhesus 
macaques. Red and blue backgrounds represent ALVAC- and NYVAC-based vaccination regimens, respectively. gpe: 
Gag-Pol-Env genes expressed by the vector. IV: intravenous; RLD: repeated low-dose;  IR: intrarectal; Ref.: reference. 
 
Materials and Methods 
 
Animals, vaccines and SIVmac251 challenge 
The vaccination and challenge phases were designed and supervised by Shari Gordon, Animal 
Models and Retroviral Vaccines Section, National Cancer Institute, NIH, Bethesda, Maryland, USA. 
All the animals included in this study were female rhesus macaques (Macaca mulatta) of Chinese 
origin, obtained from the Washington National Primate Research Center (Seattle, WA). The care 
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and use of the animals were in compliance with all relevant institutional (NIH) guidelines. A total 
of 65 female Rhesus macaques of Chinese origins were randomized in 5 groups (referred in the 
text as ALVAC-SIV, NYVAC-SIV, ALVAC-control, NYVAC-control or naïve) according to the major 
histocompatibility status. The animals in the ALVAC- or NYVAC-SIV/groups were immunized at 
weeks 0, 4, 12 and 24 with intramuscular inoculations at 108 PFU either of ALVAC (vCP180) or 
NYVAC (VP1071) expressing the proteins env-gag-pol of the attenuated SIVmac142 clone of 
SIVmac251. At weeks 12 and 24, the animals from these groups received a bivalent monomeric 
alum-formulated gp120 protein boost in the opposite deltoid of the vector immunization, 
containing 200 mg of the native form of SIVmac251/gp120TM (Sanofi Pasteur) (referred in the 
chapter as gp120). 
The control groups included 10 animals each, which received either parental ALVAC or NYVAC 
vectors and alum. 5 naïve control animals were included directly in the challenge phase without 
receiving previous immunization.  
Animals were challenged 4 weeks following the last immunization (week 28), with SIVmac251 at 
120 TCID50 for each challenge. Animals that tested negative for SIV-RNA in plasma were re-
challenged with up to a maximum of 12 weekly administrations. 
The animals shared the same site of origin, but given the large number of macaques, the study 
was split in two parts. Animals from part 1 (n= 24; 8 ALVAC-SIV; 8 NYVAC-SIV; 4 ALVAC-control; 4 
NYVAC-control) were housed, immunized and challenged at Washington National Primate 
Research Center (WaNPRC, Seattle, WA); and animals from part 2 (n= 41; 12 ALVAC-SIV; 12 
NYVAC-SIV; 6 ALVAC-control; 6 NYVAC-control; 5 naïve) were housed, immunized and challenged 
at Advanced Bioscience Laboratories (ABL, Inc., Rockville, MD).  
 
Measurement of viral RNA and DNA 
Viral RNA was measured by contractors at the Washington National Primate Research Center, 
Seattle, Washington, USA and by Ranajit Pal, Advanced Bioscience Laboratories, Frederick, 
Maryland, USA. Mucosal viral DNA was measured by Hye Chung from Advanced Bioscience 
Laboratories. 
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Plasma SIVmac251 RNA levels were quantified by nucleic acid sequence-based amplification, as 
described in reference 391. SIV/DNA levels in mucosal biopsies from week 2 post-infection were 




IFN-γ ELISpot was carried out by Sampa Santra, Center for Virology and Vaccine Research, Beth 
Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 
IFN-γ production by CD4+ T cells or CD8+ T cells was assessed through ELISpot assays, as a reaction 
toward the optimal CTL epitope peptide p18393 or a pool of 47, 15 aa-long overlapping HIV-1 IIIB 
Env gp120 peptides (Centralized Facility for AIDS Reagents, Potters Bar, U.K.). 96-well multiscreen 
plates (Millipore, Bedford, MA) were coated overnight with 10 μg/ml rat anti-mouse IFN-γ (BD 
PharMingen, San Diego, CA) in PBS (100 μl/well) then washed with 0.25% Tween 20 endotoxin-
free Dulbecco’s PBS (Life Technologies, Gaithersburg, MD). The reaction was blocked for 2 hours 
at 37°C with PBS containing 5% FBS. After washing the plates three times with 0.25% Tween 20 
Dulbecco’s PBS, they were rinsed with 10% FBS-RPMI 1640, and incubated in triplicate with 5 × 
105 PBMCs/well in a 100-μl reaction volume with peptide at a concentration of 8 μg/ml. After an 
18-hour incubation, Dulbecco’s PBS containing 0.25% Tween 20 was used to wash the plates five 
times, and distilled water once. After a 16-hour incubation with 75 μl/well 5 μg/ml biotinylated 
rat anti-mouse IFN-γ, the plates were washed six times with Coulter wash (Coulter, Miami, FL), 
and incubated with a 1/500 dilution of streptavidin-AP (Southern Biotechnology Associates, 
Birmingham, AL) for 2.5 hours. Later, the plates were washed five times with Coulter wash and 
once with PBS, then developed with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl 
phosphate chromogen (Pierce, Rockford, IL) and stopped by washing with tap water. Last, the 
plates were air-dried and read using an ELISPOT reader (Hitech Instruments, Edgement, PA). 
 
IgG binding antibody assay 
IgG binding antibody assays were measured by contractors at Advanced Bioscience Laboratories, 
Frederick, Maryland, USA. Quantitation of anti-gp120 mucosal responses was performed by 
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Georgia Tomaras, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, 
North Carolina, USA. Anti-cV2 responses were evaluated by Hung and Peachman, Antigens and 
Immunology Section, U.S. Military HIV Research Program, Silver Spring, Maryland, USA. 
The total macaque IgG were measured by macaque IgG ELISA; custom SIV bAb multiplex assay 
(SIV-BAMA) was used to quantify SIV Env-specific IgG antibodies in serum and mucosal secretions 
as previously described 316,394,395. For mucosal samples, specific activity was calculated as a ratio 
of MFI (in the linear range of the standard curve)/µg/ml total macaque IgG, measured by 
macaque IgG ELISA to normalise the data to the amount of recovered antibody per sample. Rectal 
swab samples in solution were spun, filtered and concentrated to approximately half of the 
starting volume, then examined for blood contamination and measured for semi-quantitative 
evaluation of haemoglobin. Purified IgG (DBM5) from a SIV-infected macaque (kindly provided 
by M. Roederer, VRC, NIH) was used as the positive control to extrapolate the concentration of 
SIV antibody. Levy Jennings Plot was used to track positive controls for each antigen. Specific 
activity was calculated from the total macaque IgG levels and the SIV specific concentrations. The 
quantitation of antibodies against native V1V2 epitopes was performed through binding assays 
against native SIV V1V2 antigens expressed as gp70-fusion proteins related to the CaseA2 antigen 
used in the RV144 correlate study (provided by A. Pinter). These synthetic proteins contain the 
glycosylated, disulphide-bonded V1/V2 regions of SIVmac239, SIVmac251 and SIVsmE660 
(corresponding to AA 120-204 of HXB2 Env), linked to the residue 263 of the SU (gp70) protein 
of Friend  Murine Leukaemia Virus (Fr-MuLV). 
To detect for binding to cV2, ELISA plates were coated overnight with 100 ng/well of streptavidin 
(Sigma) at 4˚C. Contents were then dumped and 2.8 ng of biotinylated cV2 in bicarbonate buffer 
were added to each well and incubated for 1h at 37˚C. Serial dilutions of mucosal secretions were 
then added to each well and incubated for 1h at 37˚C. Plates were finally washed and 40 µl of 
anti-monkey IgG1 linked to horseradish peroxidase (clone 7H11) diluted 1:5,000 were dispensed 
to each well and incubated for 1h at 37˚C. After washing, 40µl of ELISA ultra TBM substrate 
(Thermo Fisher) were added to each well and incubated at room temperature for 10 minutes. 
1M sulfuric acid was used to stop the reaction and the results were read at a VICOT-3 (Perkin 
Elmer) at 450 nm. 
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IgG linear epitope mapping in serum  
Serum IgG ELISA mapping was carried out by Irene Kalisz, Advanced Bioscience Laboratories, 
Frederick, Maryland, USA. 
1:20-diluted sera from the first week after the last immunization were added to ELISA plates 
coated with overlapping peptides encompassing the entire SIVK6W gp120 amino acid sequence 
316. Linear peptide mapping of serum was done by microarray (PepStar), as previously described 
396. Briefly, JPT Peptide Technologies GmbH (Germany) produced array slides designed by Dr. B. 
Korber (Los Alamos National Laboratory) by printing onto Epoxy glass slides (PolyAn GmbH, 
Germany) a library containing overlapping peptides (15-mers overlapping by 12) covering full-
length gp160 of SIVmac239 and SIVsmE660. One printing area of each quad-slide contained three 
identical sub-arrays, each containing the full peptide library. After hybridization to the slides 
using a Tecan HS4000 Hybridization Workstation, the samples were incubated with DyLight 649-
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, PA). Later, fluorescence intensity was 
measured with a GenePix 4300 scanner (Molecular Devices) and analyzed with the software 
GenePix. The background value was subtracted to the binding intensity of the post-immunization 
serum to each peptide, defined as the median signal of the pre-bleed serum for that peptide plus 
3 times the standard error among the 3 sub-arrays on slide. The total IgG concentration measured 
was used to normalize the values for each peptide as reported above (Unit = signal 
intensity/µg/ml total IgG). 
 
Plasmablast staining in peripheral blood 
Plasmablast staining was carried out by the author in collaboration with Luca Schifanella, Animal 
Models and Retroviral Vaccines Section, National Cancer Institute, NIH, Bethesda, Maryland, USA. 
We measured the frequency of plasmablasts in the peripheral blood of twenty macaques 
vaccinated with ALVAC-SIV/gp120 and twenty macaques vaccinated with NYVAC-SIV/gp120 
before vaccination and at week 25, i.e. 7 days after the last immunization. To stain the cells, the 
following markers were labelled: CD3 (SP34-2), CD14 (M5E2), CD16 (3G8), CD56 (B159) all in 
ALEXAFluor700- (BD Biosciences); CD19- PE-Cy5 (J3-119; Beckman Coulter), CD20- Qdot650 (2H7, 
eBiosciences), CD38- FITC (Clone AT-1, StemCell), CD39-BV421 (MOCP-21, BioLegend), Ki67- PE 
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(B56, BD Biosciences), and CD183-PE-CF594 (CXCR3; 1C6 BD, Biosciences); Dr. A. A. Ansari kindly 
provided the anti-α4β7 (Act-1) reagent (cat#11718) through the NIH AIDS (NIAD) Reagent 
Program, Division of AIDS. Cytofix/Cytoperm (BD Biosciences) which was used to allow 
intracellular staining. LSR II (BD Biosciences) was used to evaluate acquisition and the resulting 
data were analyzed with FlowJo (TreeStar). Gating of - (CD3-/CD14-/CD16-/ CD56-)/ CD20+/CD21-
/ Ki67+/ CD38+/CD39+ was used to identify plasmablasts 397. The frequency of the expression of 
CXCR3 or α4β7 on the plasmablasts was calculated.  
 
NK staining in vaginal mucosa  
NK staining was carried out by Namal Liyanage, Animal Models and Retroviral Vaccines Section, 
National Cancer Institute, NIH, Bethesda, Maryland, USA. 
The isolation of mononuclear cells from the tissues was carried out as previously described 398,399. 
2,106 cells were used for the phenotypic characterization, and flow cytometry staining was 
performed for cell surfaces and intracellular molecules through standard protocols. After 
stimulation with phorbol myristate acetate (50 ng/mL) and ionomycin (1 μg/mL), NK cell 
functions were analysed using 3,106 cells. Alternatively, we added 721.221 cells directly to each 
tube at an effector-target ratio of 5:1. 721.221 is a MHC-devoid, MICA/MICB-negative human cell 
line. In each tube, we added Anti-CD107a (eBioH4A3) at a concentration of 20 μL/mL, and Golgi 
PlugTM (Brefeldin A) and Golgi StopTM (Monensin) at 6 μg/mL. Samples were then cultured at 
37°C in 5% CO2 for 12h. Negative controls were represented by unstimulated (medium alone) 
samples. After incubation, cells were washed and stained for surface markers. Then, 
Cytofix/Cytoperm (BD Biosciences) was used to allow intracellular staining. For the staining, we 
used the following anti-human fluorochrome-conjugated mAbs, which are described to cross-
react with rhesus macaques antigens: V450 anti-IFN-γ (B27), PE-Cy7 anti-CD56 (NCAM 16.2), 
Alexa Fluor 700 anti-CD3 (SP34-2), Allophycocyanin-Cy7 anti CD3 (SP34-2), PerCP Cy5.5 anti-
CCR6, V450 anti-Caspase 3 (C92-605), Alexa Fluor 700 anti- Ki67 (B56) (all from BD Biosciences, 
San Jose, CA); PE-Cy5 anti- CD107a (eBioH4A3), Alexa 488 anti-IL17 (eBio64DEC17), eFluor 605NC 
anti-CD20 (2H7), and eFluor 605NC anti-CD8a (RPA-T8) (all from eBioscience, San Diego, CA); PE 
anti-NKG2A (Z199), ECD anti- CD16 (3G8), PE-Cy5 anti-NKp46 (BAB281)(Beckman Coulter, Full- 
erton, CA), Fluorescein anti CCR5 (CTC5) (R and D) and allophyco- cyanin anti-NKp44 (P44-8) and 
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PerCP/Cy5.5 anti-TNF- (Mab11) (BioLegend, San Diego, CA). Dead cells were excluded through 
yellow and aqua LIVE/DEAD viability dyes (Invitrogen). At least 500,000 singlet events (PBMCs) 
or 50,000 CD3 singlet events (mucosal mononuclear cells) were acquired on a LSR II (BD 
Biosciences). FlowJo Software (TreeStar) was used to analyse the data. 
 
Monocytes staining in blood 
Monocyte staining was carried out by Dallas Brown, Animal Models and Retroviral Vaccines 
Section, National Cancer Institute, NIH, Bethesda, Maryland, USA. 
To allow identification of monocytic myeloid cells, PBMCs (5–10 × 106 cells) were stained with PE-
Cy7 anti-CD20 (2H7; 560735, BD Biosciences), PE-Cy7 anti-CD3 (SP34-2; 563916, BD Biosciences), 
APC anti-CD14 (M5E2; 561390, BD Biosciences), BV786 anti-NHP-CD45 (D058-1283; 563861, BD 
Biosciences), HLA-DR-APC-Cy7 (L243; 307618, BioLegend), BV421 anti-CD192 (CCR2) (48607; 
564067, BD Biosciences), FITC anti-CD16 (3G8; 555406, BD Biosciences) and PE-CF594 anti-CD184 
(CXCR4) (12G5; 562389, BD Biosciences), as well as Aqua LIVE/DEAD kit (L34966, Invitrogen) to 
dismiss dead cells. CD45+Lin− (CD3 and CD20) was considered as a signature of myeloid cell 
populations. Monocyte populations were further recognised and sub-categorised according to 
the expression of CD14 and CD16, where: (i) classical monocytes were identified as 
Lin−CD45+CD14+CD16−HLA-DR+, intermediate as Lin−CD45+CD14+CD16+HLA-DR+ and non-classical 
as Lin−CD45+CD14−CD16+HLA-DR+. Acquisition was then done on an LSRII (BD Biosciences), and 
marker expression was examined in real-time using the software FACSDiva (BD Biosciences). Data 
were analysed more in detail with FlowJo version 10.1 (Treestar, Inc.).  
 
CD4+ T cell staining in blood 
T cell staining was carried out by Monica Vaccari, Animal Models and Retroviral Vaccines Section, 
National Cancer Institute, NIH, Bethesda, Maryland, USA. 
Cells were stained as described elsewhere 362. Briefly, blood CD4+ T cells from part two only, due 
to limited availability of samples, were analysed from time point week 26. PBMCs were stained 
with PerCPCy5.5 anti-CD4 (L200; cat. #552838), AlexaFluor 700 anti-CD3 (SP34-2, cat. #557917), 
and BV650 anti-CCR5 (3A9), PeCy5 anti-CD95 (DX2, #559773; BD Biosciences, San Jose, CA), PE-
eFluor 610 anti-CD185 (CXCR5; MU5UBEE, #61-9185-42; eBiocence, FITC anti-Ki67), and CD-38-
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PE and APC anti-α4β7, provided by the NIH Nonhuman Primate Reagent Resource (R24 
OD010976; NIAID contract HHSN272201300031C). Gating was performed on live CD3+CD4+ cells 
and on vaccine induced Ki67+ cells. The CXCR5 was used for circulating Tfh. FACSDiva (BD 
Biosciences) and FlowJo Software (TreeStar) were used to examine marker expression in real-
time and to analyse the final data, respectively. 
 
Statistical analysis  
Statistical analyses were carried out or reviewed by David Venzon, National Cancer Institute, NIH, 
Bethesda, Maryland, USA. 
Continuous factors between the two groups were compared through the Mann-Whitney-
Wilcoxon test. The Spearman rank correlation was used to perform correlation analyses, with the 
calculation of exact permutation p values. The LogRank test of the discrete-time proportional 
hazards model allowed the definition of the number of the challenges before acquisition of 
infection. The changes in plasmablasts levels from pre- to post-vaccination were evaluated 
through the Wilcoxon signed rank test. The Kruskal-Wallis test was used for multiple comparisons 
where specified in figure legends. 
  
Chapter 3            ALVAC- but not NYVAC-based vaccination decreases the risk of SIVmac251 acquisition in macaques 
   102 
Scientist Contribution 
Giacomo Gorini Study management from second part onward, sample processing, distribution of 
samples to collaborators, data analysis, graph editing, coordination of 
collaborations, plasmablasts staining and data collection. 
Shari Gordon Study design and management up to first part included, sample processing, 




Measurement of viral RNA blood levels. 
Ranajit Pal Measurement of viral RNA blood levels. 
Hye Chung Measurement of viral DNA mucosal levels. 




IgG binding antibody assays. 
Georgia Tomaras Quantitation of anti-gp120 mucosal responses. 
Irene Kalisz Serum IgG ELISA mapping. 
Luca Schifanella Plasmablast staining, collection and elaboration of plasmablast-related data. 
Namal Liyanage NK cell staining, collection and elaboration of NK cell-related data. 
Dallas Brown Monocyte staining, collection and elaboration of monocyte-related data. 
Monica Vaccari T cell staining, collection and elaboration of T cell-related data. 
David Venzon Validation of statistical analyses. 




ALVAC- but not NYVAC-based vaccination reduced the risk of SIVmac251 acquisition 
Our study was not powered to compare the relative efficacy of the ALVAC- or NYVAC-based 
vaccines to each other but rather to compare each platform to the control groups. Forty female 
rhesus macaques characterized for their major histocompatibility complex (MHC)-I alleles, age 
and weight were equally distributed into two vaccination groups (Table 3.4). The animals were 
immunized at week 0 and 4 with either ALVAC-SIV or NYVAC-SIV and boosted at week 12 and 24 
with the corresponding viral vector and the monomeric SIVmac251 gp120 formulated in alum 
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(Figure 3.1). In addition, 25 macaques were used as control groups: two groups of 10 macaques 
each were immunised with sham viral vectors and adjuvant only, while 5 animals were left naïve. 
The challenge was performed weekly for up to 12 intravaginal low doses of the same stock of 
SIVmac251, starting at 4 weeks following the last immunization.   
 
Table 3. 4: Distribution of the animals into the vaccination groups. Of the 65 rhesus macaques that were sorted into 
the groups, 62 underwent the challenge phase. *Groups in which macaques were sacrificed before challenge for 
unrelated causes. 
 
Figure 3. 1: Study design. Animals were immunized with either ALVAC (vCP180) or NYVAC (VP1071) inducing the 
expression of gag-pro-env of the attenuated SIVmac142 clone of SIVmac251 and boosted with the native form of 
SIVmac251/gp120TM (referred in the text as gp120) adjuvanted in alum (200 mg). *of the 20 animals that were 
included in the ALVAC-group, 2 died before the challenge phase for vaccine-unrelated reasons. ** of the 10 animals 
that were included in the NYVAC mock group, 1 died before the challenge phase for unrelated reasons.  
Group
Facility
TotalPart 1 Part 2
ALVAC-SIV/gp120 7* 11* 18
NYVAC-SIV/gp120 8 12 20
ALVAC-control 4 6 10
NYVAC-control 3* 6 9
Naïve / 5 5
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Because of the large number of animals included (n=65), the study was divided in two parts and 
carried out in different facilities at different times (Washington University Primate Research 
Center for Part 1, and Advanced Bioscience Laboratories, Inc. for Part 2, Table 3.4). It was planned 
prior to study initiation that in case no difference in the rate of SIVmac251 acquisition was 
observed in the sham and naive controls, the data from the animals in all control groups could 
be pooled and compared with the vaccinated groups. As the infection rates in the naïve and sham 
NYVAC and ALVAC control groups did not differ significantly (Figure 3.2), the infection rates of 
the animals in the ALVAC-SIV group were compared to the infection rates of the control groups 
(ALVAC-control, NYVAC-control and naïve from both parts of the study), with an estimated 
vaccine efficacy of 50% at each challenge (Log-rank test: p=0.0471; Figure 3.3A). In contrast, 
NYVAC-SIV vaccination failed to protect animals (Log-rank test: p=0.2062; Figure 3.3B).  
 
 
Figure 3. 2: Acquisition of SIVmac251 in the control groups from each part of the study. Naïve animals were present 
only in the second part. The null hypothesis of equal survival distributions in the five control groups is not rejected 
by the Log Rank test, allowing for the combination of the animals into one control group. 
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Figure 3. 3: Acquisition curves of SIVmac251 administered intravaginally in the A) ALVAC-vaccinated and B) NYVAC-
vaccinated groups, as compared to the pooled control groups. P values calculated with LogRank test. 
The animals that became infected in both vaccine groups did not differ from the controls in the 
level of plasma virus (Figure 3.4A) except for the NYVAC-SIV group at two weeks from infection 
(P = 0.0035; Figure 3.4B). However, this containment of plasma viral levels was lost thereafter 
(Figure 3.4C).  
 
Figure 3. 4: Mean SIV viral loads of infected macaques. A) Logarithmic mean + s.d. of SIV/RNA levels in the plasma 
of the infected animals in the three animal groups (ALVAC-SIV, NYVAC-SIV and pooled controls). (B, C) Logarithmic 
mean ± s.d. of SIV/RNA levels in the plasma of infected animals in the B) acute and C) chronic phase of infection. 
Data in B and C analysed Mann-Whitney test. Only the P value of significant differences is shown. 
To determine whether vaccination affected virus levels in mucosal tissues we quantified the SIV 
DNA levels in the vaginal and rectal biopsies of the infected animals at 2 weeks post-infection, 
but we observed no significant differences in the ALVAC-SIV- or NYVAC-SIV-vaccinated animals 
and the control group (Figure 3.5A, B). 
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Figure 3. 5: SIV/DNA copy numbers in the A) vaginal and B) rectal mucosa of the infected animals amongst the 
vaccinated and control groups at week 2 post infection (horizontal lines: median ± s.d.). Mann-Whitney test revealed 
no statistically significant differences between control and treated groups. 
 
Adaptive responses induced by the ALVAC- and NYVAC-SIV vaccines that correlates with 
SIVmac251 acquisition 
Vaccine-induced CD4+ lymphoproliferation was among the strongest vaccine-induced responses 
detected in the patients enrolled in the RV144 trial, and the intensity of CD4+T-cell responses was 
a secondary correlate of vaccine protection 382. The NYVAC-SIV vaccine regimen induced higher 
responses to Env and Gag as measured by IFN-γ ELISpot (Figure 3.6A and 6B), but following the 
last immunization only the Env-specific response was significantly higher in the NYVAC–SIV than 
the ALVAC-SIV group (P = 0.012, Figure 3.6C).  
 
Figure 3. 6: Vaccine-induced T cell responses as measured by IFN-γ ELISpot. (A, B) IFN-γ-secreting cells (mean ± SEM) 
measured by ELISpot in response to SIV A) Env or B) Gag. Arrows represent immunization time points. C) Dot plot of 
the Env-specific ELISpot responses at week 27 (3 weeks after the last immunisation)(mean ± s.d.). Statistical analysis 
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In regard to the vaccine-induced humoral immune responses, the kinetic of antibody production 
against SIVmac251 gp120 was faster in the NYVAC-SIV group and before the administration of 
gp120/alum serum titres above 103, but by the end of the immunisation regimens, gp120-binding 
antibody titres in the two groups reached equivalent levels (Figure 3.7). 
 
Figure 3. 7: Vaccine-induced serum IgG responses. Logarithmic mean + s.d. of SIVmac251 gp120-specific IgG titres 
in the two vaccination and one control groups. Arrows represent immunisation time points. 
Both vaccination approaches induced similar patterns of recognition of gp120-overlapping linear 
peptides, including the V1 and V2 regions (Figure 3.8). 
 
Figure 3. 8: Average serum IgG binding at week 25 to 89 overlapping peptides that span gp120 in the two vaccination 
groups. 1:20 diluted sera from the first week after the last immunisation were added to ELISA plates coated with 15-
mer overlapping peptides encompassing the entire SIVK6W SU amino acid sequence. Samples were incubated with 
secondary antibody and absorbance at 450 nm was measured, with subtraction of background value, defined as the 
median signal of the pre-immunisation serum for that peptide plus three times the standard error. Total IgG sample 
concentration was used to normalise the values for each peptide. 
Similarly, the IgG responses to the envelope gp130 SIVmac251 and the gp70 V1V2 scaffold of 
SIVmac251 in the vaginal secretions also did not differ significantly in the two groups (Figure 3.9A 
and B). Surprisingly, mucosal antibody binding data to cV2 revealed almost absent antigen 
recognition in the ALVAC-SIV group and baseline recognition in the NYVAC-SIV as compared to 
the control group (Figure 3.10). 
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Figure 3. 9: Vaginal mucosa antibody recognition (mean ± s.d.) of V1/V2 as presented on A) gp130 and B) gp70 fusion 
proteins. Mann-Whitney test revealed no statistically significant differences between control and treated groups. 
 
Figure 3. 10: Vaginal mucosa antibody recognition of A) SIVmac251 cV2 and B) SIVsmE543 cV2. Extremely low 
binding activity prevented informative comparison of the study groups. 
 
Plasmablast migration affects vaccine efficacy  
We studied how the vaccine regimens altered the frequency of PBs in blood at one week after 
the last immunization and found that neither NYVAC- nor ALVAC-SIV vaccination increased the 
percentage of total circulating blood PBs after immunisation. However, the different frequency 
(delta) between the total post- and pre-vaccination PB levels positively correlated with the 
mucosal IgG levels specific for SIV/gp120-V1V2 scaffolds in the ALVAC-SIV (P = 0.0272, Figure 
3.11C) and the NYVAC-SIV (P = 0.0296, Figure 3.11D) groups.  
To determine the PBs homing marker following immunisation, the expression of two homing 
markers, i.e. α4β7 and CXCR3A, was investigated on the surface of PBs. α4β7 is an integrin that 
mediates lymphocytes migration to the mucosal sites through binding to MAdCAM-1, expressed 
on the inner surface of the mucosal venules 400. The chemokine receptor CXCR3 binds the 
chemokines CXCL9 and 10 generally released at the site of inflammation, where CXCR3A-
expressing cells are recruited 401. Interestingly, we found a decrease in the percentage of α4β7+ 
PBs (P = 0.0106, Figure 3.12A) and a rise in the levels of CXCR3+PBs (P = 0.0324, Figure 3.12B) in 
the blood of NYVAC-SIV animals in the post-vaccination (week 25) as compared to the pre-
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Figure 3. 11: Vaccine-induced plasmablast responses. Comparison (Mann-Whitney test) of the vaccine-induced 
variations in frequency of total peripheral PBs before vaccination (week 0) and post-vaccination (week 25) revealed 
no significant difference in the A) ALVAC-SIV and B) NYVAC-SIV groups. Bars represent mean ± s.d. Pearson 
correlation of the differential between PBs post- and pre-vaccination to vaginal mucosa C) anti-SIVsmE660-V1/V2 
IgGs in the ALVAC-vaccinated group and D) anti-SIVmac239-V1/V2 in the NYVAC-vaccinated group. 
 
populations were observed in the ALVAC-SIV vaccinated macaques (Figure 3.12C and D) and 
interestingly, the difference between the frequency of the α4β7+ PBs pre- and post- vaccination 
was associated with delayed acquisition in the ALVAC-SIV but not the NYVAC-SIV group as 
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Figure 3. 12: Comparison (Mann-Whitney test) of the vaccine-induced variations in frequency of α4β7+ (A and C) and 
CXCR3+ (B and D) peripheral PBs before vaccination (week 0) and post-vaccination (week 25) of the two vaccinated 
groups. Bars represent mean ± s.d. P value reported only for significant differences. 
 
 
Figure 3. 13: Acquisition curves of macaques with higher post-pre α4β7+ PB differential in the A) ALVAC-SIV and the 
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Innate responses induced by ALVAC-SIV and NYVAC-SIV correlate with SIVmac251 acquisition 
The cells of the myeloid lineage play a key role in antigen presentation and the generation of 
adaptive CD4+, CD8+ T and B cell responses 402. Once believed to be a homogeneous population, 
since the 1980s several subpopulations of monocytes were identified, each one with distinct 
functions403,404: (i) classical CD14+CD16- monocytes are phagocytic cells that also mediate 
inflammation; (ii) intermediate CD14+CD16+ monocytes are a transitional population involved in 
the production of anti-inflammatory and pro-inflammatory cytokines and CD4+ T cell 
proliferation (iii) non-classical CD14-CD16+ monocytes are mainly involved in tissue repair and 
removal of debris from the vasculature.  
We found that the two vaccine regimens did not significantly change the overall blood frequency 
of total classical, intermediate, or nonclassical CD16+ monocyte subsets (Figure 3.14).  
Through microarray data, we have previously shown89 that ALVAC-based prime/boost strategies 
activate the inflammasome pathways within classical monocytes which in turn associates with 
protection from rectal exposures to SIVmac251 in rhesus macaques. Indeed, in the ALVAC-SIV 
group, the frequency of total monocytes (Figure 3.15A) and of the classical monocyte subset 
(Figure 3.15B) significantly correlated with protection against vaginal challenges with the same 
virus stock in Chinese macaques (P = 0.0277, r = 0.7038 and P = 0.0208, r = 0.7285, respectively). 
On the contrary, the levels of non-classical monocytes were correlated with risk of SIV acquisition 
(p = 0.0313, R = –0.6915) (Figure 3.15C). 
 
Figure 3. 14: Frequency of monocyte subpopulations at week 25 in the total population of leukocytes (as identified 
by positivity to CD45 staining, the leukocyte common antigen). Frequencies of A) classical, B) intermediate and C) 
non-classical monocytes are shown. Bars represent mean ± s.d. Due to limited availability of samples, only data from 
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Figure 3. 15: Pearson correlation of myeloid cells subsets with SIVmac251 acquisition in the ALVAC-SIV group. 
Correlation with A) the total percentage of monocytes, B) of CD14+ CD16- classical monocytes and C) CD14-CD16+ 
non-classical monocytes to the time of virus acquisition. Because of limited sample availability, only data from part 
2 of the study were collected. 
Overall, the intermediate CD14+CD16+ monocytes correlated directly with the percentage of 
cytotoxic NK cells in the vaginal mucosa in the ALVAC-SIV group (Figure 3.16A), although the 
levels of the CCR2+CD14++CD16+ intermediate monocyte subsets were significantly higher in the 
NYVAC-SIV immunised animals (Figure 3.16B), with CCR2 being a chemokine receptor marker of 
macrophage activation which mediates the infiltration of the monocyte to the site of 
inflammation 405. 
Finally, myeloid-derived suppressor cells (MDSCs) were found to correlate with faster virus 
acquisition in the ALVAC-SIV group if positive for CXCR4 (Figure 3.17). MDSCs are a population of 
cells generated in a large array of pathologic conditions such as infection and cancer, with the 
ability to suppress T cell function, and are considered to be a pathologic state of activation of 
monocytes and immature neutrophils 406. 
A B C 
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Figure 3. 16: Interplay of the innate immunity as revealed. A) Pearson correlation of intermediate monocytes with 
NK response in the ALVAC-SIV group and B) prevalence in the vaccination groups of CCR2+ intermediate monocytes. 
Bars in B represent mean ± s.d., with statistical significance revealed by one-way non-parametric ANOVA test. Due 
to limited availability of samples, only data from part 2 of the study were collected. 
 
Figure 3. 17: CXCR4+ MDSCs Pearson correlation with time of acquisition in the ALVAC-SIV group. Due to limited 
availability of samples, only data from part 2 of the study are reported. 
We next investigated whether the two vaccine regimens differed in their ability to harness NK 
cells. In prior studies, we found that the ALVAC-SIV regimen induced the production of IL-17 by 
NKp44+ cells in the rectal mucosa that correlated with delayed virus acquisition362. This type of 
cells is responsible for promoting epithelial integrity and mucosal homeostasis362. Additionally, 
substituting the ALVAC-SIV priming with DNA resulted in changes in classical monocytes and MDC 
frequency that affected the SIV specific CD4+ T cells and, consequently, vaccine efficacy.  
NK cells are considered to be the first-line of defence against viral infections 407 because of their 
ability to exert cytotoxic activity toward virus-infected cells without the need of MHC-mediated 
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activation. Neither vaccination regimen induced variations in the overall prevalence of NK cells 
(CD45+, CD3-, CD20-, CD14-, NKG2A+) in vaginal mucosa (Figure 3.18A) and, surprisingly, we found 
no detectable levels of NKp44+ cells in this compartment (data not shown). Although one week 
after the last immunization the frequency of NKG2A+ NK cells with cytotoxic profiles (CD107a+) 
increased significantly in the ALVAC-SIV compared to the NYVAC-SIV and the control groups 
(Figure 3.18B), the frequency of the NKG2A+CD107+ cells did not correlate with SIVmac251 
acquisition (data not shown). 
 
Figure 3. 18: Relative frequency of NK cells (defined as CD45+, CD3-, CD20-, CD14-) A) NKG2A+ and B) NKG2A+ 
CD107+cells at week 13 of the animals included in the ALVAC-SIV, NYVAC-SIV and control groups from part 2 of the 
study (horizontal lines: mean ± s.d). Due to limited availability of samples, only data from part 2 of the study were 
collected. P values between vaccinated and control groups in B were below 0.0001 by Mann-Whitney t test. 
 
Blood CD4+ T cell responses  
NYVAC-vaccinated animals were found to have a significantly higher percentage of activated 
(CD38+) (Figure 3.19A) and gut homing (47+) CD4+ T cells (Figure 3.19B) than ALVAC-vaccinated 
animals in the blood at week 26 (p = 0.029 and p= 0.0010 by the Mann-Whitney test, 
respectively).  The levels of CD4+ T cells expressing the HIV/SIV co-receptor CCR5, and of 
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Figure 3. 19: Vaccine-induced CD4+ T cell subsets. A) Percentage of activated vaccine-induced Ki67+ CD38+ CD4+ T 
and B) gut-homing 47+ CD4+ T cells. Due to limited availability of samples, only data from part 2 of the study were 
collected; data from samples with detectable results are reported in figure. P values were calculated with the Mann-
Whitney test. 
Interestingly, the two vaccine strategies induced different subsets of CD4+ T cells, measured by 
the subset CXCR3 and CCR6 marker discriminators in the blood at week 26 (Figure 3.20). The 
ALVAC-SIV vaccinated macaques had significantly higher TH1-type CD4+ T cells (CXCR3+ CCR6–, p 
= 0.006), (Figure 3.20A) and significantly lower TH 2-type cells (CXCR3– CCR6–, p = 0.009) (Figure 
3.20B) than the NYVAC-SIV animals. Picture 3.20 B: edit legend to Th2 
 
Figure 3. 20: Vaccine-induced CD4+ TH cell subsets at week 26. A) Percentage of vaccine-induced TH1 and B) TH2 cells. 
Due to limited availability of samples, only data from part 2 of the study were collected; data from samples with 
detectable results are reported in figure. P values were calculated with the Mann-Whitney test. 
Importantly, the frequency of ALVAC-induced TH1 was found to be associated with the number 
of challenges to infection (Figure 3.21A) and with the levels of classical monocytes at week 25 
(Figure 3.21B), suggesting a role for T cell-monocyte crosstalk in protection from SIV acquisition. 
No differences were found in the percentage of other subsets (TH17 and Tfh cells), and no 
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Figure 3. 21: Vaccine-induced CD4+ T cell subsets in protection and monocyte cross talk. A) Direct significant 
associations between the levels of ALVAC- induced TH1 cells at week 26 and the number of challenges to infection 
and B) to classical monocytes at week 25 in blood. Due to limited sample availability, only data from part 2 of the 
study were collected; data from samples with detectable results are reported in figure. Statistical analysis performed 
by Spearman correlation test. 
Discussion 
The RV144 phase III trial tested the efficacy on 16,402 patients of a vaccine regimen based on the 
administration of the canarypox vector ALVAC driving the expression of HIV-1 antigens in 
combination with the protein boost AIDSVAX, containing the HIV-1 surface glycoprotein gp120 
formulated in the alum adjuvant. The significant but limited protection induced by this vaccine 
was nevertheless indicative in allowing the identification of possible mediators of protection.  
In this study, we tested in the rigorous SIVmac251 animal model a second poxvirus vector, the 
vaccinia–derivative NYVAC, previously proved to be highly immunogenic in preclinical and clinical 
studies, in an attempt to increase vaccine efficacy382. The NYVAC-SIV vaccine regimen was 
modelled on RV144 and run in parallel with the ALVAC-SIV vaccine. In both vaccines, the 
immunogens expressed by the two vectors were identical as were the protein boosts.  
The animals underwent repeated low dose intravaginal challenge to mimic the heterosexual 
transmission of HIV in female patients, and the study was powered to compare the vaccination 
groups to control groups of animals, immunised with one of the empty vectors and adjuvant only 
or not immunized. Contrary to our expectations, the higher immunogenicity of NYVAC described 
in previous clinical and preclinical studies by other groups382,389,408,409, and hereby confirmed by 
the data on Env-specific IFN-γ ELISpot after immunisation, failed to translate into an increase in 
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vaccine efficacy. In contrast, only the ALVAC-based vaccination resulted in a significant estimated 
vaccine efficacy of 50%.  
In the infected animals, both vaccination regimens failed to demonstrate long-term control of 
viral load in the peripheral blood, or of SIV/DNA levels in the rectal or vaginal mucosa. 
Similarly to the human trial, our results provide clues to the possible mechanisms that mediate 
protection from viral acquisition, indicating that the quality over the quantity of the immune 
responses may be key in providing protection from SIV acquisition in the macaque model. 
Although NYVAC-SIV proved generally more immunogenic, an association between higher 47+ 
PBs responses and delayed viral acquisition was observed only in the ALVAC-SIV group, although 
no differences were observed in terms of total circulating 47+ PBs between the NYVAC-SIV and 
the ALVAC-SIV group post-vaccination. This indicates that, besides 47+ PBs per se, a milieu of 
background immune responses elicited by the ALVAC-SIV but not the NYVAC-SIV vaccination 
might be necessary to favour protection. 
This hypothesis is further corroborated by the observation that although no significant difference 
was identified between the levels of monocyte subsets in the ALVAC-SIV and NYVAC-SIV group, 
delayed viral acquisition was found to correlate with the classical subset of monocytes only in 
the ALVAC-SIV group. The subset of classical CD14+CD16- monocytes is constituted by cells that 
mediate inflammation and exert phagocytic activity, and it is therefore possible that one of these 
two mechanisms might be the mediator of protection from viral acquisition. Since our 
collaborating group at the NIH has shown that ALVAC-based vaccination strategies activate the 
inflammasome pathways within this subset of cells which in turn associates with protection from 
rectal SIV exposures in rhesus macaques89, it is possible that it is a general inflammation state 
elicited by the classical monocyte subset to be mediating protection. Another possibility is that 
classical monocytes might be mediating protection through ADCP, a mechanism by which 
immune complexes or antibody-opsonised infected cells activate the FcγR on the surface of 
monocytes thus triggering phagocytosis and boosting the antiviral activity of non-neutralising or 
neutralising antibodies85. The results of ongoing microarray analyses will elucidate the extent to 
which these two monocyte-related functions, inflammation or phagocytosis, contribute to the 
delay of viral acquisition observed in the ALVAC-SIV group. 
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In contrast to the observations in the classical subset, non-classical monocyte and MDSC levels 
correlated negatively in this group. Because the quantity of monocytes that correlated with 
protection was not vaccine-induced, we hypothesise that the gene expression and the overall 
activity of these cell types was altered by the vaccine to ultimately mediate protection. Again, 
this hypothesis is in line with previous observations from our collaborating group at the NIH, 
classical monocytes function rather than titres associated with protection from mucosal 
exposure to SIVmac251 in groups of rhesus macaques89. 
 
A crosstalk between NK cells and monocytes that causes mutual amplification between the two 
cell types and results in recruitment of inflammatory cells to the sites of inflammation has been 
described before410. In the ALVAC-SIV group, intermediate monocytes correlated positively with 
the levels of cytotoxic NK cells in the vaginal mucosa, which were observed to be significantly 
increased in the ALVAC-SIV group, but not in the NYVAC-SIV group. The observation that 
intermediate monocytes might be mediating an increase of cytotoxic NK cells in the mucosa, 
without a total difference of intermediate monocytes between the two vaccination groups 
corroborates the hypothesis that the two vaccines have differently affected the functionality of 
myeloid subsets. 
Although the levels of mucosal cytotoxic NK cells did not correlate with delayed acquisition in the 
ALVAC-SIV group, the fact that we found a positive correlation between the total number of 
monocytes and the classical subset and acquisition in the ALVAC-SIV group, still supports that 
innate immunity might be a key mediator of protection upon vaccination. Importantly, the role 
of innate immunity in providing protection from viral infection has also been identified following 
HIV vaccination studies: D.J.M. Lewis and collaborators observed that vaginal immunisation with 
an HIVgp140 vaccine linked to the 70kDa heat shock protein downregulated HIV coreceptor CCR5 
and increased the expression of the HIV resistance factor apolipoprotein B mRNA-editing, 
enzyme-catalytic, polypeptide-like 3G (APOBEC3G) in women, effects which correlated with HIV 
suppression ex vivo411. 
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While the results of the ongoing gene expression analyses are necessary to further define what 
immune mechanisms it is necessary to elicit to protect from mucosal SIV acquisition in rhesus 
macaques, the data hereby presented sustain two conclusions: (i) the quality over the quantity 
of the immune responses is key in providing protection from SIV acquisition in rhesus macaques. 
Therefore, it is not to be expected that more immunogenic approaches will result in increased 
protection; (ii) contrary to the traditional mechanisms of vaccine-induced protection, where the 
induction of a protective adaptive humoral immune response is desired to provide protection 
from viral acquisition, more and more data of this and other animal studies on SIV as well as HIV 
vaccines reiterate the role of the innate immune response in providing protection, although the 
precise effector mechanisms remain to be elucidated. 
These data provide insights into mechanisms associated with HIV vaccine protection, and 
alternative strategies to refine and improve protocols for higher efficacy. 
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CHAPTER 4: Passive administration of a mAb with strong inhibitory activity  
of 47 to V2 interaction fails to protect rhesus macaques  
from SIVmac251 intrarectal challenge 
 
Introduction 
While the induction of potent neutralising antibodies has been the end goal of most HIV vaccine 
researchers, to date no vaccination approach tested in animals or humans has induced bnAbs: 
the protection, albeit limited, in RV144 was achieved in the absence of detectable bnAbs 286,309. 
In contrast, non-neutralising humoral immune responses targeting the V2 region of gp120 have 
been found to be a correlate of protection from HIV and SIV both in the human RV144 trial and 
macaque studies, respectively 309,362,412,413. 
Non-neutralising anti-HIV/SIV antibody immunity is increasingly associated to Fc-related 
antibody functions, also considering that in RV144 a correlation was found with ADCC and high 
levels of anti-V2 serum IgGs if anti-gp120 IgA titres were low 309,414,415. Yet, no studies report that 
antibody effector functions alone are able to prevent HIV/SIV infection in the absence of 
neutralisation 245. In neonatal macaques, non-neutralising polyclonal preparations that displayed 
strong ADCC did not protect animals from oral SIVmac251 challenge416. Similarly, no protection 
was detected with the passive administration of non-neutralising antibodies highly enriched for 
ADCC activity and derived from HIV-infected individuals417. Therefore, despite a statistical 
association with reduced risk of infection by anti-V2 IgGs in RV144 vaccinees and animal models 
that displayed post-infection viral control, the antiviral activity exerted by the Fc region alone has 
not proven to be sufficient to prevent infection 245. Similarly, enhancing Fc receptor binding 
efficiency of bnmAb b12 did not provide protection from SHIV challenge in macaques 418. 
Although these studies evaluated the possibility that ADCC might act alone or in combination 
with viral neutralisation as a mediator of protection from viral acquisition, no passive transfer 
studies have been performed to evaluate if the humoral non-neutralising anti-V2 response could 
delay viral acquisition. To date, the only anti-V2 mAb tested in passive transfer macaque studies 
is the broadly neutralising PG9, which targets the anti-V1V2 glycopeptides and was able to afford 
protection in 4 out of 6 macaques 419. 
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We hypothesise that the non-neutralising anti-V2 response might be a mediator of protection by 
preventing interaction of viral envelope gp120 with human 47. The pivotal role of this integrin 
in HIV infection has been demonstrated by the studies of Byrareddy et al. on infected macaques 
treated with ART in combination with the anti-47 mAb vedolizumab337. When treatment was 
withdrawn, the animals maintained low to undetectable viral loads and normal CD4+ T cell counts 
in plasma and GI tract for more than nine months337. Notably, the authors identified a skew of 
the antibody response towards the V2 domain among the correlates of viral control, while 
neutralisation and ADCC failed to demonstrate correlation. 
While the mechanisms by which vedolizumab infusion contributed to prolonged viral load control 
are yet to be defined in detail, some propose that this mAb might target 47 incorporated in 
the viral envelope of the virions during the budding process, and thus prevent the virus from 
targeting the intestinal tissue 420. However, it is possible that viral control might be due to the 
disruption of the interaction between 47 and V2, either directly by 47-bound vedolizumab 
or indirectly through the treatment-induced boost of anti-V2 humoral responses. 
 
The present study was designed to evaluate whether passive infusion of the non-neutralising 
anti-V2 mAbs NCI09 and NCI05 isolated from the vaccinated, protected rhesus macaque P770 
and described in chapter 2 are able to provide protection from mucosal SIVmac251 RLD challenge 
in groups of rhesus macaques. A further group was included to test for the protection efficacy of 
the weakly SIVmac251-neutraliser anti-V2 mAb ITS09, which was isolated from an infected 
animal 364. While NCI05 did not display any activity of inhibition between human 47 and 
deglycosylated SIVmac251 gp120, both NCI09 and ITS09 proved to significantly disrupt this 
interaction, with NCI09 being the greatest inhibitor amongst the mAbs tested in the binding assay 
360. 
Because of the high doses of mAb administered per animal (50 mg/kg) require a total of 
approximately 5 mg of mAb to be prepared before an animal group can undergo immunisation, 
only the control and ITS09 group have been tested to date, while sufficient quantities of NCI09 
and NCI05 mAbs should be ready for infusion before the end of 2018.  
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Materials and Methods 
 
Monoclonal Antibodies 
Current-Good Manufactory Practice (cGMP) ITS09.01 (ITS09) was produced by Drs. Elizabeth 
Scheideman, Abasha Williams, Stephanie Golub, Daniel Ragheb, Nga Tran, Lena Wang, Vaccine 
Production Program, VRC, NIAID, NIH, Gaithersburg, MD, USA. 
An expression vector encoding the heavy chain and light chain genes of ITS09-LS along with a dhfr 
selection marker was transfected into CHO-DG44 cells by electroporation using the AmaxaTM 4D 
NucleofectorTM (Lonza). Transfected cells were cultivated in an Infors Multitron shaker set to 
37°C, 5% CO2, and 80% relative humidity with a shaking speed of 130 rpm (orbital throw of 1 inch) 
in CDM4CHO medium with 6 mM L-glutamine. Forty-eight hours after transfection, methotrexate 
(MTX) was added to the culture to a final concentration of 100 nM. Viable cell density and viability 
for the culture was assessed every three to four days using the Cedex HiRes. Once a week, the 
cells were centrifuged at 100 x g for 10 minutes and resuspended in fresh CDM4CHO medium 
with 6 mM L-glutamine and 100 nM MTX. When the viability of the pools recovered to ≥ 80%, 
the medium was replaced with ActiCHO P medium containing 6 mM L-glutamine and 100 nM 
MTX. 
 
ITS09-LS production was carried out in two 50L single-use bioreactors (SUB).  The pool was 
expanded in a 50L WAVE bioreactor in 12L ActiCHO P with 6mM L-glutamine for three days with 
ViCell and NOVA BioProfile FLEX measurements taken daily.  The cells were then seeded into a 
50L SUB in 40L ActiCHO P with 6 mM L-glutamine. The cells were maintained in the SUB for 14 
days with ViCell and NOVA BioProfile FLEX measurements taken daily. Samples were also taken 
for protein A HPLC titre analysis starting on day 6.  Starting on day 3, 1.5% Feed A and 0.15% Feed 
B were added daily and reduced as needed based on glucose and lactate utilization rates.  
Additional glucose supplementation was provided when levels dropped below 1 g/L as measured 
on the NOVA meter to maintain residual glucose at 1 g/L.  
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Following clarification of the harvest with Clarisolve® and Millistak+® depth filters and subsequent 
filtration, the mAb was purified by Protein A capture and endotoxin removal was performed by 
a salt-tolerant interaction chromatography (STIC) anion exchange step. The final product was 
concentrated to greater than 10 mg/mL and buffer exchanged into 1X PBS prior to sterile 
filtration.  
 
Animals, vaccines and SIVmac251 challenge 
The staff at the National Cancer Institute Animal Facility directly handled the animal models in 
respect of all the relevant guidelines of our institute. 
The animals of this study were male colony-bred rhesus macaques (Macaca mulatta) of Indian 
origins obtained from the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (Rockville, Maryland, USA). Animals were housed and treated in respect of all the 
relevant guidelines of our institute (NIH) in the NCI  Animal Facility. A total of 60 macaques were 
randomised in groups of 8 animals according to their major histocompatibility alleles. The animals 
underwent passive immunoprophylaxis through a total of three subcutaneous administrations of 
the anti-V2 mAb ITS09.01 at a dose of 50 mg/kg every three weeks (Figure 4.1). Control group 
animals received an equal volume of PBS through the same route with the same frequency.  
Animals were challenged weekly for a total of nine times, starting from five days after the first 
mAb administration, with intrarectal SIVmac251 at 120 TCID50. 
Immunisation was discontinued for animals that tested positive for SIV-RNA and their blood viral 
loads were tested weekly until symptom development. 
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Figure 4. 1: Study design. Animals underwent a total of three subcutaneous passive immunisations with mAb ITS09 
(dashed arrows) every three weeks throughout the repeated low dose challenge phase, which consisted of a total 
of nine weekly intrarectal SIVmac251 administrations (solid arrows). Control animals were administered PBS instead 
of ITS09. 
Measurement of viral RNA and DNA 
Viral RNA levels were investigated by Ranajit Pal, Advanced Bioscience Laboratories, Frederick, 
Maryland, USA. Data was co-analysed by Isabela S. de Castro, Animal Models and Retroviral 
Vaccines Section, NCI, NIH, Bethesda, MD, USA.  
Plasma SIVmac251 RNA levels were evaluated by nucleic acid sequence-based amplification, as 
described in chapter 3 and in reference 391.  
 
Serum ITS09 titration  
Serum ITS09 reactivity to V2 was evaluated by ELISA. Samples from three PBS-treated control 
animals were used for reference. ELISA plates were coated overnight at room temperature with 
100 ng per well of 1J08 scaffold SIVsmE660.CR54, kindly provided by Dr. Mario Roederer (VRC) 
and described in chapter 2 and in reference 364. The contents were then dumped and 1% PBS-
BSA was added to the well to block. 40 μl of serial 1:4 dilutions of monkey plasma starting from 
1:100 were dispensed in each well and incubated for 1 h at 37 °C. Each plate also included a 1:5 
serial dilution of purified mAb ITS09, starting from 20 μg ml–1. Plates were washed using a plate 
washer and 40 μl of 1:5,000-diluted anti-monkey IgG1 + horseradish peroxidase (clone 7H11) 
were dispensed in each well and incubated for 1 h at 37 °C. After washing and incubation with 
streptavidin-HRP (KPL) for 1 hr at 37°C, signal was developed through incubation with 3,3’,5,5’ 
(Week)	Day
Week 0 1 2 3 4 5 6 7 8
(0)	-5 (3)	-5 (6)	-5 (9)	-5
SIVmac251
ITS09 ITS09 ITS09
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TMB substrate (Thermo Fisher Scientific) and Optical density (OD) read at 450 nm. Plasma 
dilutions in the linear range of the curve were compared to the binding curve of the ITS09 
standard to interpolate ITS09 plasma concentration values. 
 
Statistical analysis 
The LogRank test of the discete-time proportional hazards model was used to identify the 
number of the challenges before acquisition of infection. Viral loads were compared through the 
Mann-Whitney Wilcoxon test. 
 
Scientist Contribution 
Giacomo Gorini Study design, virus and mAb dilution and aliquot preparation for animal use, 
sample processing, supervision of animal immunisation and challenge, anti-V2 
plasma IgG titration, data processing, graph editing. 
Staff of Vaccine 
Production Program 
cGMP production of ITS09.01. 
Ranajit Pal Titration of viral RNA. 
Isabela S. de Castro Processing of part of the data of viral RNA levels. 
National Cancer 
Institute Animal Facility 
Staff responsible for animal handling and treatment. 
Table 4. 1: List of collaborators that directly contributed to the experiments summarised in this chapter. 
Results 
 
ITS09 failed to reduce the risk of SIVmac251 acquisition 
This study was designed to compare the efficacy of each mAb to the control group. To date, only 
the results of the group treated with the mAb ITS09, derived from an SIVsmE660-infected 
macaque 364, are available. Surprisingly, despite the potent inhibition of 47 and V2 interaction 
that this mAb displayed in vitro 360, subcutaneous infusion of ITS09 failed to significantly protect 
from viral acquisition as compared to the PBS-treated group (Log-rank test: p=0.8725; Figure 4.2). 
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Figure 4. 2: Acquisition curves of SIVmac251 administered intrarectally in the ITS09-treated group, as compared to 
the PBS-treated control group. Statistical analysis: LogRank test. 
 
ITS09 increased viral loads in the chronic phase 
The animals that did contract infection did not display significant control of viremia as compared 
to the control groups (Figure 4.3). On the contrary, ITS09-treated animals displayed significantly 
higher plasma viral loads in the chronic phase as compared to the control group (p <0.0001, 
Figure 4.3D). However, these results are difficult to interpret because of the lack of a suitable 
control group of animals treated with an irrelevant mAb, that is a mAb that does not bind to SIV 
antigen. To allow better understanding of future results, a group of animals receiving irrelevant 
antibody has been included in the study. 
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Figure 4. 3: Viral loads of infected macaques at 1-15 weeks post-infection (p.i.). A) SIV/RNA levels in the plasma of 
each separate infected animal in the ITS09-treated and control (blue and black, respectively) group. B) Logarithmic 
mean ± s.d. of SIV/RNA levels in the plasma of infected animals, pooled by group, after infection. C) Logarithmic 
mean ± s.d. of SIV/RNA levels in the plasma of infected animals in the acute phase of infection. The Mann-whitney 
test reveals not significant difference between the two groups at this stage of infection.  D). Values from weeks 4 to 
15 p.i. were pooled to compare viral loads throughout the chronic phase of infection, with significant difference 
between groups revealed by the Mann-Whitney test. Lack of an animal group receiving control antibody hinders the 
correct interpretation of the increased viremia in animals treated with ITS09. 
ITS09 reached stable blood titres after the second mAb administration 
ITS09 plasma levels were monitored as anti-V1V2 IgG plasma reactivity throughout the 
immunisation, challenge phase (Figure 4.4). After the first mAb administration, ITS09 levels 
reached between 1,500 and 2,000 µg/ml in the treated animals, while remaining negative in the 
controls. While mAb titres were found to drop in the following weeks, the second and third 
administration recovered and maintained steady blood mAb levels for the duration of the 
challenge phase. In the infected animals, the anti-V1V2 plasma reactivity was confirmed to 
decrease upon treatment interruption. 
C D 
A B 
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Figure 4. 4: ITS09 levels measured as anti-V1V2 activity in the plasma of control (black), treated uninfected (blue) 
and treated post-infection (red) animals. Plasma binding activity was detected by ELISA against fixed 
SIVsmE660.CR54 1J08-V1V2 antigen, and ITS09 concentration in samples interpolated against a control curve of 
known concentrations of ITS09. 
Discussion 
The 47 integrin has been demonstrated to bind to the V2 domain of both HIV-1 and SIV 
envelope glycoprotein gp120231,360, with this interaction likely enhancing virus transmission.  
While administration of anti-47 antibodies has resulted in inhibition of SIV in the macaque 
challenge model327, the potential of antibodies targeting V2 to result in a similar effect has not 
yet been demonstrated.  
While the molecular details of the interaction between 47 and gp120 remain controversial, 
studies have demonstrated that glycosylation is a key modulator of the V1V2 conformation and 
binding to the integrin, with partially glycosylated, but not fully glycosylated envelope proteins 
as preferred substrates for 47  binding363. In addition, it has been observed that monomers, 
not functional trimers are strong binders of 47363. It seems therefore that the V2 domain of 
poorly glycosylated monomeric gp120 allows binding of the virion to 47, with this integrin 
bringing the virion closer to the target cell surface, where functional Env trimers proceed to 
engage coreceptors and CD4 to initiate the entry process363. Thus, while the gp120 monomers 
present on the surface of the virion have often been referred in literature as “defective” Env 
products, it seems that these forms have a precise function and have been positively selected by 
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This study was designed to determine if non-neutralising anti-V2 antibodies elicited by ALVAC-
SIV vaccination can be mediators of protection when passively administered to naïve rhesus 
macaques, possibly by hindering the interaction between 47 and the poorly glycosylated, 
monomeric Env proteins present on the surface of the virions.  
Although the results of the passive immunoprophylaxis with the two mAbs NCI05 and NCI09 
isolated from the immunised, protected macaque P770 have not yet been produced, some 
observations can nonetheless be made on the negative outcome of the passive administration of 
ITS09. First of all, the fact that ITS09 showed detectable inhibition of 47 binding to V2 (Figure 
2.11) and yet failed to protect suggests that the disruption of gp120 binding to the integrin is not 
alone a predictor of the efficacy of a treatment in preventing mucosal SIV infection. Secondly, 
the presence in the bloodstream of ITS09 not only failed to contain, but also seemed to increase 
plasma viral loads of the treated animals in the chronic phase of infection. While it would be 
tempting to conclude that ITS09 directly mediated an increment in SIV virulence, the lack of a 
control group treated with an irrelevant mAb results in difficult interpretation of this finding. For 
this reason, a further control group scheduled to be receiving equal doses of an irrelevant mAb 
will be included in the study. 
 
While the results with ITS09 are sufficient to make these observations, complementing the study 
with the NCI05 and NCI09 immunisation groups will certainly prove more insights into the role of 
the anti-V2 humoral response in protection, regardless of the outcome. 
 
In case of protection with NCI05 and/or NCI09, one might hypothesise that the positive outcome 
is due to the source of the mAbs, that is a vaccinated, protected macaque. However, protection 
could only suggest that the NCI mAbs display biological features with which ITS09 is not endowed, 
without demonstrating that NCI-like antibodies might not be elicited during infection. It would, 
however, be finally confirmed beyond statistical correlation that the elicitation of antibodies that 
bind to V2 is a mechanism by which ALVAC-SIV vaccination provides protection from HIV/SIV. 
This could possibly be due to the prevention of binding of gp120 to 47 in the mucosal site, or 
possibly through different mAb(s)-induced biologic activities that would need further 
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investigation.  
 
Considering however that passive infusion of ITS09 did not prove protective despite detectable 
inhibition of binding of 47 to viral V2 in vitro, it is a concrete possibility that the NCI mAbs will 
not prove protective either. A negative outcome would thus corroborate the hypothesis that the 
inflammatory milieu produced by the ALVAC prime elicits innate immune responses necessary to 
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CHAPTER 5: Conclusions 
  
Nine years after the outcome of the RV144 clinical trial, the exact immunological mechanisms 
that mediated partial protection from HIV-1 infection remain to be elucidated.  
While antibody responses to vaccines have traditionally been associated with protection in many 
immunisation approaches approved for clinical practice, RV144 proved atypical when virus 
neutralisation was not identified as a mechanism of protection. However, the humoral immune 
response still proved to be important in preventing HIV-1 acquisition when vaccine-induced 
serum IgG levels targeting the V2 loop of gp120 were found to correlate with protection309.  
The key role played by the non-neutralising humoral immune response in protection from 
immunodeficiency virus infection was also confirmed by an RV144-like regimen which yielded 
similar protection rates in rhesus macaques vaccinated against SIV, while also eliciting anti-V2 
IgGs which correlated with delayed acquisition362. 
 
The findings reported in my thesis offer further insight into the immunological mechanisms of 
protection by providing information on three main themes: (i) the anti-V2 humoral response in 
the animal model; (ii) the role of the innate immunity elicited by vaccination in mediating 
protection and  (iii) a potential new mechanism of escape from the humoral immune response 
of the host. 
 
Blocking of the 47 to V2 interaction 
Of the anti-V2 mAbs isolated from macaque P770, NCI09 demonstrated the most potent 
inhibition of binding between human 47 and SIV gp120 in the human B lymphoma cell assay 
RPMI8866. That blocking this interaction could be the mechanism underlying protection from 
viral acquisition observed first in RV144 and later in macaques studies has been hypothesised by 
many, but not yet proven experimentally.  
This hypothesis has been formulated following three main observations: (i) data of both clinical 
and preclinical studies found correlations between the levels of anti-V2 antibody responses and 
delayed viral acquisition 309,362; (ii) in vitro experiments showed that V2 binds to the integrin 47 
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and this interaction can be blocked by anti V2-mAbs231,360 and (iii) treatment with the anti-47 
mAb vedolizumab both protected macaques from viral acquisition and suppressed the viral load 
in infected animals for several weeks after ART+mAb discontinuation327,337.  
 
However, while extensive data with the mAb vedolizumab proved that targeting 47 can be a 
strategy of viral prevention and control, no direct proof has been provided that targeting V2 with 
the humoral immune response may lead to protection. Passive infusion of anti-V2 mAbs in the 
macaque model would be key in validating this potentially protective mechanism.  
In the setting of passive immunoprophylaxis in the RLD challenge model of rhesus macaque, 
ITS09 was unable to prevent viral acquisition despite a detectable inhibitory activity of 47-V2 
interaction. Conversely, this mAb was found to increase viremia levels throughout the chronic 
phase of infection in the animals that acquired the virus, although this observation needs to be 
further investigated. 
From the two contrasting results that we obtained with ITS09 (the first one consisting in 
detectable inhibition of binding between gp120 and 47, the second one being apparent 
increase of the chronic viremia in the vivo model), it could be hypothesised that more than simple 
blocking of 47 and V2 interaction alone is needed to impede viral entry and replication in 
target cells.  
 
The lack of a suitable cell line to study how the interaction between gp120 and the integrin affects 
viral replication rates hinders the study of what exact mechanisms are at play. While TZM-bl cells 
expressing CD4 and viral entry coreceptors CXCR4 and CCR5 have traditionally been the gold-
standard system to study viral entry and replication and antibody-mediated viral neutralisation, 
this cell line lacks detectable levels of activated 47 on the cell membrane (personal 
communication by James Arthos, NIAID). The implementation of an 47+ cell system to study 
viral neutralisation and anti-V2 antibody-mediated inhibition of viral entry is becoming a pressing 
need in the field. 
  
Chapter 5                                                                                                                                                                        Conclusions 
   133
Innate immune response 
In Chapter 3, the ALVAC/NYVAC comparison study generated two main conclusions: (i) greater 
immunogenicity of the vaccine vector component did not directly lead to higher protection from 
viral acquisition, and (ii) the innate response, particularly through the monocyte subsets, plays a 
key role in preventing mucosal transmission of SIV in rhesus macaques following vaccination. 
As for the higher activation of the adaptive immune response not being a correlate of protection, 
it could be that the increased NYVAC-SIV-induced T cell activation as observed by IFN- ELISpot 
led to a metabolic activation of target cells thus favouring SIV replication. The key role of the 
innate response in providing protection from viral acquisition has already been described both in 
HIV411 and SIV89 vaccination. Notably, the SIV study pointed to the protective effect being 
mediated in part by the monocyte subsets, although it is not clear whether protection might be 
mediated by a pro-inflammatory activity of this subset or by FcR-, antibody-dependent functions 
such as ADCP. Microarray data will likely provide insights into the mechanism by which this cell 
subset might mediate protection. However, the ALVAC-NYVAC study corroborated the 
hypothesis that an effective HIV/SIV vaccine would require not only the induction of a memory 
humoral immune response towards V2, but also an optimal stimulation of innate immune 
responses. 
 
While ITS09 passive treatment has failed to provide protection in macaques, no data is yet 
available on NCI05 and NCI09 (which are currently under production for passive transfer studies). 
It is a possibility that these mAbs will similarly fail to protect without having the ALVAC-induced 
background of innate responses that I and others described to play a role in providing immunity.  
A further arm has recently been added to the passive transfer study, where these mAbs will be 
administered together with an ALVAC-SIV prime without a gp120 boost. The hypothesis is that 
the ALVAC prime will elicit a complementary innate immune response to provide protection. A 
gp120 boost has not been included in the study for two main reasons: (i) to evaluate the exclusive 
role of anti-V2 NCI mAbs in preventing infection in the absence of vaccine-induced anti-gp120 
polyclonal responses and (ii) to exclude the possibility that vaccine-induced antibodies might 
interfere with mAb binding to the challenge virus  
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Antibody interference 
The main goal of the studies reported in this thesis was to lead to further mechanistic insight into 
the protective immune response generated by vaccination regimens against HIV/SIV. In doing so, 
I have provided additional knowledge on intrinsic SIV properties, which may be confirmed to exist 
in HIV as well. I observed that SIV has evolved a structural plasticity within the V1V2 domain that 
prevents gp120 from binding to too many ligands at the same time. I described this property as 
directed mAb-to-mAb (antibody interference), while previous studies318 have shown a mAb-to-
47 interfering activity (ligand interference). While the former might be detrimental in vaccine 
protection, allowing the virus to escape some of the humoral response by preventing binding of 
too many immunoglobulins at a time, the latter is a desirable goal of vaccination. 
 
The identification of antibody interference, where non-protective antibodies disrupt the binding 
of potentially protective antibodies targeting distant epitopes, has important implications in the 
design of novel immunogens. This escape mechanism is to be avoided either by designing 
immunogens that are depleted of areas where interfering, non-protective antibodies are more 
likely to bind or, alternatively, that stimulate high-affinity antibodies targeting regions associated 
with protection. The binding of lower-affinity interfering antibodies would then be less disruptive 
of the high-affinity protective immunity, shifting the equilibrium of target-bound 
immunoglobulins towards protection. At the same time, I hypothesise that it is essential to 
maximise immunoglobulin access to key antigenic sites that, when bound, lead to an alteration 
of the V2 structure sufficient to prevent binding of 47 to the putative binding site on gp120. 
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Final remarks 
 
I would like to conclude this thesis by reproposing, in an edited version, a few considerations that 
I had the pleasure and honour to have published as a guest blogger on the website of the United 
States Agency for International Development (USAID) on HIV Vaccine Awarness Day, 2017, in a 
joint article written with and upon invitation of my friend and mentor Dr. Margaret McCluskey, 
Senior Technical Advisor for HIV Vaccines in the Office of HIV/AIDS, Bureau for Global Health, 
USAID421. 
 
It has been more than 35 years since the discovery of the HIV virus in 1983 and the only vaccine 
that ever demonstrated protection in a phase III clinical trial showed a 31.2% efficacy rate. 
Despite extensive efforts, the mechanisms behind the immunity afforded in some of the 
vaccinated individuals still have not yet been clearly elucidated. While it was announced soon 
after the discovery of HIV-1 that a vaccine would be following within two years, the scientific 
community has encountered a number of insurmountable obstacles. The genomic integration of 
HIV into key cells of the immune system, the high mutation rates and a cunning ability of this 
pathogen to take advantage of the pathways needed to activate the immune system itself have 
proven to be tough scientific challenges that have pushed the goal of a vaccine back much farther 
than originally predicted. More than twenty years ago, on 18 May 1997, President Clinton said:  
 
“We are grateful that new and effective anti-HIV strategies are available and bringing longer and 
better lives to those who are infected, but we dare not be complacent. HIV is capable of mutating 
and becoming resistant to therapies and could well become even more dangerous. Only a truly 
effective, preventive HIV vaccine can limit and eventually eliminate the threat of AIDS.” 
 
Twenty years from the announcement of that 18 May, now marked as HIV Vaccine Awareness 
Day, one wonders how close we are to the discovery of this final major Public Health tool to 
finally end the HIV/AIDS epidemic. This day has the goal of not only praising scientists for their 
efforts, but also the participation of many clinical volunteers.  
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At the 2017 Keystone HIV vaccine scientific conference that I attended, I had the pleasure to have 
dinner with a small group of senior scientists who have been working on HIV vaccines for many 
years. I soon found myself involved in a discussion over the difficulties that still lay ahead of the 
scientific community in this effort. 
To my surprise, this conversation revealed a shared frustration. While on the one hand I 
understood their sentiment, I still believe that the development of an effective vaccine is an 
achievable goal. Our field continues to attract talented young investigators, which are 
continuously joining  forces with more senior scientists. As one of the young scientists who joined 
this international effort, I feel that its future success lies in novel ideas, rather than old ones that 
have yet to show some strong signs of efficacy. I am a firm believer that a successful, cost-
effective and accessible vaccine will be developed as long as the research on the HIV field goes 
hand-in-hand with the invention and evolution of new technologies, and continued investment 
to test new ideas and concepts.  
I have no doubts that, as technologies progress, following generations of scientists will be up to 
the task to deliver a final, highly effective HIV vaccine. 
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